Skip to main content Skip to search
+34 659 496 544

Oncología Torácica y Clínico-Traslacional

Publicaciones

2026

Majem, M, Alonso-Fernández, P, López, PG, Gayete, A, Hernando, F, López-Guerra, JL, Lozano, MD, Massuti, B, Paz-Ares, L, Cajal, SRY, Rodríguez-Sales, V, Seijo, L, Sisó-Almirall, A, Vicente, D, Molins, L (2026).

Recommendations for the development of an integrated lung cancer care process: an expert consensus report

Clinical & Translational Oncology. Article.
[doi:10.1007/s12094-026-04275-y]
Paz-Ares, L, Veillon, R, Majem, M, Zhou, CC, Tang, KJ, Kim, SW, Richardson, G, Girard, N, Sanborn, RE, Mansfield, AS, Park, K, Schuchard, J, Diels, J, Sermon, J, Bhattacharya, A, Lorenzini, P, Wortman-Vayn, H, Knoblauch, RE, Agrawal, T, Baig, M, Ono, A, Sabari, JK (2026).

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

LUNG CANCER. Article. 213.
[doi:10.1016/j.lungcan.2025.108788]
Paz-Ares, LG, O'Byrne, KJ, Johnson, ML, Reck, M, Girard, N, Hayashi, H, Zhou, CC, Gharpure, VS, Pisupati, R, Pacius, M, Ready, NE (2026).

TIGOS Trial: A Randomized, Double-Blind , Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer

Clinical Lung Cancer. Article. 27(2):140-145.
[doi:10.1016/j.clc.2026.01.009]
Bernardo, S, Brunet, L, Thomas, QD, Bracquemond, D, Bouclier, C, Colomb, M, Mancini, M, Fabbrizio, E, Santos, A, Rasamizafy, SF, Maacha, AM, Giry, A, Bousquet-Mur, E, Papon, L, Goussard, M, Fremin, C, Pasquier, A, Rodríguez, M, Travert, C, Pujol, JL, Linares, LK, Heron-Milhavet, L, Djiane, A, Ferrer, I, Paz-Ares, L, Quantin, X, Montuenga, LM, Tourriere, H, Maraver, A (2026).

NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum

EMBO Molecular Medicine. Article. 18(2):514-541.
[doi:10.1038/s44321-025-00354-9]
Rudin, CM, Johnson, ML, Paz-Ares, L, Nishio, M, Hann, CL, Girard, N, Rocha, P, Hayashi, H, Sakai, T, Kim, YJ, Hu, HC, Qian, M, Singh, J, Godard, J, Tang, M, Ahn, MJ (2026).

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 44(4).
[doi:10.1200/JCO-25-02142]
García, LF, Conde, E, Hernandez, S, Alonso, M, Curto, D, Dómine, M, Rojo, F, Freire, J, Gómez-Román, J, Calles, A, Cebollero, M, González-Larriba, JL, Saiz, M, Esteban, I, Gutiérrez, L, Lopez-Rios, F, de Castro, J (2026).

PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significance

Clinical & Translational Oncology. Article. 28(2):484-493.
[doi:10.1007/s12094-025-04013-w]
Reinmuth, N, Couraud, S, Paz-Ares, L, Garassino, MC, Baijal, S, Daniel, D, Garrido, P, Kato, T, Percent, I, Rittmeyer, A, Parra, HS, Mekan, S, Patel, M, Radford, M, Zhang, E, Pelligra, CG, Guo, S, Felip, E (2026).

Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial

JTO Clinical and Research Reports. Article. 7(2).
[doi:10.1016/j.jtocrr.2025.100929]
Navarro, A, Thomas, A, Cheng, V, Chen, V, Reguart, N, Voshida, T, Cousin, S, Dong, X, Vamamoto, N, Cappuzzo, F, Hallwachs, R, Bolleddula, J, Sarholz, B, Grombacher, T, Otte, M, Gounaris, I, Ferrer, J, Moulin, C, Paz-Ares, L (2026).

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)

ESMO Open. Article. 11(1).
[doi:10.1016/j.esmoop.2025.105918]
Hernandez, S, Conde, E, Alonso, M, Curto, D, Duran, F, Ast, A, Torres-Jimenez, J, Bote-de Cabo, H, Zurera, M, Baena, J, Zugazagoitia, J, Garcia-Lujan, R, Isla, D, De Castro, J, Paz-Ares, L, Lopez-Rios, F (2026).

Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study

LUNG CANCER. Article. 211.
[doi:10.1016/j.lungcan.2025.108887]

2025

Ballesteros-González, I, Hernández-Navas, I, Brehey, O, Lechuga, CG, Salmon, M, Scotece, M, Velasco-Vicente, R, Flores-Gomez, AA, Cebriá, A, Simon-Carrasco, L, Jiménez, G, Musteanu, M, Guerra, C, Domínguez, O, Caleiras, E, Blanco-Aparicio, C, Pons, T, Ferrer, I, Paz-Ares, L, Torres-Ruiz, R, Rodríguez-Perales, S, Barbacid, M, Drosten, M (2025).

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

EMBO Molecular Medicine. Article. 17(12):3377-3406.
[doi:10.1038/s44321-025-00326-z]
Isla, D, Conde, E, Romero, A, Garrido, M, Marín, JF, Massuti, B, Abdulkader-Nallib, I, Carreras, MJ, Marina, M, Calderón, JM, Gil-Bazo, I (2025).

Recommendations for diagnosis and management of non-small-cell lung carcinoma patients with ex20ins EGFR mutations: insights from a Delphi consensus

Clinical & Translational Oncology. Article. 27(12):4405-4414.
[doi:10.1007/s12094-025-03971-5]
Reinmuth, N, Goldman, JW, Chen, YB, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, M, Özgüroglu, M, Ji, JH, Garassino, MC, Poltoratskiy, A, Verderame, F, Havel, L, Bondarenko, I, Losonczy, G, Conev, N, Kummer, S, Mann, H, Chugh, P, Dalvi, T, Paz-Ares, L (2025).

Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study

Clinical Lung Cancer. Article. 26(8):626-641.
[doi:10.1016/j.cllc.2025.08.001]
Masini, S, Basa, MA, Calles, A, Cabellos, RA, Echebarria, ID, Puchol, CT, Kareaga, MM, Cabezon-Gutierrez, L, Perez, MCE, Lage, Y, Lorenzo, EG, Navarro, F, Sereno, M, Martínez, SF, García-Benito, C, Pinto, LM, Andrade, CA, Sequero, S, Martinez, JM, Lopez-Martín, A, Martínez, AA, Martín-Soberon, MC, Lucia-Gozalvez, C, Rubio, J, Tallafigo, L, Garrido, A, Peressini, M, Torres-Jimenez, J, Zurera, M, Bote, H, Ponce, S, Paz-Ares, L, Zugazagoitia, J, Baena, J (2025).

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression = 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)

Cancers. Article. 17(22).
[doi:10.3390/cancers17223643]
Isla, D, Zugazagoitia, J, Arriola, E, García-Campelo, R, Blanco, CM, Diz-Taín, MP, Lopez-Brea, M, Moreno-Vega, AL, León-Mateos, L, Oramás, J, Gutiérrez-Calderón, V, Majem, M, Sánchez-Hernández, A, Aguado, C, Alvarez-Cabellos, R, Massutí, B, Moreno, A, Fírvida-Pérez, JL, Valdivia, J, González-Cordero, M, Zafra-Poves, M, Dómine, M, Garcia-Navalon, FJ, Villanueva, N, Provencio, M, Juan-Vidal, O, Rivas-Corredor, C, García, MEO, Palmero, R, López-Castro, R, Carcereny, E, Lechuga, JL, Domínguez, M, Callejo, A, Paz-Ares, L (2025).

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

LUNG CANCER. Article. 209.
[doi:10.1016/j.lungcan.2025.108763]
Ahn, MJ, Lisberg, A, Goto, Y, Sands, J, Hong, MH, Paz-Ares, L, Pons-Tostivint, E, Pérol, M, Felip, E, Sugawara, S, Hayashi, H, Cho, BC, Blumenschein, G Jr, Shum, E, Lee, JS, Heist, RS, Cornelissen, R, Chang, WC, Kowalski, D, Zebger-Gong, H, Chargualaf, M, Gu, W, Lan, L, Howarth, P, Joseph, R, Okamoto, I (2025).

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Journal of Thoracic Oncology. Article. 20(11):1669-1682.
[doi:10.1016/j.jtho.2025.06.002]
Aldea, M, Rotow, JK, Arcila, M, Hatton, M, Sholl, L, Rolfo, C, Tagliamento, M, Radonic, T, Schalper, KA, Subbiah, V, Malapelle, U, Roden, AC, Manochakian, R, Tsao, MS, Linardou, H, Hui, RA, Novello, S, Greystoke, A, Saqi, A, Lantuejoul, S, Hwang, DM, Nevins, K, Wynes, M, Waqar, S, Han, YC, Yatabe, Y, Chang, WC, Hayashi, T, Kim, TJ, Hofman, P, Tavora, F, Hirsch, FR, Denninghoff, V, Leighl, NB, Drilon, A, Cooper, WA, Dacic, S, Mohindra, P, Pavlakis, N, Lopez-Rios, F (2025).

Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology. Article. 20(11):1594-1614.
[doi:10.1016/j.jtho.2025.07.009]
Paz-Ares, LG, Juan-Vidal, O, Mountzios, GS, Felip, E, Reinmuth, N, de Marinis, F, Girard, N, Patel, VM, Takahama, T, Owen, SP, Reznick, DM, Badin, FB, Cicin, I, Mekan, S, Patel, R, Zhang, E, Karumanchi, D, Garassino, MC (2025).

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer

Future Oncology. Editorial Material. 21(25):3245-3257.
[doi:10.1080/14796694.2025.2489339]
Owonikoko, TK, Byers, L, Cheng, Y, Hayashi, H, Paz-Ares, L, Pérol, M, Hu, HC, Qian, M, Garcia, CR, Godard, J, Tang, M, Rudin, CM (2025).

IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer

Future Oncology. Article. 21(25):3275-3282.
[doi:10.1080/14796694.2025.2565995]
Sacher, AG, Miller, WH, Patel, MR, Paz-Ares, L, Santoro, A, Ahn, MJ, Dziadziuszko, R, Freres, P, Luo, J, Bowyer, S, Desai, J, Markman, B, De Miguel, M, Deva, S, Falcon, A, Alonso, G, Guedes, JD, Kim, SH, Krebs, MG, Laurie, SA, Massarelli, E, Medina, L, Prenen, H, Amatu, A, Van Dongen, M, Choi, Y, Hou, XF, Qi, T, Lin, MT, Koli, K, Mayo, MC, Yau, KK, Royer-Joo, S, Chang, J, Jun, T, Dharia, NV, Schutzman, JL, Lorusso, P (2025).

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

JOURNAL OF CLINICAL ONCOLOGY. Article. 43(30).
[doi:10.1200/JCO-25-00040]
Redin, E, Otegui, N, Santos, M, Leon, S, Redrado, M, Serrano, D, de Pierola, EF, Russo-Cabrera, JS, Ferrer, I, Olmedo, M, Diaz-Lagares, A, Houry, M, Vicent, S, Vilalta, A, Mondelo-Macía, P, García-González, J, León-Mateos, L, Gonzalez, A, Paz-Ares, L, López, R, Sanmamed, MF, Montuenga, L, Calvo, A (2025).

Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy

CANCER RESEARCH. Article. 85(20):3910-3929.
[doi:10.1158/0008-5472.CAN-24-2772]
Yang, JCH, Wang, MZ, Doucet, L, Fan, Y, Lv, DQ, Sun, ML, Huang, DZ, Greillier, L, Planchard, D, Hong, QY, Mazieres, J, Felip, E, Li, XY, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Pellini, B, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, RM, Zalcman, G, Carpeno, JD, Di Noia, V, Parra, HS, Streich, G, Lee, DH, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquin, AB, Liu, GF, Antonuzzo, L, Hinojal, GF, Le, XN, Zheng, L, Jänne, PA (2025).

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)

JOURNAL OF CLINICAL ONCOLOGY. Article. 43(29).
[doi:10.1200/JCO-25-00788]
Gazzah, A, Ricordel, C, Italiano, A, Cho, BC, Calvo, E, Kim, DW, Helissey, C, Kim, JS, Villar, MV, Ghiringhelli, F, Moreno, V, Cousin, S, Paz-Ares, L, Fagniez, N, Chadjaa, M, Bauchet, AL, Soufflet, C, Masson, N, Barlesi, F (2025).

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5

JTO Clinical and Research Reports. Article. 6(10).
[doi:10.1016/j.jtocrr.2025.100844]
Seguí, E, Brasó-Maristany, F, Pascual, T, Sanfeliu, E, Victoria, I, Saura, C, Hierro, C, López-González, A, Izarzugaza, Y, Ciruelos, E, Gavilá, J, Racca, F, Cejalvo, JM, Amillano, K, Paz-Ares, L, Juan, M, Felip, E, Garralda, E, González, B, Arance, A, Martín-Liberal, J, Conte, B, Walbaum, B, Indacochea, A, Castillo, O, Blasco, P, Pardo, F, Aguirre, A, Sirenko, V, González, X, Galván, P, Vivancos, A, Ferrero-Cafiero, JM, Mulero-Sánchez, A, Salvador, F, Villacampa, G, Mesía, R, Cervantes, A, Prat, A, Tabernero, J (2025).

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

ESMO Open. Article. 10(10).
[doi:10.1016/j.esmoop.2025.105838]
Peters, S, Regan, MM, Paz-Ares, LG, Reck, M, Borghaei, H, O'Byrne, KJ, Brahmer, JR, Penrod, JR, Li, J, Tracy, L, Yuan, Y, Bushong, J, Lee, A, Eccles, LJ, Ray, S, Ramalingam, SS (2025).

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

Journal of Thoracic Oncology. Article. 20(10):1505-1516.
[doi:10.1016/j.jtho.2025.05.019]
Leighl, NB, Paz-Ares, L, Abreu, DR, Hui, RN, Baka, S, Bigot, F, Nishio, M, Smolin, A, Ahmed, S, Schoenfeld, AJ, Daher, S, Cortinovis, DL, Di Noia, V, Linardou, H, Gainor, JF, Dutcus, C, Okpara, CE, Deng, X, Kush, D, Arunachalam, A, Song, A, Cho, BC (2025).

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy

Journal of Thoracic Oncology. Article. 20(10):1489-1504.
[doi:10.1016/j.jtho.2025.05.020]
de Castro, J, Alonso-Fernández, P, Castrodeza, JJ, Gayete, A, Hernando, F, Martínez-Olmos, J, Massuti, B, Paz-Ares, L, Sisó-Almirall, A, Vicente, D, Molins, L (2025).

Monitoring of the oncological process for lung cancer in Spain: an expert consensus report

Clinical & Translational Oncology. Article. 27(10):3867-3876.
[doi:10.1007/s12094-025-03883-4]
Alvarez-Perez, JC, Sanjuán-Hidalgo, J, Arenas, AM, Hernández-Navas, I, Benitez-Cantos, MS, Andrades, A, Calabuig-Fariñas, S, Jantus-Lewintre, E, Paz-Ares, L, Ferrer, I, Medina, PP (2025).

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

Nature Communications. Article. 16(1).
[doi:10.1038/s41467-025-62350-4]
Falcón, A, Ponce, S, Cote, GM, Gil, A, Lin, JJ, Bockorny, B, Martinez, J, Kahatt, C, Martinez, S, Zubiaur, P, Siguero, M, Cullell-Young, M, Jimenez, J, Zugazagoitia, J, Paz-Ares, L (2025).

Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors

INVESTIGATIONAL NEW DRUGS. Article. 43(4):955-967.
[doi:10.1007/s10637-025-01583-y]
Garassino, MC, Cheng, Y, Rodriguez-Abreu, D, Novello, S, Mazieres, J, Robinson, AG, Powell, SF, Halmos, B, Gray, JE, Wang, MH, Chen, C, Yang, J, Souza, F, Schwarzenberger, P, Paz-Ares, L (2025).

Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer

Oncology and Therapy. Article. 13(3):667-681.
[doi:10.1007/s40487-025-00350-6]
Reck, M, Paz-Ares, LG (2025).

Response to the letter Re: "Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial"

EUROPEAN JOURNAL OF CANCER. Letter. 226.
[doi:10.1016/j.ejca.2025.115610]
Alborelli, I, Demes, M, Wild, P, Hernandez, S, Lopez-Rios, F, Bordone, O, Bontoux, C, Hofman, P, De Luca, C, Troncone, G, Righi, L, Malapelle, U, da Silva, RS, Cirnes, L, Schmitt, F, Keller, E, Jermann, PM, Longshore, J, Bubendorf, L (2025).

ERBB2 Mutation Testing in NSCLC: A Pan-European Real-World Evaluation of the Oncomine Precision Assay

Journal of Molecular Pathology. Article. 6(3).
[doi:10.3390/jmp6030019]
Paulus, A, Zemaitis, M, Cicenas, S, Zvirbule, Z, Sanfridson, A, Millrud, CR, Magnusson, S, Losic, N, Tersago, D, Garcia-Ribas, I, Thorsson, L, Paz-Ares, LG (2025).

Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet

LUNG CANCER. Article. 206.
[doi:10.1016/j.lungcan.2025.108664]
Skoulidis, F, Li, BT, de Langen, AJ, Hong, DS, Lena, H, Wolf, J, Dy, GK, Fontecedro, AC, Tomasini, P, Velcheti, V, van der Wekken, AJ, Dooms, C, Rodriguez, LPA, Mountzios, G, Sacher, A, Nadal, E, Couraud, S, Kim, SW, O'Byrne, K, Rocco, D, Toyozawa, R, Chmielewska, I, Lindsay, CR, Hindoyan, A, Mukundan, L, Wilmanski, T, Anderson, A, Ardito-Abraham, C, Pati, A, Reddy, A, Mehta, B, Schuler, M (2025).

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer

NATURE MEDICINE. Article. 31(8):2755-2767.
[doi:10.1038/s41591-025-03732-5]
Mountzios, G, Sun, LH, Cho, BC, Demirci, U, Baka, S, Gümüs, M, Lugini, A, Zhu, B, Yu, Y, Korantzis, I, Han, JY, Ciuleanu, TE, Ahn, MJ, Rocha, P, Mazières, J, Lau, SCM, Schuler, M, Blackhall, F, Yoshida, T, Owonikoko, TK, Paz-Ares, L, Jiang, T, Hamidi, A, Gauto, D, Recondo, G, Rudin, CM (2025).

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

NEW ENGLAND JOURNAL OF MEDICINE. Article. 393(4):349-361.
[doi:10.1056/NEJMoa2502099]
del Rey-Vergara, R, Galindo-Campos, MA, Rocha, P, Carpes, M, Martínez, C, Masfarré, L, Menéndez, S, Quimis, F, Rossell, A, Iñañez, A, Pérez-Buira, S, Rojo, F, Gimeno, R, Isla, D, Zugazagoitia, J, Blanco, CM, García-Campelo, R, Moreno-Vega, A, León-Mateos, L, Mellén, AC, Park, KS, Heeke, S, Heymach, JV, Taus, A, Paz-Ares, L, Rovira, A, Arriola, E (2025).

MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer

Cell Reports Medicine. Article. 6(7).
[doi:10.1016/j.xcrm.2025.102194]
Cirauqui, C, Ojeda, L, Otano, I, Pazos, I, Santos, A, Garrido-Martín, EM, Yagüe, P, Ramos-Paradas, J, Molina-Pinelo, S, Roncador, G, Solórzano, JL, Muñoz, MT, Cozar, P, Plaza, P, Suárez, R, Jiménez, M, Moreno, R, Rosado, A, Gámez, P, García-Luján, R, Zugazagoitia, J, Sweet-Cordero, EA, Barbacid, M, Carnero, A, Ferrer, I, Paz-Ares, L (2025).

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

Clinical and Translational Medicine. Article. 15(7).
[doi:10.1002/ctm2.70374]
Paz-Ares, L, Borghaei, H, Liu, S, Peters, S, Herbst, RS, Stencel, K, Majem, M, Sendur, MAN, Czyzewicz, G, Caro, RB, Lee, KH, Johnson, ML, Karadurmus, N, Grohé, C, Baka, S, Csoszi, T, Ahn, JS, Califano, R, Yang, TY, Kemal, Y, Ballinger, M, Cuchelkar, V, Graupner, V, Lin, YC, Chakrabarti, D, Bhatt, K, Cai, G, Iannone, R, Reck, M (2025).

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

LANCET. Article. 405(10495).
[doi:10.1016/S0140-6736(25)01011-6]
Carbone, DP, Ciuleanu, TE, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Felip, E, Cheng, Y, Juan-Vidal, O, Alexandru, A, Mizutani, H, Reinmuth, N, Lu, S, Reck, M, John, T, Scherpereel, A, De Marchi, P, Aoyama, T, Sathyanarayana, P, Grootendorst, DJ, Hu, N, Ip, V, Hung, YH, Paz-Ares, LG (2025).

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

ESMO Open. Article. 10(6).
[doi:10.1016/j.esmoop.2025.105123]
Garassino, MC, Khalifa, J, Reck, M, Chouaid, C, Bischoff, H, Reinmuth, N, Cove-Smiths, L, Mansy, T, Cortinovis, DL, Migliorino, MR, Delmonte, A, Sánchez, JG, Velarde, LEC, Bernabe, R, Paz-Ares, L, Chander, P, Perez, ID, Foroutanpour, K, Emeribe, U, Faivre-Finns, C (2025).

Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancerdfinal analysis from the phase II PACIFIC-6 trial

ESMO Open. Article. 10(6).
[doi:10.1016/j.esmoop.2025.105071]
Spira, AI, Paz-Ares, L, Han, JY, Shih, JY, Mascaux, C, Roy, UB, Zugazagoitia, J, Kim, YJ, Chiu, CH, Kim, SW, Nadal, E, Gil-Bazo, I, Murphy, SP, Anderson, BG, Xia, YC, Wang, GR, Bauml, JM, Chioda, M, Simoes, J, Mahadevia, PJ, Lopes, G (2025).

Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report

Journal of Thoracic Oncology. Article. 20(6):809-816.
[doi:10.1016/j.jtho.2025.01.018]
Özgüroglu, M, Goldman, JW, Chen, YB, Garassino, MC, Medic, N, Mann, H, Chugh, P, Dalvi, T, Paz-Ares, L (2025).

Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study

Future Oncology. Article. 21(12):1511-1523.
[doi:10.1080/14796694.2025.2491297]
Paz-Ares, L, Gupta, B, Baena, J, Liu, S (2025).

Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer

Clinical Lung Cancer. Article. 26(3):168-178.
[doi:10.1016/j.cllc.2025.02.015]
Besse, B, Goto, K, Wang, YS, Lee, SH, Marmarelis, ME, Ohe, Y, Bernabe, R, Kim, DW, Lee, JS, Cousin, S, Ichihara, E, Li, YS, Paz-Ares, L, Ono, A, Sanborn, RE, Watanabe, N, de Miguel, MJ, Helissey, C, Shu, CA, Spira, AI, Tomasini, P, Yang, JCH, Zhang, YP, Felip, E, Griesinger, F, Waqar, SN, Calles, A, Neal, JW, Baik, CS, Jaenne, PA, Shreeve, SM, Curtin, JC, Patel, B, Gormley, M, Lyu, X, Chen, J, Chu, PL, Mahoney, J, Trani, L, Bauml, JM, Thayu, M, Knoblauch, RE, Cho, BC (2025).

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

Journal of Thoracic Oncology. Article. 20(5):651-664.
[doi:10.1016/j.jtho.2024.12.029]
Lauer, UM, Awada, A, Postel-Vinay, S, Shapiro, GI, Thieblemont, C, Piha-Paul, SA, Paik, PK, Shepard, DR, Docampo, LI, Galot, R, Rottey, S, Sadrolhefazi, B, Marzin, K, Musa, H, Schöffski, P (2025).

Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma

ESMO Open. Article. 10(5).
[doi:10.1016/j.esmoop.2025.104499]
de Langen, AJ, Johnson, ML, Mazieres, J, Dingemans, AMC, Mountzios, G, Pless, M, Wolf, J, Schuler, M, Lena, H, Skoulidis, F, Yoneshima, Y, Kim, SW, Linardou, H, Novello, S, van der Wekken, AJ, Chen, YB, Peters, S, Felip, E, Solomon, BJ, Ramalingam, SS, Dooms, C, Lindsay, CR, Ferreira, CG, Blais, N, Obiozor, CC, Wang, Y, Mehta, B, Varrieur, T, Ngarmchamnanrith, G, Stollenwerk, B, Waterhouse, D, Paz-Ares, L (2025).

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary

Future Oncology. Editorial Material. 21(9):1033-1044.
[doi:10.1080/14796694.2025.2474789]
Chiang, AC, Garcia, MEO, Carlisle, JW, Dowlati, A, Reguart, N, Felip, E, Jost, PJ, Steeghs, N, Stec, R, Gadgeel, SM, Loong, HH, Jiang, W, Hamidi, A, Parkes, A, Paz-Ares, L (2025).

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

ESMO Open. Article. 10(4).
[doi:10.1016/j.esmoop.2025.104538]
Hummel, HD, Ahn, MJ, Blackhall, F, Reck, M, Akamatsu, H, Ramalingam, SS, Borghaei, H, Johnson, M, Dirnberger, F, Cocks, K, Huang, S, Mukherjee, S, Paz-Ares, L (2025).

Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial

ADVANCES IN THERAPY. Article. 42(4):1950-1964.
[doi:10.1007/s12325-025-03136-4]
Sands, J, Ahn, MJ, Lisberg, A, Cho, BC, Blumenschein, G, Shum, E, Tostivint, EP, Goto, Y, Yoh, K, Heist, R, Shimizu, J, Lee, JS, Baas, P, Planchard, D, Pérol, M, Felip, E, Su, WC, Zebger-Gong, H, Lan, L, Liu, C, Howarth, P, Chiaverelli, R, Paz-Ares, L (2025).

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

JOURNAL OF CLINICAL ONCOLOGY. Article. 43(10).
[doi:10.1200/JCO-24-01349]
Nakagawa, K, Garon, EB, Seto, T, Nishio, M, Aix, SP, Paz-Ares, L, Chiu, CH, Park, K, Novello, S, Nadal, E, Nishino, K, Yoh, K, Shih, JY, Chik, JYK, Moro-Sibilot, D, Puri, T, Varughese, SC, Frimodt-Moller, B, Visseren-Grul, C, Reck, M (2025).

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

Journal of Thoracic Oncology. Article. 20(4):487-499.
[doi:10.1016/j.jtho.2024.11.032]
Chou, TY, Dacic, S, Wistuba, I, Beasley, MB, Berezowska, S, Chang, YC, Chung, JH, Connolly, C, Han, YC, Hirsch, FR, Hwang, DM, Janowczyk, A, Joubert, P, Kerr, KM, Lin, DM, Minami, Y, Mino-Kenudson, M, Nicholson, AG, Papotti, M, Rekhtman, N, Roden, AC, von der Thuesen, JH, Travis, W, Tsao, MS, Yatabe, Y, Yeh, YC, Bubendorf, L, Chang, WC, Denninghoff, V, Tavora, FRF, Hayashi, T, Hofman, P, Jain, D, Kim, TJ, Lantuejoul, S, Le Quesne, J, Lopez-Rios, F, Matsubara, D, Noguchi, M, Radonic, T, Saqi, A, Schalper, K, Shim, HS, Sholl, L, Weissferdt, A, Cooper, WA (2025).

Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee

Journal of Thoracic Oncology. Article. 20(3):311-330.
[doi:10.1016/j.jtho.2024.11.016]
Hofman, P, Christopoulos, P, D'Haene, N, Gosney, J, Normanno, N, Schuuring, E, Tsao, MS, Quinn, C, Russell, J, Keating, KE, López-Rios, F (2025).

Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer

LUNG CANCER. Article. 201.
[doi:10.1016/j.lungcan.2025.108107]
Bote-de Cabo H, Siringo M, Conde E, Hernández S, López-Ríos F, Castelo-Loureiro A, García-Lorenzo E, Baena J, Herrera M, Enguita AB, Ruano Y, Zugazagoitia J, Paz-Ares L (2025).

Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC.

JTO Clinical and Research Reports. Article. 6(3):100778-100778.
[doi:10.1016/j.jtocrr.2024.100778]
Ramos-Guerra, AD, Farina, B, Pérez, JR, Vilalta-Lacarra, A, Zugazagoitia, J, Peces-Barba, G, Seijo, LM, Paz-Ares, L, Gil-Bazo, I, Gómez, MD, Ledesma-Carbayo, MJ (2025).

Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data

CANCER IMMUNOLOGY IMMUNOTHERAPY. Article. 74(4).
[doi:10.1007/s00262-025-03966-9]
Ribrag, V, Iglesias, L, De Braud, F, Ma, B, Yokota, T, Zander, T, Spreafico, A, Subbiah, V, Illert, AL, Tan, D, Santoro, A, Munster, PN, Suehiro, Y, Wang, YS, Ji, DM, Chen, SQ, Beltz, K, Suenaga, N, Ramkumar, T, Luo, FJ, Lai, C, Wainberg, ZA (2025).

A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies

EUROPEAN JOURNAL OF CANCER. Article. 216.
[doi:10.1016/j.ejca.2024.115122]
Ahn, MJ, Tanaka, K, Paz-Ares, L, Cornelissen, R, Girard, N, Pons-Tostivint, E, Baz, DV, Sugawara, S, Cobo, M, Perol, M, Mascaux, C, Poddubskaya, E, Kitazono, S, Hayashi, H, Hong, MH, Felip, E, Hall, R, Juan-Vidal, O, Brungs, D, Lu, S, Garassino, M, Chargualaf, M, Zhang, Y, Howarth, P, Uema, D, Lisberg, A, Sands, J (2025).

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

JOURNAL OF CLINICAL ONCOLOGY. Article. 43(3).
[doi:10.1200/JCO-24-01544]
Spigel, DR, Dowlati, A, Chen, YB, Navarro, A, Yang, JCH, Stojanovic, G, Jove, M, Rich, P, Andric, ZG, Wu, YL, Rudin, CM, Chen, HY, Zhang, L, Yeung, SL, Benzaghou, F, Paz-Ares, L, Bunn, PA (2025).

Reply to P. de Boissieu et al

JOURNAL OF CLINICAL ONCOLOGY. Letter. 43(3).
[doi:10.1200/JCO-24-01374]
Peters, S, Paz-Ares, LG, Reck, M, Carbone, DP, Brahmer, JR, Borghaei, H, Lu, S, O'Byrne, KJ, John, T, Ciuleanu, TE, Schenker, M, Caro, RB, Nishio, M, Cobo, M, Lee, JS, Zurawski, B, Pluzanski, A, Aoyama, T, Tschaika, M, Devas, V, Grootendorst, DJ, Ramalingam, SS (2025).

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Journal of Thoracic Oncology. Article. 20(1):94-108.
[doi:10.1016/j.jtho.2024.09.1439]

2024

Jiménez-Reinoso, A, Molero-Abraham, M, Cirauqui, C, Blanco, B, Garrido-Martin, EM, Nehme-Alvarez, D, Domínguez-Alonso, C, Ramírez-Fernández, A, Díez-Alonso, L, Nuñez-Buiza, A, González-Murillo, A, Tobes, R, Pareja, E, Ramírez-Orellana, M, Rodriguez-Peralto, JL, Ferrer, I, Zugazagoitia, J, Paz-Ares, L, Alvarez-Vallina, L (2024).

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

OncoImmunology. Article. 13(1):2392897-2392897.
[doi:10.1080/2162402X.2024.2392897]
Molina-Pinelo S, Ferrer Sánchez I, Najarro P, Paz-Ares L, Fernández L, Castelló N, Richart López LA, Rodríguez Gambarte JD, Sanz García M, Salinas A, Suárez R, Romero-Romero B, Martín-Juan J, Viñuela ME, Butler RG, de Pedro N (2024).

Telomere-based risk models for the early diagnosis of lung cancer.

Heliyon. Article. 10(24):41040-41040.
[doi:10.1016/j.heliyon.2024.e41040]
Ahn, MJ, Cho, BC, Felip, E, Korantzis, I, Ohashi, K, Majem, M, Juan-Vidal, O, Handzhiev, S, Izumi, H, Lee, JS, Dziadziuszko, R, Wolf, J, Blackhall, F, Reck, M, Alvarez, JB, Hummel, HD, Dingemans, AMC, Sands, J, Akamatsu, H, Owonikoko, TK, Ramalingam, SS, Borghaei, H, Johnson, ML, Huang, S, Mukherjee, S, Minocha, M, Jiang, T, Martinez, P, Anderson, ES, Paz-Ares, L (2024).

Plain language summary: tarlatamab for patients with previously treated small cell lung cancer

Future Oncology. Article. 20(40):3355-3364.
[doi:10.1080/14796694.2024.2402152]
Passiglia F, Listì A, Bironzo P, Merlini A, Benso F, Napoli F, Barbu FA, Zambelli V, Tabbò F, Reale ML, Sini C, Roca E, Taveggia PA, Simionato F, Buffoni L, Mazilu L, Barbieri V, Pignataro D, Araujo A, Paz-Ares L, Felip E, Secen N, Comanescu A, Ramizi KM, Bettini AC, Scotti V, Linardou H, Mohorcic K, Meoni G, Giannarelli D, Volante M, Malapelle U, Vallone S, Scagliotti G, Righi L, Novello S (2024).

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

Journal of Thoracic Oncology. Article. 20(5):614-624.
[doi:10.1016/j.jtho.2024.12.010]
Sternberg, CN, Loriot, Y, Choy, E, Castellano, D, Lopez-Rios, F, Banna, GL, Zengerling, F, De Giorgi, U, Gedye, C, Masini, C, Bamias, A, del Muro, XG, Duran, I, Powles, T, Retz, M, Gamulin, M, Geczi, L, Huddart, RA, Calabrò, F, Kandula, G, Skamnioti, P, Merseburger, AS (2024).

Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma

European Urology Focus. Article. 10(6):938-946.
[doi:10.1016/j.euf.2024.05.007]
Meyer ML, Peters S, Mok TS, Lam S, Yang PC, Aggarwal C, Brahmer J, Dziadziuszko R, Felip E, Ferris A, Forde PM, Gray J, Gros L, Halmos B, Herbst R, Jänne PA, Johnson BE, Kelly K, Leighl NB, Liu S, Lowy I, Marron TU, Paz-Ares L, Rizvi N, Rudin CM, Shum E, Stahel R, Trunova N, Bunn PA, Hirsch FR (2024).

Lung cancer research and treatment: global perspectives and strategic calls to action.

ANNALS OF ONCOLOGY. Article. 35(12):1088-1104.
[doi:10.1016/j.annonc.2024.10.006]
Reck, M, Ciuleanu, TE, Schenker, M, Bordenave, S, Cobo, M, Juan-Vidal, O, Reinmuth, N, Richardet, E, Felip, E, Menezes, J, Cheng, Y, Mizutani, H, Zurawski, B, Alexandru, A, Carbone, DP, Lu, S, John, T, Aoyama, T, Grootendorst, DJ, Hu, N, Eccles, LJ, Paz-Ares, LG (2024).

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

EUROPEAN JOURNAL OF CANCER. Article. 211:114296-114296.
[doi:10.1016/j.ejca.2024.114296]
Facchinetti, F, Loriot, Y, Brayé, F, Vasseur, D, Bahleda, R, Bigot, L, Barbé, R, Nobre, C, Combarel, D, Michiels, S, Italiano, A, Smolenschi, C, Tselikas, L, Scoazec, JY, Ponce-Aix, S, Besse, B, André, F, Olaussen, KA, Hollebecque, A, Friboulet, L (2024).

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

CLINICAL CANCER RESEARCH. Article. 30(21):4943-4956.
[doi:10.1158/1078-0432.CCR-24-1834]
Alonso-Gordoa, T, Jimenez-Fonseca, P, Martinez-Trufero, J, Navarro, M, Porras, I, Rubió-Casadevall, J, Valles, MA, Basté, N, Hernando, J, Docampo, LI (2024).

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

Clinical & Translational Oncology. Article. 26(11):2902-2916.
[doi:10.1007/s12094-024-03736-6]
Reck, M, De, TL, Paz-Ares, L, Edmondson-Jones, M, Yuan, Y, Yates, G, Zoffoli, R, Chaudhary, MA, Lee, AD, Varol, N, Penrod, JR (2024).

Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer

Clinical Lung Cancer. Article. 25(7):362-368.
[doi:10.1016/j.clc.2024.06.005]
Molero, A, Hernandez, S, Alonso, M, Peressini, M, Curto, D, Lopez-Rios, F, Conde, E (2024).

Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms

JOURNAL OF CLINICAL PATHOLOGY. Article. 78:456-464.
[doi:10.1136/jcp-2024-209766]
Carretero-Barrio, I, Pijuan, L, Illarramendi, A, Curto, D, López-Ríos, F, Estébanez-Gallo, A, Castellvi, J, Granados-Aparici, S, Compañ-Quilis, D, Noguera, R, Esteban-Rodríguez, I, Sánchez-Güerri, I, Ramos-Guerra, AD, Ortuño, JE, Garrido, P, Ledesma-Carbayo, MJ, Benito, A, Palacios, J (2024).

Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

SCIENTIFIC REPORTS. Article. 14(1):24163-24163.
[doi:10.1038/s41598-024-75175-w]
Dowlati, A, Hummel, HD, Champiat, S, Olmedo, ME, Boyer, M, He, K, Steeghs, N, Izumi, H, Johnson, ML, Yoshida, T, Bouchaab, H, Borghaei, H, Felip, E, Jost, PJ, Gadgeel, S, Chen, X, Yu, YF, Martinez, P, Parkes, A, Paz-Ares, L (2024).

Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(29):3392-3399.
[doi:10.1200/JCO.24.00553]
Felip, E, Metro, G, Soo, RA, Wolf, J, Solomon, BJ, Tan, DSW, Ardizzoni, A, Lee, DH, Sequist, LV, Barlesi, F, Ponce-Aix, S, Abreu, DR, Campelo, MRG, Sprauten, M, Djentuh, LO, Smith, N, Jary, A, Belli, R, Glaser, S, Zou, MK, Cui, XM, Giovannini, M, Yang, JCH (2024).

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer

EUROPEAN JOURNAL OF CANCER. Article. 208:114182-114182.
[doi:10.1016/j.ejca.2024.114182]
Felip, E, Cho, BC, Gutiérrez,, Alip, A, Besse, B, Lu, S, Spira, AI, Girard, N, Califano, R, Gadgeel, SM, Yang, JCH, Yamamoto, S, Azuma, K, Kim, YJ, Lee, KH, Danchaivijitr, P, Ferreira, CG, Cheng, Y, Sendur, MAN, Chang, GC, Wang, CC, Prabhash, K, Shinno, Y, Stroyakovskiy, D, Paz-Ares, L, Rodriguez-Cid, JR, Martin, C, Campelo, MRG, Hayashi, H, Nguyen, D, Tomasini, P, Gottfried, M, Dooms, C, Passaro, A, Schuler, M, Gelatti, ACZ, Owen, S, Perdrizet, K, Ou, SHI, Curtin, JC, Zhang, J, Gormley, M, Sun, T, Panchal, A, Ennis, M, Fennema, E, Bauml, JM, Daksh, M, Sethi, S, Lee, SH (2024).

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

ANNALS OF ONCOLOGY. Article. 35(9):805-816.
[doi:10.1016/j.annonc.2024.05.541]
Sánchez-Ortega M, Garrido A, Cirauqui C, Sanz-Gonzalez L, Hernández MC, González-García A, Obregon K, Ferrer I, Paz-Ares L, Carrera AC (2024).

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.

Redox Biology. Article. 75:103305-103305.
[doi:10.1016/j.redox.2024.103305]
Meyer, ML, Fitzgerald, BG, Paz-Ares, L, Cappuzzo, F, Jaenne, PA, Peters, S, Hirsch, FR (2024).

New promises and challenges in the treatment of advanced non-small-cell lung cancer

LANCET. Review. 404(10454):803-822.
[doi:10.1016/S0140-6736(24)01029-8]
Paz-Ares, LG, Juan-Vidal, O, Mountzios, GS, Felip, E, Reinmuth, N, de Marinis, F, Girard, N, Patel, VM, Takahama, T, Owen, SP, Reznick, DM, Badin, FB, Cicin, I, Mekan, S, Patel, R, Zhang, ER, Karumanchi, D, Garassino, MC (2024).

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(24):2860-2872.
[doi:10.1200/JCO.24.00733]
Paz-Ares, L, Mehta, B, Wang, Y, Waterhouse, D, Langen, AJD (2024).

Sotorasib versus docetaxel: evidence supporting CodeBreaK 200

LANCET ONCOLOGY. Letter. 25(8):334-334.
[doi:10.1016/S1470-2045(24)00388-7]
Provencio, M, de Lope, LR, Serna-Blasco, R, Nadal, E, Tain, PD, Massuti, B, González-Larriba, JL, Insa, A, Sánchez-Hernández, A, Casal-Rubio, J, Garcia-Campelo, R, López, SS, Rogado, J, Martínez-Martí, A, Bosch-Barrera, J, Bernabé, R, Estévez, SV, Ponce, S, de Castro, J, Sarto, JC, Reguart, N, Dómine, M, Aguilar, A, Majem, M, Estival, A, Cabia, SP, Martín, AL, González, MAS, Cobo, M, Camps, C, Barneto, I, Calvo, V, Collazo-Lorduy, A, Cruz-Bermúdez, A, Romero, A (2024).

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

LUNG CANCER. Article. 194:107865-107865.
[doi:10.1016/j.lungcan.2024.107865]
Luke, JJ, Long, GV, Robert, C, Carlino, MS, Choueiri, TK, Haas, NB, O'Brien, M, Paz-Ares, L, Peters, S, Powles, T, Leiby, MA, Lin, JX, Zhao, YJ, Krepler, C, Perini, RF, Pietanza, MC, Samkari, A, Gruber, T, Ibrahim, N, Eggermont, AMM (2024).

Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non - small cell lung cancer, and renal cell carcinoma

EUROPEAN JOURNAL OF CANCER. Article. 207:114146-114146.
[doi:10.1016/j.ejca.2024.114146]
Gadgeel, SM, Rodríguez-Abreu, D, Halmos, B, Garassino, MC, Kurata, T, Cheng, Y, Jensen, E, Shamoun, M, Rajagopalan, K, Paz-Ares, L (2024).

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

Journal of Thoracic Oncology. Article. 19(8):1228-1241.
[doi:10.1016/j.jtho.2024.04.011]
Tokito, T, Kolesnik, O, Sorensen, J, Artac, M, Quintela, ML, Lee, JS, Hussein, M, Pless, M, Paz-Ares, L, Leopold, L, Daniel, J, Munteanu, M, Samkari, A, Xu, L, Butts, C (2024).

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

BMC CANCER. Article. 23(SUPPL 1):1251-1251.
[doi:10.1186/s12885-023-11203-8]
Zugazagoitia, J, Osma, H, Baena, J, Ucero, AC, Paz-Ares, L (2024).

Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer

CLINICAL CANCER RESEARCH. Review. 30(14):2872-2883.
[doi:10.1158/1078-0432.CCR-23-1159]
Peressini, M, Garcia-Campelo, R, Massuti, B, Marti, C, Cobo, M, Gutiérrez, V, Dómine, M, Fuentes, J, Majem, M, de Castro, J, Córdoba, JF, Diz, MP, Isla, D, Esteban, E, Carcereny, E, Vila, L, Moreno-Vega, A, Ros, S, Moreno, A, García, FJ, Huidobro, G, Aguado, C, Cebey-López, V, Valdivia, J, Palmero, R, Lianes, P, López-Brea, M, Vidal, OJ, Provencio, M, Arriola, E, Baena, J, Herrera, M, Bote, H, Molero, M, Adradas, V, Ponce-Aix, S, Nuñez-Buiza, A, Ucero, A, Hernandez, S, Lopez-Rios, F, Conde, E, Paz-Ares, L, Zugazagoitia, J (2024).

Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

CLINICAL CANCER RESEARCH. Article. 30(14):3036-3049.
[doi:10.1158/1078-0432.CCR-24-0104]
Spigel, DR, Dowlati, A, Chen, YB, Navarro, A, Yang, JCH, Stojanovic, G, Jove, M, Rich, P, Andric, ZG, Wu, YL, Rudin, CM, Chen, HY, Zhang, L, Yeung, SL, Benzaghou, F, Paz-Ares, L, Bunn, PA (2024).

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(19):2317-2326.
[doi:10.1200/JCO.23.02110]
Sholl, LM, Awad, M, Roy, UB, Beasley, MB, Cartun, RW, Hwang, DM, Kalemkerian, G, Lopez-Rios, F, Mino-Kenudson, M, Paintal, A, Reid, K, Ritterhouse, L, Souter, LA, Swanson, PE, Ventura, CB, Furtado, LV (2024).

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. Article. 148(7):757-774.
[doi:10.5858/arpa.2023-0536-CP]
Figarol, S, Delahaye, C, Gence, R, Doussine, A, Cerapio, JP, Brachais, M, Tardy, C, Béry, N, Asslan, R, Colinge, J, Villemin, JP, Maraver, A, Ferrer, I, Paz-Ares, L, Kessler, L, Burrows, F, Lajoie-Mazenc, I, Dongay, V, Morin, C, Florent, A, Pagano, S, Taranchon-Clermont, E, Casanova, A, Pradines, A, Mazieres, J, Favre, G, Calvayrac, O (2024).

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies

Nature Communications. Article. 15(1):5345-5345.
[doi:10.1038/s41467-024-49360-4]
Repetto, M, Garassino, MC, Loong, HH, Lopez-Rios, F, Mok, T, Peters, S, Planchard, D, Popat, S, Rudzinski, ER, Drilon, A, Zhou, CC (2024).

NTRK gene fusion testing and management in lung cancer

CANCER TREATMENT REVIEWS. Review. 127:102733-102733.
[doi:10.1016/j.ctrv.2024.102733]
Wheatley, DA, Berardi, R, Duran, MAC, Tomiak, A, Greystoke, AP, Joshua, AM, Arkenau, HT, Geczi, L, Corbacho, JG, Paz-Ares, LG, Hussain, SA, Petruzelka, L, Delmonte, A, Chappey, C, Masters, JC, Michelon, E, Murphy, DA, Mwewa, S, Cesari, R, de Speville, BD (2024).

First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Cancer Research Communications. Article. 4(6):1609-1619.
[doi:10.1158/2767-9764.CRC-23-0459]
Xie, MC, Vuko, M, Rodriguez-Canales, J, Zimmermann, J, Schick, M, O'Brien, C, Paz-Ares, L, Goldman, JW, Garassino, MC, Gay, CM, Heymach, JV, Jiang, HY, Barrett, JC, Stewart, RA, Lai, ZW, Byers, LA, Rudin, CM, Shrestha, Y (2024).

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Molecular Cancer. Article. 23(1):115-115.
[doi:10.1186/s12943-024-02014-x]
Segal, NH, Melero, I, Moreno, V, Steeghs, N, Marabelle, A, Rohrberg, K, Rodriguez-Ruiz, ME, Eder, JP, Eng, C, Manji, GA, Waterkamp, D, Leutgeb, B, Bouseida, S, Flinn, N, Das Thakur, M, Elze, MC, Koeppen, H, Jamois, C, Martin-Facklam, M, Lieu, CH, Calvo, E, Paz-Ares, L, Tabernero, J, Argiles, G (2024).

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Nature Communications. Article. 15(1):4091-4091.
[doi:10.1038/s41467-024-48479-8]
Hernández, JJC, Arrula, VA, Alvarez, YE, Castaño, AG, de Castro, JJG, Docampo, LI, Sorrosal, JL, Segura, PP, Domínguez, AR, Campos-Lucas, FJ, Rodríguez, IS, Bessa, M, Gratal, P, Caballero-Martínez, F, Martín, DM, Antón-Rodríguez, C, López, R (2024).

Indicators to evaluate quality of care in head and neck cancer in Spain

Clinical & Translational Oncology. Article. 26(5):1089-1097.
[doi:10.1007/s12094-023-03298-z]
Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

DRUGS. Review. 84(5):527-548.
[doi:10.1007/s40265-024-02030-7]
Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Apr, 10.1007/s40265-024-02030-7, 2024)

DRUGS. Correction. 84(5):621-621.
[doi:10.1007/s40265-024-02044-1]
Riudavets, M, Auclin, E, Mosteiro, M, Dempsey, N, Majem, M, Prelaj, A, López-Castro, R, Bosch-Barrera, J, Pilotto, S, Escalera, E, Tagliamento, M, Mosquera, J, Zalcman, G, Nana, FA, Ponce, S, Albarrán-Artahona, V, Dal Maso, A, Spotti, M, Mielgo, X, Mussat, E, Reyes, R, Benítez, JC, Lupinacci, L, Duchemann, B, De Giglio, A, Blaquier, JB, Audigier-Valette, C, Scheffler, M, Nadal, E, Lopes, G, Signorelli, D, Garcia-Campelo, R, Menis, J, Bluthgen, V, Campayo, M, Recondo, G, Besse, B, Mezquita, L, Planchard, D (2024).

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer

Clinical Lung Cancer. Article. 25(3).
[doi:10.1016/j.cllc.2023.11.007]
Remon, J, Besse, B, Aix, SP, Callejo, A, Al-Rabi, K, Bernabe, R, Greillier, L, Majem, M, Reguart, N, Monnet, I, Cousin, S, Garrido, P, Robinet, G, Campelo, RG, Madroszyk, A, Mazieres, J, Curcio, H, Wasag, B, Pretzenbacher, Y, Grillet, F, Dingemans, AMC, Dziadziuszko, R (2024).

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(12):1350-1356.
[doi:10.1200/JCO.23.01521]
Conde, E, Hernandez, S, Carrillo, JLR, Martinez, R, Alonso, M, Curto, D, Jimenez, B, Caminoa, A, Benito, A, Garrido, P, Clave, S, Arriola, E, Esteban-Rodriguez, I, De Castro, J, Sansano, I, Felip, E, Rojo, F, Dómine, M, Abdulkader, I, Garcia-Gonzalez, J, Teixido, C, Reguart, N, Compañ, D, Insa, A, Mancheño, N, Palanca, S, Juan-Vidal, O, Baixeras, N, Nadal, E, Cebollero, M, Calles, A, Martin, P, Salas, C, Provencio, M, Aranda, I, Massuti, B, Lopez-Vilaro, L, Majem, M, Paz-Ares, L, Lopez-Rios, F (2024).

RET Fusion Testing in Patients With NSCLC: The RETING Study

JTO Clinical and Research Reports. Article. 5(4):100653-100653.
[doi:10.1016/j.jtocrr.2024.100653]
Smit, EF, Felip, E, Uprety, D, Nagasaka, M, Nakagawa, K, Rodríguez, LPA, Pacheco, JM, Li, BT, Planchard, D, Baik, C, Goto, Y, Murakami, H, Saltos, A, Pereira, K, Taguchi, A, Cheng, YK, Yan, Q, Feng, WQ, Tsuchihashi, Z, Jänne, PA (2024).

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

LANCET ONCOLOGY. Article. 25(4):439-454.
[doi:10.1016/S1470-2045(24)00064-0]
Bar, J, Esteban, E, Rodríguez-Abreu, D, Aix, SP, Szalai, Z, Felip, E, Gottfried, M, Provencio, M, Robinson, A, Fülöp, A, Rao, SB, Camidge, DR, Speranza, G, Townson, SM, Kobie, J, Ayers, M, Dettman, EJ, Hunkapiller, N, Mcdaniel, R, Jung, BYS, Burkhardt, D, Mauntz, R, Csoszi, T (2024).

Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782

LUNG CANCER. Article. 190:107506-107506.
[doi:10.1016/j.lungcan.2024.107506]
Mestre-Ferrándiz, J, Camino, BF, Hidalgo, A, Núñez-Cortés, AD, Señaris, JED, Lumbreras, B, Pedraza, DB, Nuño-Solinís, R, Paz-Ares, L, Cajal, SRY, Rodríguez, MJ (2024).

Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain

Clinical & Translational Oncology. Article. 26(4):985-990.
[doi:10.1007/s12094-023-03338-8]
Jager, VDD, Timens, W, Bayle, A, Botling, J, Brcic, L, Büttner, R, Fernandes, MGO, Havel, L, Hochmair, MJ, Hofman, P, Janssens, A, Johansson, M, van Kempen, L, Kern, I, Lopez-Rios, F, Lüchtenborg, M, Machado, JC, Mohorcic, K, Paz-Ares, L, Popat, S, Ryska, A, Taniere, P, Wolf, J, Schuuring, E, van der Wekkenz, AJ (2024).

Advancements in Non-Small Cell Lung Cancer Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

Lancet Regional Health-Europe. Article. 38.
[doi:10.1016/j.lanepe.2024.100838]
-Ares, LP, Goto, Y, Lim, DWT, Halmos, B, Cho, BC, Cobo, M, Larriba, JLG, Zhou, CC, Demedts, I, Atmaca, A, Baka, S, Mookerjee, B, Portella, S, Zhu, ZW, Wu, JC, Demanse, D, Dharan, B, Reck, M (2024).

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

LUNG CANCER. Article. 189:107451-107451.
[doi:10.1016/j.lungcan.2023.107451]
Hernandez, S, Conde, E, Molero, A, Suarez-Gauthier, A, Martinez, R, Alonso, M, Plaza, C, Camacho, C, Chantada, D, Juaneda-Magdalena, L, Garcia-Toro, E, Saiz-Lopez, P, Rojo, F, Abad, M, Boni, V, del Carmen, S, Regojo, RM, Sanchez-Frias, ME, Teixido, C, Paz-Ares, L, Lopez-Rios, F (2024).

Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. Article. 148(3):318-326.
[doi:10.5858/arpa.2022-0443-OA]
Paz-Ares, L, Garassino, MC, Chen, YB, Reinmuth, N, Hotta, K, Poltoratskiy, A, Trukhin, D, Hochmair, MJ, Özgüroglu, M, Ji, JH, Statsenko, G, Conev, N, Bondarenko, I, Havel, L, Losonczy, G, Xie, MC, Lai, ZW, Godin-Heymann, N, Mann, H, Jiang, HY, Shrestha, Y, Goldman, JW (2024).

Durvalumab ± Tremelimumab plus Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

CLINICAL CANCER RESEARCH. Article. 30(4):824-835.
[doi:10.1158/1078-0432.CCR-23-1689]
Viñolas, N, Mezquita, L, Corral, J, Cobo, M, Gil-Moncayo, F, Paz-Ares, L, Remon, J, Rodríguez, M, Ruano-Raviña, A, Conde, E, Majem, M, Garrido, P, Felip, E, Isla, D, de Castro, J (2024).

The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

Clinical & Translational Oncology. Article. 26(2):352-362.
[doi:10.1007/s12094-023-03262-x]
Peters, S, Trigo, J, Besse, B, Moreno, V, Navarro, A, Olmedo, ME, Paz-Ares, L, Grohe, C, Lopez-Vilariño, JA, Fernández, C, Kahatt, C, Alfaro, V, Nieto, A, Zeaiter, A, Subbiah, V (2024).

Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases

LUNG CANCER. Article. 188:107448-107448.
[doi:10.1016/j.lungcan.2023.107448]
Vokes, EE, Mornex, F, Sezer, A, Cheng, Y, Fang, J, Baz, DV, Cil, T, Adjei, AA, Ahn, MJ, Barlesi, F, Felip, E, Garon, EB, Audhuy, F, Ito, R, Sato, M, Eggleton, SP, Martin, CM, Reck, M, Robinson, CG, Paz-Ares, L (2024).

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Journal of Thoracic Oncology. Article. 19(2):285-296.
[doi:10.1016/j.jtho.2023.09.1452]
Carbone, DP, Ciuleanu, TE, Schenker, M, Cobo, M, Bordenave, S, Juan-Vidal, O, Menezes, J, Reinmuth, N, Richardet, E, Cheng, Y, Mizutani, H, Felip, E, Zurawski, B, Alexandru, A, Paz-Ares, L, Lu, S, John, T, Zhang, XQ, Mahmood, J, Hu, N, De, TL, Santi, I, Penrod, JR, Yuan, Y, Lee, A, Reck, M (2024).

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Journal for ImmunoTherapy of Cancer. Article. 12(2).
[doi:10.1136/jitc-2023-008189]
Paz-Ares, L, Mehta, B, Wang, Y, Obiozor, C, Waterhouse, D, de Langen, AJ (2024).

Sotorasib in KRASG12C mutated lung cancer - Authors' reply

LANCET. Letter. 403(10422):145-146.
[doi:10.1016/S0140-6736(23)02036-6]
Tan, DSW, Felip, E, de Castro, G, Solomon, BJ, Greystoke, A, Cho, BC, Cobo, M, Kim, TM, Ganguly, S, Carcereny, E, Paz-Ares, L, Bennouna, J, Garassino, MC, Schenker, M, Kim, SW, Brase, JC, Bury-Maynard, D, Passos, VQ, Deudon, S, Dharan, B, Song, YB, Caparica, R, Johnson, BE (2024).

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(2):192-204.
[doi:10.1200/JCO.23.00980]
Garon, EB, Lu, S, Goto, Y, De Marchi, P, Paz-Ares, L, Spigel, DR, Thomas, M, Yang, JCH, Ardizzoni, A, Barlesi, F, Orlov, S, Yoshioka, H, Mountzios, G, Khanna, S, Bossen, C, Carbini, M, Turri, S, Myers, A, Cho, BC (2024).

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(2):180-191.
[doi:10.1200/JCO.23.00910]
Gridelli, C, Peters, S, Mok, T, Garassino, M, Paz-Ares, L, Attili, I, de Marinis, F (2024).

Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)

LUNG CANCER. Article. 187:107441-107441.
[doi:10.1016/j.lungcan.2023.107441]
Li, DE, Loriot, Y, Burgoyne, AM, Cleary, JM, Santoro, A, Lin, DN, Aix, SP, Garrido-Laguna, I, Sudhagoni, R, Guo, X, Andrianova, S, Paulson, S (2024).

Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)

EClinicalMedicine. Article. 67:102376-102376.
[doi:10.1016/j.eclinm.2023.102376]

2023

Arroyo-Andrés, J, Agud-Dios, M, Rubio-Muniz, CA, Postigo, C, Cortijo-Cascajares, S, Ortiz-Romero, PL (2023).

Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series

INTERNATIONAL JOURNAL OF DERMATOLOGY. Letter. 63(2):57-59.
[doi:10.1111/ijd.16979]
Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Jänne PA (2023).

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(35):5363-5375.
[doi:10.1200/JCO.23.01476]
Desai, J, Alonso, G, Kim, SH, Cervantes, A, Karasic, T, Medina, L, Shacham-Shmueli, E, Cosman, R, Falcon, A, Gort, E, Guren, T, Massarelli, E, Miller, WH, Paz-Ares, L, Prenen, H, Amatu, A, Cremolini, C, Kim, TW, Moreno, V, Ou, SH, Passardi, A, Sacher, A, Santoro, A, Stec, R, Ulahannan, S, Arbour, K, Lorusso, P, Luo, J, Patel, MR, Choi, Y, Shi, Z, Mandlekar, S, Lin, MT, Royer-Joo, S, Chang, J, Jun, T, Dharia, N, Schutzman, JL, Han, SW (2023).

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

NATURE MEDICINE. Article. 30(1):271.
[doi:10.1038/s41591-023-02696-8]
Borghaeit, H, O'Byrnet, KJ, Paz-Ares, L, Ciuleanu, TE, Yu, X, Pluzanski, A, Nagrial, A, Havel, L, Kowalyszyn, RD, Valette, CA, Brahmer, JR, Reck, M, Ramalingam, SS, Zhang, L, Ntambwe, I, Rabindran, SK, Nathan, FE, Balli, D, Wu, YL (2023).

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

ESMO Open. Article. 8(6).
[doi:10.1016/j.esmoop.2023.102065]
Conde, E, Hernandez, S, Alonso, M, Lopez-Rios, F (2023).

Pan-TRK Immunohistochemistry to Optimize the Detection of NTRK Fusions: Removing the Hay When Looking for the Needle

MODERN PATHOLOGY. Editorial Material. 36(12).
[doi:10.1016/j.modpat.2023.100346]
Cho, BC, Lee, JS, Wu, YL, Cicin, I, Dols, MC, Ahn, MJ, Cuppens, K, Veillon, R, Nadal, E, Dias, JM, Martin, C, Reck, M, Garon, EB, Felip, E, Paz-Ares, L, Mornex, F, Vokes, EE, Adjei, AA, Robinson, C, Sato, M, Vugmeyster, Y, Machl, A, Audhuy, F, Chaudhary, S, Barlesi, F (2023).

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Journal of Thoracic Oncology. Article. 18(12):1731-1742.
[doi:10.1016/j.jtho.2023.08.018]
Le, XN, Paz-Ares, LG, Van Meerbeeck, J, Viteri, S, Galvez, CC, Smit, EF, Garassino, M, Veillon, R, Baz, DV, Pradera, JF, Sereno, M, Kozuki, T, Kim, YC, Yoo, SS, Han, JY, Kang, JH, Son, CH, Choi, YJ, Stroh, C, Juraeva, D, Vioix, H, Bruns, R, Otto, G, Johne, A, Paik, PK (2023).

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

Cell Reports Medicine. Article. 4(11).
[doi:10.1016/j.xcrm.2023.101280]
Siringo M, Baena J, Bote de Cabo H, Torres-Jiménez J, Zurera M, Zugazagoitia J, Paz-Ares L (2023).

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer.

Cancers. Review. 15(23).
[doi:10.3390/cancers15235505]
Kerr, KM, Bubendorf, L, Lopez-Rios, F, Khalil, F, Roy-Chowdhuri, S, Joubert, P, Hartmann, A, Guerini-Rocco, E, Yatabe, Y, Hofman, P, Cooper, WA, Dacic, S (2023).

Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists

HISTOPATHOLOGY. Review. 84(3):429-439.
[doi:10.1111/his.15078]
Griesinger, F, Curigliano, G, Subbiah, V, Baik, CS, Tan, DSW, Lee, DH, Misch, D, Garralda, E, Kim, DW, van der Wekken, AJ, Gainor, JF, Paz-Ares, L, Liu, S, Kalemkerian, GP, Bowles, DW, Mansfield, AS, Lin, JJ, Smoljanovic, V, Rahman, A, Zalutskaya, A, Louie-Gao, M, Boral, AL, Mazières, J (2023).

Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study

Future Oncology. Article. 20(6):297-306.
[doi:10.2217/fon-2023-0155]
Zhou, CC, Tang, KJ, Cho, BC, Liu, BG, Paz-Ares, L, Cheng, SSN, Kitazono, S, Thiagarajan, M, Goldman, JW, Sabari, JK, Sanborn, RE, Mansfield, AS, Hung, JY, Boyer, M, Popat, S, Dias, JM, Felip, E, Majem, M, Gumus, M, Kim, SW, Ono, A, Xie, JH, Bhattacharya, A, Agrawal, T, Shreeve, SM, Knoblauch, RE, Park, K, Girard, N, PAPILLON Investigators (2023).

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

NEW ENGLAND JOURNAL OF MEDICINE. Article. 389(22):2039-2051.
[doi:10.1056/NEJMoa2306441]
Ahn, MJ, Cho, BC, Felip, E, Korantzis, I, Ohashi, K, Majem, M, Juan-Vidal, O, Handzhiev, S, Izumi, H, Lee, JS, Dziadziuszko, R, Wolf, J, Blackhall, F, Reck, M, Alvarez, JB, Hummel, HD, Dingemans, AMC, Sands, J, Akamatsu, H, Owonikoko, TK, Ramalingam, SS, Borghaei, H, Johnson, ML, Huang, S, Mukherjee, S, Minocha, M, Jiang, TY, Martinez, P, Anderson, ES, Paz-Ares, L (2023).

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 389(22):2063-2075.
[doi:10.1056/NEJMoa2307980]
Macaya, I, Roman, M, Welch, C, Entrialgo-Cadierno, R, Salmon, M, Santos, A, Feliu, I, Kovalski, J, Lopez, I, Rodriguez-Remirez, M, Palomino-Echeverria, S, Lonfgren, SM, Ferrero, M, Calabuig, S, Ludwig, IA, Lara-Astiaso, D, Jantus-Lewintre, E, Guruceaga, E, Narayanan, S, Ponz-Sarvise, M, Pineda-Lucena, A, Lecanda, F, Ruggero, D, Khatri, P, Santamaria, E, Fernandez-Irigoyen, J, Ferrer, I, Paz-Ares, L, Drosten, M, Barbacid, M, Gil-Bazo, I, Vicent, S (2023).

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Nature Communications. Article. 14(1).
[doi:10.1038/s41467-023-41828-z]
Hofman, P, Calabrese, F, Kern, I, Adam, J, Alarcao, A, Alborelli, I, Anton, NT, Arndt, A, Avdalyan, A, Barberis, M, Bégueret, H, Bisig, B, Blons, H, Boström, P, Brcic, L, Bubanovic, G, Buisson, A, Caliò, A, Cannone, M, Carvalho, L, Caumont, C, Cayre, A, Chalabreysse, L, Chenard, MP, Conde, E, Copin, MC, Côté, JF, D'Haene, N, Dai, HY, de Leval, L, Delongova, P, Dencic-Fekete, M, Fabre, A, Ferenc, F, Forest, F, de Fraipont, F, Garcia-Martos, M, Gauchotte, G, Geraghty, R, Guerin, E, Guerrero, D, Hernandez, S, Hurník, P, Jean-Jacques, B, Kashofer, K, Kazdal, D, Lantuejoul, S, Leonce, C, Lupo, A, Malapelle, U, Matej, R, Merlin, JL, Mertz, KD, Morel, A, Mutka, A, Normanno, N, Ovidiu, P, Panizo, A, Papotti, MG, Parobkova, E, Pasello, G, Pauwels, P, Pelosi, G, Penault-Llorca, F, Picot, T, Piton, N, Pittaro, A, Planchard, G, Pote, N, Radonic, T, Rapa, I, Rappa, A, Roma, C, Rot, M, Sabourin, JC, Salmon, I, Prince, SS, Scarpa, A, Schuuring, E, Serre, I, Siozopoulou, V, Sizaret, D, Smojver-Jezek, S, Solassol, J, Steinestel, K, Stojsic, J, Syrykh, C, Timofeev, S, Troncone, G, Uguen, A, Valmary-Degano, S, Vigier, A, Volante, M, Wahl, SGF, Stenzinger, A, Ilié, M (2023).

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe

ESMO Open. Article. 8(5).
[doi:10.1016/j.esmoop.2023.101628]
Ramos, AS, Sánchez, DG, Expósito, PP, Paz-Ares, L, Sánchez, IF (2023).

Understanding the basis for intrinsic resistance to KRASG12C inhibitors

ANNALS OF ONCOLOGY. Meeting Abstract. 34:753-753.
[doi:10.1016/j.annonc.2023.09.788]
Paz-Ares, LG (2023).

Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA"

Journal of Thoracic Oncology. Letter. 18(9):102-103.
[doi:10.1016/j.jtho.2023.05.022]
Marrugal, A, Ferrer, I, Quintanal-Villalonga, A, Ojeda, L, Pastor, MD, García-Lujan, R, Carnero, A, Paz-Ares, L, Molina-Pinelo, S (2023).

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Article. 24(18).
[doi:10.3390/ijms241813830]
Ponce, S, Cedrés, S, Ricordel, C, Isambert, N, Viteri, S, Herrera-Juarez, M, Martinez-Marti, A, Navarro, A, Lederlin, M, Serres, X, Zugazagoitia, J, Vetrhus, S, Jaderberg, M, Hansen, TB, Levitsky, V, Paz-Ares, L (2023).

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Journal for ImmunoTherapy of Cancer. Article. 11(9).
[doi:10.1136/jitc-2023-007552]
Sacher, A, LoRusso, P, Patel, MR, Miller, WH, Garralda, E, Forster, MD, Santoro, A, Falcon, A, Kim, TW, Paz-Ares, L, Bowyer, S, de Miguel, M, Han, SW, Krebs, MG, Lee, JS, Cheng, ML, Arbour, K, Massarelli, E, Choi, Y, Shi, Z, Mandlekar, S, Lin, MT, Royer-Joo, S, Chang, J, Dharia, NV, Schutzman, JL, Desai, J (2023).

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

NEW ENGLAND JOURNAL OF MEDICINE. Article. 389(8):710-721.
[doi:10.1056/NEJMoa2303810]
Provencio, M, Nadal, E, González-Larriba, JL, Martínez-Martí, A, Bernabé, R, Bosch-Barrera, J, Casal-Rubio, J, Calvo, V, Insa, A, Ponce, S, Reguart, N, de Castro, J, Mosquera, J, Cobo, M, Aguilar, A, Vivanco, GL, Camps, C, López-Castro, R, Morán, T, Barneto, I, Rodríguez-Abreu, D, Serna-Blasco, R, Benitez, R, de la Rosa, CA, Palmero, R, Hernando-Trancho, F, Martín-López, J, Cruz-Bermúdez, A, Massuti, B, Romero, A (2023).

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 389(6):504-513.
[doi:10.1056/NEJMoa2215530]
Rubió-Casadevall, J, Cirauqui, BC, Trufero, JM, Serrahima, MP, Castaño, AG, Maseda, AC, Docampo, LI, Segura, PP, Lenza, IC, Calderón, VG, Salvà, JF, Alvarez, CP, Hernandez, I, Morillo, ED, Conde, MC, Galán, JM, Sánchez, MD, Quiroga, V, Ortega, E, Mesia, R (2023).

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

Frontiers in Oncology. Article. 13.
[doi:10.3389/fonc.2023.1226939]
Gosney, JR, Paz-Ares, L, Jänne, P, Kerr, KM, Leighl, NB, Lozano, MD, Malapelle, U, Mok, T, Sheffield, BS, Tufmah, A, Wistuba, II, Peters, S (2023).

Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

ESMO Open. Article. 8(4).
[doi:10.1016/j.esmoop.2023.101587]
Garon, EB, Reck, M, Nishio, K, Heymach, JV, Nishio, M, Novello, S, Paz-Ares, L, Popat, S, Aix, SP, Graham, H, Butts, BD, Visseren-Grul, C (2023).

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

ESMO Open. Article. 8(4).
[doi:10.1016/j.esmoop.2023.101580]
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A (2023).

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

CANCER RESEARCH. Article. 83(15):2513-2526.
[doi:10.1158/0008-5472.CAN-22-3023]
Reck, M, Ciuleanu, TE, Lee, JS, Schenker, M, Zurawski, B, Kim, SW, Mahave, M, Alexandru, A, Peters, S, Pluzanski, A, Caro, RB, Linardou, H, Burgers, JA, Nishio, M, Martinez-Marti, A, Azuma, K, Axelrod, R, Paz-Ares, LG, Ramalingam, SS, Borghaei, H, O'Byrne, KJ, Li, L, Bushong, J, Gupta, RG, Grootendorst, DJ, Eccles, LJ, Brahmer, JR (2023).

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Journal of Thoracic Oncology. Article. 18(8):1055-1069.
[doi:10.1016/j.jtho.2023.04.021]
Agulló-Ortuño, MT, Mancebo, E, Grau, M, Sobrino, JAN, Paz-Ares, L, López-Martín, JA, Flández, M (2023).

Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Article. 24(16).
[doi:10.3390/ijms241613005]
Nadal, E, Saleh, M, Aix, SP, Ochoa-de-Olza, M, Patel, SP, Antonia, S, Zhao, YM, Gueorguieva, I, Man, MC, Estrem, ST, Liu, JA, Avsar, E, Lin, WH, Benhadji, KA, Gandhi, L, Guba, SC, Diaz, IA (2023).

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

BMC CANCER. Article. 23(1).
[doi:10.1186/s12885-023-11153-1]
Hernandez, S, Conde, E, Alonso, M, Illarramendi, A, de Cabo, HB, Zugazagoitia, J, Paz-Ares, L, Lopez-Rios, F (2023).

A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

Translational lung cancer research. Review. 12(7):1549-1562.
[doi:10.21037/tlcr-22-855]
Nishio, M, Paz-Ares, L, Reck, M, Nakagawa, K, Garon, EB, Popat, S, Ceccarelli, M, Graham, HT, Visseren-Grul, C, Novello, S (2023).

RELAY, Ramucirumab Plus Erlotinib (RAM plus ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR plus NSCLC) : Association Between TP53 Status and Clinical Outcome

Clinical Lung Cancer. Article. 24(5):415-428.
[doi:10.1016/j.cllc.2023.02.010]
García-Lizarribar, A, Villasante, A, Lopez-Martin, JA, Flandez, M, Soler-Vázquez, MC, Serra, D, Herrero, L, Sagrera, A, Efeyan, A, Samitier, J (2023).

3D bioprinted functional skeletal muscle models have potential applications for studies of muscle wasting in cancer cachexia

Biomaterials Advances. Article. 150.
[doi:10.1016/j.bioadv.2023.213426]
Rudin, CM, Reck, M, Johnson, ML, Blackhall, F, Hann, CL, Yang, JCH, Bailis, JM, Bebb, G, Goldrick, A, Umejiego, J, Paz-Ares, L (2023).

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

Journal of Hematology & Oncology. Review. 16(1).
[doi:10.1186/s13045-023-01464-y]
Herrera-Juárez, M, Serrano-Gómez, C, Bote-de-Cabo, H, Paz-Ares, L (2023).

Targeted therapy for lung cancer: Beyond EGFR and ALK.

CANCER. Review. 129(12):1803-1820.
[doi:10.1002/cncr.34757]
Girard, N, Aix, SP, Cedres, S, Berghmans, T, Burgers, S, Toffart, AC, Popat, S, Janssens, A, Gervais, R, Hochstenbag, M, Silva, M, Burger, IA, Prosch, H, Stahel, R, Xenophontos, E, Pretzenbaher, Y, Neven, A, Peters, S (2023).

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

ESMO Open. Article. 8(3).
[doi:10.1016/j.esmoop.2023.101576]
Yarza, R, Bover, M, Herrera-Juarez, M, Rey-Cardenas, M, Paz-Ares, L, Lopez-Martin, JA, Haanen, J (2023).

Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis

ONCOLOGIST. Article. 28(6):406-415.
[doi:10.1093/oncolo/oyad078]
Bilé-Silva, A, Lopez-Beltran, A, Blanca, A, Lopez-Rios, F, Gómez-Gómez, E, Cimadamore, A, Montironi, R, Vau, N, Cheng, L (2023).

Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward

EXPERT OPINION ON BIOLOGICAL THERAPY. Review. 23(5):407-418.
[doi:10.1080/14712598.2023.2201371]
Isla, D, Lozano, MD, Paz-Ares, L, Salas, C, de Castro, J, Conde, E, Felip, E, Gómez-Román, J, Garrido, P, Enguita, AB (2023).

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Dec, 10.1007/s12094-022-03046-9, 2022)

Clinical & Translational Oncology. Correction. 25(5):1488-1488.
[doi:10.1007/s12094-023-03103-x]
Remon, J, Besse, B, Aix, SP, Callejo, A, Al-Rabi, K, Bernabe, R, Greillier, L, Majem, M, Reguart, N, Monnet, I, Cousin, S, Garrido, P, Robinet, G, Campelo, RG, Madroszyk, A, Mazieres, J, Curcio, H, Wasag, B, Pretzenbacher, Y, Fournier, B, Dingemans, AMC, Dziadziuszko, R (2023).

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

ANNALS OF ONCOLOGY. Article. 34(5):468-476.
[doi:10.1016/j.annonc.2023.02.012]
Köbel, M, Kang, EY, Weir, A, Rambau, PF, Lee, CH, Nelson, GS, Ghatage, P, Meagher, NS, Riggan, MJ, Alsop, J, Anglesio, MS, Beckmann, MW, Bisinotto, C, Boisen, M, Boros, J, Brand, AH, Brooks-Wilson, A, Carney, ME, Coulson, P, Courtney-Brooks, M, Cushing-Haugen, KL, Cybulski, C, Deen, S, El-Bahrawy, MA, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Gayther, SA, Barquin-Garcia, A, Gentry-Maharaj, A, Gilks, CB, Gronwald, H, Grube, M, Harnett, PR, Harris, HR, Hartkopf, AD, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Huang, YJ, Jakubowska, A, Jimenez-Linan, M, Jones, ME, Kennedy, CJ, Kluz, T, Koziak, JM, Lesnock, J, Lester, J, Lubinski, J, Longacre, TA, Lycke, M, Mateoiu, C, McCauley, BM, McGuire, V, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Paz-Ares, L, Cajal, TRY, Rothstein, JH, Ruebner, M, Schoemaker, MJ, Shah, MT, Sharma, R, Sherman, ME, Shvetsov, YB, Singh, N, Steed, H, Storr, SJ, Talhouk, A, Traficante, N, Wang, C, Whittemore, AS, Widschwendter, M, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, dos Reis, FJC, Campbell, I, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Fortner, RT, García, MJ, Goodman, MT, Goode, EL, Gronwald, J, Huntsman, DG, Karlan, BY, Kelemen, LE, Kommoss, S, Le, ND, Martin, SG, Menon, U, Modugno, F, Pharoah, PDP, Schildkraut, JM, Sieh, W, Staebler, A, Sundfeldt, K, Swerdlow, AJ, Ramus, SJ, Brenton, JD (2023).

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Journal of Pathology Clinical Research. Article. 9(3):208-222.
[doi:10.1002/cjp2.311]
Aldea, M, Marinello, A, Duruisseaux, M, Zrafi, W, Conci, N, Massa, G, Metro, G, Monnet, I, Iranzo, PG, Tabbo, F, Bria, E, Guisier, F, Vasseur, D, Lindsay, CR, Ponce-Aix, S, Cousin, S, Citarella, F, Fallet, V, Minatta, JN, Eisert, A, Basile, HD, Audigier-Valette, C, Mezquita, L, Calles, A, Mountzios, G, Tagliamento, M, Masip, JR, Raimbourg, J, Terrisse, S, Russo, A, Cortinovis, D, Rochigneux, P, Pinato, DJ, Cortellini, A, Leonce, C, Gazzah, A, Ghigna, MR, Ferrara, R, Dall'Olio, FG, Passiglia, F, Ludovini, V, Barlesi, F, Felip, E, Planchard, D, Besse, B (2023).

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Journal of Thoracic Oncology. Article. 18(5):576-586.
[doi:10.1016/j.jtho.2022.12.018]
Paredes-Ruiz, D, López-López, F, Núñez-Sobrino, JA, Gómez-Martin, C, Díaz-Pedroche, C, Lizasoain, M (2023).

Cytomegalovirus reactivation in patients with immune-mediated gastritis

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. Article. 41(5):298-300.
[doi:10.1016/j.eimc.2022.03.005]
Novello, S, Kowalski, DM, Luft, A, Gümüs, M, Vicente, D, Mazières, J, Rodríguez-Cid, J, Tafreshi, A, Cheng, Y, Lee, KH, Golf, A, Sugawara, S, Robinson, AG, Halmos, B, Jensen, E, Schwarzenberger, P, Pietanza, MC, Paz-Ares, L (2023).

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(11):1999-2006.
[doi:10.1200/JCO.22.01990]
Isla D, Lozano MD, Paz-Ares L, Salas C, de Castro J, Conde E, Felip E, Gómez-Román J, Garrido P, Belén Enguita A (2023).

Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica.

Revista Espanola de Patologia. Article. 56(2):97-112.
[doi:10.1016/j.patol.2023.02.002]
Reck, M, Ciuleanu, TE, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Cheng, Y, Sakai, H, Paz-Ares, L, Lu, S, John, T, Sun, XW, Moisei, A, Taylor, F, Lawrance, R, Zhang, XQ, Sylvester, J, Yuan, Y, Blum, SI, Penrod, JR, Carbone, DP (2023).

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

EUROPEAN JOURNAL OF CANCER. Article. 183:174-187.
[doi:10.1016/j.ejca.2023.01.015]
de Langen, AJ, Johnson, ML, Mazieres, J, Dingemans, AMC, Mountzios, G, Pless, M, Wolf, J, Schuler, M, Lena, H, Skoulidis, F, Yoneshima, Y, Kim, SW, Linardou, H, Novello, S, van der Wekken, AJ, Chen, YB, Peters, S, Felip, E, Solomon, BJ, Ramalingam, SS, Dooms, C, Lindsay, CR, Ferreira, CG, Blais, N, Obiozor, CC, Wang, Y, Mehta, B, Varrieur, T, Ngarmchamnanrith, G, Stollenwerk, B, Waterhouse, D, Paz-Ares, L (2023).

Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

LANCET. Article. 401(10378):733-746.
[doi:10.1016/S0140-6736(23)00221-0]
Boyero, L, Noguera-Uclés, JF, Castillo-Peña, A, Salinas, A, Sánchez-Gastaldo, A, Alonso, M, Benedetti, JC, Bernabé-Caro, R, Paz-Ares, L, Molina-Pinelo, S (2023).

Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer

Cancers. Article. 15(5).
[doi:10.3390/cancers15051466]
Brahmer, JR, Lee, JS, Ciuleanu, TE, Bernabe Caro R, Nishio, M, Urban, L, Audigier-Valette, C, Lupinacci, L, Sangha, R, Pluzanski, A, Burgers, J, Mahave, M, Ahmed, S, Schoenfeld, AJ, Paz-Ares, LG, Reck, M, Borghaei, H, O'Byrne, KJ, Gupta, RG, Bushong, J, Li, L, Blum, SI, Eccles, LJ, Ramalingam, SS (2023).

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(6):1200-1212.
[doi:10.1200/JCO.22.01503]
Paz-Ares, LG, Ciuleanu, TE, Cobo, M, Bennouna, J, Schenker, M, Cheng, Y, Juan-Vidal, O, Mizutani, H, Lingua, A, Reyes-Cosmelli, F, Reinmuth, N, Menezes, J, Jassem, J, Protsenko, S, Richardet, E, Felip, E, Feeney, K, Zurawski, B, Alexandru, A, Jimenez, ED, Dakhil, S, Lu, S, Reck, M, John, T, Hu, N, Zhang, XQ, Sylvester, J, Eccles, LJ, Grootendorst, DJ, Balli, D, Neely, J, Carbone, DP (2023).

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Journal of Thoracic Oncology. Article. 18(2):204-222.
[doi:10.1016/j.jtho.2022.10.014]
Borghaei, H, Ciuleanu, TE, Lee, JS, Pluzanski, A, Caro, RB, Gutierrez, M, Ohe, Y, Nishio, M, Goldman, J, Ready, N, Spigel, DR, Ramalingam, SS, Paz-Ares, LG, Gainor, JF, Ahmed, S, Reck, M, Maio, M, O'Byrne, KJ, Memaj, A, Nathan, F, Tran, P, Hellmann, MD, Brahmer, JR (2023).

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.

ANNALS OF ONCOLOGY. Article. 34(2):173-185.
[doi:10.1016/j.annonc.2022.11.006]
Ready, NE, Audigier-Valette, C, Goldman, JW, Felip, E, Ciuleanu, TE, Campelo, MRG, Jao, K, Barlesi, F, Bordenave, S, Rijavec, E, Urban, L, Aucoin, JS, Zannori, C, Vermaelen, K, Frontera, OA, Fontecedro, AC, Sánchez-Gastaldo, A, Juan-Vidal, O, Linardou, H, Poddubskaya, E, Spigel, DR, Ahmed, S, Maio, M, Li, SN, Chang, H, Fiore, J, Acevedo, A, Paz-Ares, L (2023).

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Journal for ImmunoTherapy of Cancer. Article. 11(2).
[doi:10.1136/jitc-2022-006127]
Andric, Z, Gálffy, G, Dols, MC, Szima, B, Stojanovic, G, Petrovic, M, Felip, E, Baz, DV, Aix, SP, Juan-Vidal, O, Szalai, Z, Losonczy, G, Blanco, AC, Bernabe, R, Ledo, GG, Hernández, AA, Duecker, K, Zhou, DL, Schroeder, A, Guezel, G, Ciardiello, F (2023).

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

JTO Clinical and Research Reports. Article. 4(2).
[doi:10.1016/j.jtocrr.2022.100461]
Weir, A, Kang, EY, Meagher, NS, Nelson, GS, Ghatage, P, Lee, CH, Riggan, MJ, Gentry-Maharaj, A, Ryan, A, Singh, N, Widschwendter, M, Alsop, J, Anglesio, MS, Beckmann, MW, Berger, J, Bisinotto, C, Boros, J, Brand, AH, Brenton, JD, Brooks-Wilson, A, Carney, ME, Cunningham, JM, Cushing-Haugen, KL, Cybulski, C, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Paz-Ares, L, Gayarre, J, Gilks, BC, Grube, M, Harnett, PR, Harris, HR, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Heublein, S, Huang, YJ, Huzarski, T, Jakubowska, A, Jimenez-Linan, M, Kennedy, CJ, Kommoss, FKF, Koziak, JM, Kraemer, B, Le, ND, Lesnock, J, Lester, J, Lubinski, J, Menkiszak, J, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Robles-Diaz, L, Ruebner, M, Shah, M, Sharma, R, Shvetsov, YB, Steed, H, Talhouk, A, Taylor, SE, Traficante, N, Vierkant, RA, Wang, C, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, dos Reis, FJC, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Garcia, MJ, Goode, EL, Goodman, MT, Gronwald, J, Huntsman, DG, Karlan, BY, Kommoss, S, Modugno, F, Schildkraut, JM, Sinn, HP, Staebler, A, Kelemen, LE, Ford, CE, Menon, U, Pharoah, PDP, Kobel, M, Ramus, SJ, Bowtell, D, DeFazio, A, Traficante, N, Fereday, S, Brand, A, Harnett, P, Sharma, R (2023).

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

BRITISH JOURNAL OF CANCER. Article. 128(1):137-147.
[doi:10.1038/s41416-022-02014-y]
Paz-Ares, L, Champiat, S, Lai, WV, Izumi, H, Govindan, R, Boyer, M, Hummel, HD, Borghaei, H, Johnson, ML, Steeghs, N, Blackhall, F, Dowlati, A, Reguart, N, Yoshida, T, He, K, Gadgeel, SM, Felip, E, Zhang, YR, Pati, A, Minocha, M, Mukherjee, S, Goldrick, A, Nagorsen, D, Hashemi Sadraei, Nooshin, Owonikoko, TK (2023).

Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(16):2202823-2202823.
[doi:10.1200/JCO.22.02823]
Aix, SP, Núñez-Benjumea, FJ, Cervera-Torres, S, Flores, A, Arnáiz, P, Fernández-Luque, L (2023).

Data-Driven Personalized Care in Lung Cancer: Scoping Review and Clinical Recommendations on Performance Status and Activity Level of Patients With Lung Cancer Using Wearable Devices

JCO Clinical Cancer Informatics. Review. 7.
[doi:10.1200/CCI.23.00016]
Dziadziuszko, R, Peled, N, Mok, T, Peters, S, Aix, SP, Alatorre-Alexander, J, Vicuna, BD, Maclennan, M, Bhagawati-Prasad, V, Shagan, SM, Schleifman, E, Ruf, T, Mathisen, MS, Gadgeel, SM (2023).

High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY. Article. 27(4):217-223.
[doi:10.5114/wo.2023.135246]
Paz-Ares, LG, Ciuleanu, TE, Pluzanski, A, Lee, JS, Gainor, JF, Otterson, GA, Audigier-Valette, C, Ready, N, Schenker, M, Linardou, H, Caro, RB, Provencio, M, Zurawski, B, Lee, KH, Kim, SW, Caserta, C, Ramalingam, SS, Spigel, DR, Brahmer, JR, Reck, M, O'Byrne, KJ, Girard, N, Popat, S, Peters, S, Memaj, A, Nathan, F, Aanur, N, Borghaei, H (2023).

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Journal of Thoracic Oncology. Article. 18(1):79-92.
[doi:10.1016/j.jtho.2022.08.014]
Aix, SP, Ciuleanu, TE, Navarro, A, Cousin, S, Bonanno, L, Smit, EF, Chiappori, A, Olmedo, ME, Horvath, I, Grohe, C, Farago, AF, Lopez-Vilarino, JA, Cullell-Young, M, Nieto, A, Vasco, N, Gomez, J, Kahatt, C, Zeaiter, A, Carcereny, E, Roubec, J, Syrigos, K, Lo, G, Barneto, I, Pope, A, Sanchez, A, Kattan, J, Zarogoulidis, K, Waller, CF, Bischoff, H, Juan-Vidal, O, Reinmuth, N, Domine, M, Paz-Ares, L (2023).

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Lancet Respiratory Medicine. Article. 11(1):74-86.
[doi:10.1016/S2213-2600(22)00309-5]
Garassino, MC, Gadgeel, S, Novello, S, Halmos, B, Felip, E, Speranza, G, Hui, RA, Garon, EB, Horinouchi, H, Sugawara, S, Rodriguez-Abreu, D, Reck, M, Cristescu, R, Aurora-Garg, D, Loboda, A, Lunceford, J, Kobie, J, Ayers, M, Piperdi, B, Pietanza, MC, Paz-Ares, L (2023).

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.

JTO Clinical and Research Reports. Article. 4(1):100431-100431.
[doi:10.1016/j.jtocrr.2022.100431]
Bamias, A, Merseburger, A, Loriot, Y, James, N, Choy, E, Castellano, D, Lopez-Rios, F, Calabro, F, Kramer, M, de Velasco, G, Zakopoulou, R, Tzannis, K, Sternberg, CN (2023).

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors

Journal for ImmunoTherapy of Cancer. Article. 11(1).
[doi:10.1136/jitc-2022-005977]
Otano, I, Ucero, AC, Zugazagoitia, J, Paz-Ares, L (2023).

At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

Nature Reviews Clinical Oncology. Review. 20(3):143-159.
[doi:10.1038/s41571-022-00718-x]
Arriola, E, Bernabé, R, Campelo, RG, Biscuola, M, Enguita, AB, López-Ríos, F, Martínez, R, Mezquita, L, Palanca, S, Pareja, MJ, Zugazagoitia, J, Arrabal, N, García, JF, Carcedo, D, de Alava, E (2023).

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

JCO Precision Oncology. Article. 7.
[doi:10.1200/PO.22.00546]

2022

Petty, WJ, Paz-Ares, L (2022).

Emerging Strategies for the Treatment of Small Cell Lung Cancer A Review

JAMA Oncology. Review. 9(3):419-429.
[doi:10.1001/jamaoncol.2022.5631]
Isla, D, Lozano, MD, Paz-Ares, L, Salas, C, de Castro, J, Conde, E, Felip, E, Gomez-Roman, J, Garrido, P, Enguita, AB (2022).

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & Translational Oncology. Article. 25:1252-1267.
[doi:10.1007/s12094-022-03046-9]
Garassino, MC, Mazieres, J, Reck, M, Chouaid, C, Bischoff, H, Reinmuth, N, Cove-Smith, L, Mansy, T, Cortinovis, D, Migliorino, MR, Delmonte, A, Sanchez, JG, Velarde, LEC, Bernabe, R, Paz-Ares, L, Perez, ID, Trunova, N, Foroutanpour, K, Faivre-Finn, C (2022).

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Journal of Thoracic Oncology. Article. 17(12):1415-1427.
[doi:10.1016/j.jtho.2022.07.1148]
Krebs, MG, Malapelle, U, Andre, F, Paz-Ares, L, Schuler, M, Thomas, DM, Vainer, G, Yoshino, T, Rolfo, C (2022).

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.

JAMA Oncology. Review. 8(12):1830-1839.
[doi:10.1001/jamaoncol.2022.4457]
Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H, Sholl LM, Brambilla E, Chou TY, Connolly C, Wistuba I, Kerr KM, Lantuejoul S (2022).

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee.

Journal of Thoracic Oncology. Review. 17(12):1335-1354.
[doi:10.1016/j.jtho.2022.09.109]
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A (2022).

YES1 Is a Druggable Oncogenic Target in SCLC.

Journal of Thoracic Oncology. Article. 17(12):1387-1403.
[doi:10.1016/j.jtho.2022.08.002]
Conde, E, Hernandez, S, Lopez-Rios, F (2022).

Rethinking the role of biomarkers for operable non-small cell lung carcinoma: an effective collaboration with artificial intelligence algorithms

MODERN PATHOLOGY. Editorial Material. 35(12):1754-1756.
[doi:10.1038/s41379-022-01167-8]
Rugo, HS, Kabos, P, Beck, JT, Jerusalem, G, Wildiers, H, Sevillano, E, Paz-Ares, L, Chisamore, MJ, Chapman, SC, Hossain, AM, Chen, YY, Tolaney, SM (2022).

Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study

npj Breast Cancer. Article. 8(1):118-118.
[doi:10.1038/s41523-022-00482-2]
Villarroya-Beltri, C, Osorio, A, Torres-Ruiz, R, Gomez-Sanchez, D, Trakala, M, Sanchez-Belmonte, A, Mercadillo, F, Hurtado, B, Pitarch, B, Hernandez-Nunez, A, Gomez-Caturla, A, Rueda, D, Perea, J, Rodriguez-Perales, S, Malumbres, M, Urioste, M (2022).

Biallelic germline mutations in MAD1L1 induce a syndrome of aneuploidy with high tumor susceptibility.

Science Advances. Article. 8(44).
[doi:10.1126/sciadv.abq5914]
Prat, A, Paz-Ares, L, Juan, M, Felip, E, Garralda, E, Gonzalez, B, Arance, A, Martin-Liberal, J, Gavila, J, Lopez-Gonzalez, A, Cejalvo, JM, Izarzugaza, Y, Amillano, K, Corbacho, JG, Saura, C, Racca, F, Hierro, C, Sanfeliu, E, Gonzalez, X, Canes, J, Villacampa, G, Salvador, F, Pascual, T, Mesia, R, Cervantes, A, Tabernero, J (2022).

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

Future Oncology. Article. 18(34):3791-3800.
[doi:10.2217/fon-2022-0660]
Griesinger, F, Curigliano, G, Thomas, M, Subbiah, V, Baik, CS, Tan, DSW, Lee, DH, Misch, D, Garralda, E, Kim, DW, van der Wekken, AJ, Gainor, JF, Paz-Ares, L, Liu, SV, Kalemkerian, GP, Houvras, Y, Bowles, DW, Mansfield, AS, Lin, JJ, Smoljanovic, V, Rahman, A, Kong, S, Zalutskaya, A, Louie-Gao, M, Boral, AL, Mazieres, J (2022).

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

ANNALS OF ONCOLOGY. Article. 33(11):1168-1178.
[doi:10.1016/j.annonc.2022.08.002]
Hitt, R, Mesia, R, Lozano, A, Iglesias Docampo L, Grau, JJ, Taberna, M, Rubio-Casadevall, J, Martinez-Trufero, J, Morillo EDB, García Girón C, Vázquez Estévez S, Cirauqui, B, Cruz-Hernandez, JJ (2022).

Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.

ORAL ONCOLOGY. Article. 134:106087-106087.
[doi:10.1016/j.oraloncology.2022.106087]
Bote, H, Mesas, A, Baena, J, Herrera, M, Paz-Ares, L (2022).

Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer.

EXPERT OPINION ON EMERGING DRUGS. Review. 27(3):289-300.
[doi:10.1080/14728214.2022.2113377]
Ramos, AS, Sánchez, DG, López, SR, Expósito, PP, Paz-Ares, L, Sánchez, IF (2022).

Understanding the basis for acquired resistance to KRASG12C inhibitors

ANNALS OF ONCOLOGY. Meeting Abstract. 33(8):1411-1411.
[doi:10.1016/j.annonc.2022.09.092]
Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C (2022).

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.

ESMO Open. Article. 7(5):100562-100562.
[doi:10.1016/j.esmoop.2022.100562]
O'Brien, M, Paz-Ares, L, Marreaud, S, Dafni, U, Oselin, K, Havel, L, Esteban, E, Isla, D, Martinez-Marti, A, Faehling, M, Tsuboi, M, Lee, JS, Nakagawa, K, Yang, J, Samkari, A, Keller, SM, Mauer, M, Jha, N, Stahel, R, Besse, B, Peters, S (2022).

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

LANCET ONCOLOGY. Article. 23(10):1274-1286.
[doi:10.1016/S1470-2045(22)00518-6]
Tan, DSW, Kim, SW, Aix, SP, Sequist, LV, Smit, EF, Yang, JCH, Hida, T, Toyozawa, R, Felip, E, Wolf, J, Grohe, C, Leighl, NB, Riely, G, Cui, XM, Zou, MK, Ghebremariam, S, O'Sullivan-Djentuh, L, Belli, R, Giovannini, M, Kim, DW (2022).

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study

EUROPEAN JOURNAL OF CANCER. Article. 172:276-286.
[doi:10.1016/j.ejca.2022.05.023]
Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz-Ares L, Yang JC, Besse B, Su W, Chao BH, Drilon A (2022).

LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.

Future Oncology. Article. 18(28):3133-3141.
[doi:10.2217/fon-2022-0656]
Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G (2022).

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.

NATURE MEDICINE. Article. 28(8):1640-1645.
[doi:10.1038/s41591-022-01931-y]
Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst RS, Schalper KA, Rimm DL (2022).

Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.

Journal of Thoracic Oncology. Article. 17(8):991-1001.
[doi:10.1016/j.jtho.2022.04.009]
Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J (2022).

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.

Journal for ImmunoTherapy of Cancer. Article. 10(8).
[doi:10.1136/jitc-2022-004757]
Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL (2022).

Development of an immunohistochemical assay for Siglec-15.

LABORATORY INVESTIGATION. Article. 102(7):771-778.
[doi:10.1038/s41374-022-00785-9]
Peters S, Paz-Ares L, Herbst RS, Reck M (2022).

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.

Journal for ImmunoTherapy of Cancer. Review. 10(7).
[doi:10.1136/jitc-2022-004863]
Arroyo-Andrés, J, Agud-Dios, M, Rubio-Muniz, CA, Vico-Alonso, C, Cortijo-Cascajares, S, Ortiz-Romero, PL (2022).

Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report

INTERNATIONAL JOURNAL OF DERMATOLOGY. Letter. 61(7):267-269.
[doi:10.1111/ijd.15834]
Gonzalez-Rubio, S, Salgado, C, Manzaneda-Gonzalez, V, Muñoz-Úbeda M, Ahijado-Guzman, R, Natale, P, Almendro-Vedia, VG, Junquera, E, Barcina, JO, Ferrer, I, Guerrero-Martinez, A, Paz-Ares, L, Lopez-Montero, I (2022).

Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy.

Nanoscale. Article. 14(22):8028-8040.
[doi:10.1039/d2nr02353a]
Yang, JCH, Brose, MS, Castro, G, Kim, ES, Lassen, UN, Leyvraz, S, Pappo, A, Lopez-Rios, F, Reeves, JA, Fellous, M, Penault-Llorca, F, Rudzinski, ER, Tabatabai, G, Vassal, G, Drilon, A, Trent, J (2022).

Rationale and design of ON TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

BMC CANCER. Article. 22(1).
[doi:10.1186/s12885-022-09687-x]
Cho, BC, Abreu, DR, Hussein, M, Cobo, M, Patel, AJ, Secen, N, Lee, KH, Massuti, B, Hiret, S, Yang, JCH, Barlesi, F, Lee, DH, Ares, LP, Hsieh, RW, Patil, NS, Twomey, P, Yang, XY, Meng, RY, Johnson, ML (2022).

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

LANCET ONCOLOGY. Article. 23(6):781-792.
[doi:10.1016/S1470-2045(22)00226-1]
Chen, YB, Paz-Ares, L, Reinmuth, N, Garassino, MC, Statsenko, G, Hochmair, MJ, Özgüroglu, M, Verderame, F, Havel, L, Losonczy, G, Conev, N, Hotta, K, Ji, JH, Spencer, S, Dalvi, T, Jiang, HY, Goldman, JW (2022).

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.

JTO Clinical and Research Reports. Article. 3(6):100330-100330.
[doi:10.1016/j.jtocrr.2022.100330]
Diaz-Cano, I, Paz-Ares, L, Otano, I (2022).

Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy

International Review of Cell and Molecular Biology. Article. 370:163-192.
[doi:10.1016/bs.ircmb.2022.04.003]
Morfouace M, Novello S, Stevovic A, Dooms C, Janžic U, Berghmans T, Dziadziuszko R, Gorlia T, Felip E, Paz-Ares L, Mazieres J, O'Brien M, Bironzo P, Vansteenkiste J, Lacroix L, Dingemans AC, Golfinopoulos V, Besse B (2022).

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.

SCIENTIFIC REPORTS. Article. 12(1):8342-8342.
[doi:10.1038/s41598-022-12056-0]
Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S (2022).

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.

ANNALS OF ONCOLOGY. Article. 33(5):466-487.
[doi:10.1016/j.annonc.2022.02.003]
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Planchard D, Mezquita L (2022).

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

EUROPEAN JOURNAL OF CANCER. Article. 167:142-148.
[doi:10.1016/j.ejca.2022.02.014]
Paz-Ares L, Spigel DR, Chen Y, Jove M, Juan-Vidal O, Rich P, Hayes T, Calderón VG, Caro RB, Navarro A, Dowlati A, Zhang B, Moore Y, Yao X, Kokhreidze J, Ponce S, Bunn PA (2022).

RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.

CANCER. Article. 128(9):1801-1811.
[doi:10.1002/cncr.34123]
Paz-Ares L, Gondos A, Saldana D, Thomas M, Mascaux C, Bubendorf L, Barlesi F (2022).

Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.

LUNG CANCER. Article. 167:41-48.
[doi:10.1016/j.lungcan.2022.01.021]
Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroglu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ (2022).

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

JOURNAL OF CLINICAL ONCOLOGY. Article. 40(12):1301-1311.
[doi:10.1200/JCO.21.01308]
Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N, Valiente M (2022).

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

NATURE MEDICINE. Article. 28(4):752-765.
[doi:10.1038/s41591-022-01749-8]
Losa F, Fernández I, Etxaniz O, Giménez A, Gomila P, Iglesias L, Longo F, Nogales E, Sánchez A, Soler G (2022).

SEOM-GECOD clinical guideline for unknown primary cancer (2021).

Clinical & Translational Oncology. Article. 24(4):681-692.
[doi:10.1007/s12094-022-02806-x]
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW (2022).

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

ESMO Open. Article. 7(2):100408-100408.
[doi:10.1016/j.esmoop.2022.100408]
Senan S, Özgüroglu M, Daniel D, Villegas A, Vicente D, Murakami S, Hui R, Faivre-Finn C, Paz-Ares L, Wu YL, Mann H, Dennis PA, Antonia SJ (2022).

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

ESMO Open. Article. 7(2):100410-100410.
[doi:10.1016/j.esmoop.2022.100410]
Heitzer E, van den Broek D, Denis MG, Hofman P, Hubank M, Mouliere F, Paz-Ares L, Schuuring E, Sültmann H, Vainer G, Verstraaten E, de Visser L, Cortinovis D (2022).

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.

ESMO Open. Review. 7(2):100399-100399.
[doi:10.1016/j.esmoop.2022.100399]
Kindler, HL, Novello, S, Bearz, A, Ceresoli, GL, Aerts, JGJV, Spicer, J, Taylor, P, Nackaerts, K, Greystoke, A, Jennens, R, Calabro, L, Burgers, JA, Santoro, A, Cedres, S, Serwatowski, P, Ponce, S, Van Meerbeeck, JP, Nowak, AK, Biumenschein, G, Siegel, JM, Kasten, L, Kochert, K, Walter, AO, Childs, BH, Elbi, C, Hassan, R, Fennell, DA (2022).

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

LANCET ONCOLOGY. Article. 23(4):540-552.
[doi:10.1016/S1470-2045(22)00061-4]
Paz-Ares, L, O'Brien, MER, Mauer, M, Dafni, U, Oselin, K, Havel, L, Gonzalez, EE, Isla, D, Martinez-Marti, A, Faehling, M, Tsuboi, M, Lee, JS, Nakagawa, K, Yang, J, Keller, SM, Jha, N, Marreaud, SI, Stahel, RA, Peters, S, Besse, B (2022).

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study

ANNALS OF ONCOLOGY. Editorial Material. 33(4):451-453.
[doi:10.1016/j.annonc.2022.02.224]
Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim SW, Madelaine J, Molinier O, Özgüroglu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW (2022).

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

LUNG CANCER. Article. 166:107-113.
[doi:10.1016/j.lungcan.2022.01.023]
Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Ucero ÁC, González-Barcala FJ, Salgado FJ, Pichel JG (2022).

Correction: Alfaro-Arnedo et al. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines 2021, 9, 912.

Biomedicines. Correction. 10(4).
[doi:10.3390/biomedicines10040733]
Rojo, F, Conde, E, Torres, H, Cabezon-Gutierrez, L, Bautista, D, Ramos, I, Carcedo, D, Arrabal, N, Garcia, JF, Galan, R, Nadal, E (2022).

Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain

BMC CANCER. Article. 22(1).
[doi:10.1186/s12885-022-09397-4]
Ramos-Paradas J, Gómez-Sánchez D, Rosado A, Ucero AC, Ferrer I, García-Luján R, Zugazagoitia J, Carrizo N, Enguita AB, Conde E, Garrido-Martin EM, Paz-Ares L (2022).

Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy.

Journal of Clinical Medicine. Article. 11(6).
[doi:10.3390/jcm11061500]
Gillison, ML, Blumenschein, G, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, KJ, Kasper, S, Vokes, EE, Even, C, Worden, F, Saba, NF, Docampo, LCI, Haddad, R, Rordorf, T, Kiyota, N, Tahara, M, Jayaprakash, V, Wei, L, Ferris, RL (2022).

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

ONCOLOGIST. Article. 27(2):194-198.
[doi:10.1093/oncolo/oyab036]
Rodriguez-Garzotto, A, Iglesias-Docampo, L, Diaz-Garcia, CV, Ruppen, I, Ximenez-Embun, P, Gomez, C, Rodriguez-Peralto, JL, de Frutos, JO, Lopez-Martin, JA, Gravalos, C, Cortes-Funes, H, Agullo-Ortuno, MT (2022).

Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies

Therapeutic Advances in Medical Oncology. Article. 14.
[doi:10.1177/17588359221086911]
Pena-Couso, L, Ercibengoa, M, Mercadillo, F, Gomez-Sanchez, D, Inglada-Perez, L, Santos, M, Lanillos, J, Gutierrez-Abad, D, Hernandez, A, Carbonell, P, Leton, R, Robledo, M, Rodriguez-Antona, C, Perea, J, Urioste, M (2022).

Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients

Orphanet Journal of Rare Diseases. Article. 17(1).
[doi:10.1186/s13023-021-02079-7]
Zugazagoitia, J, Paz-Ares, L (2022).

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.

JOURNAL OF CLINICAL ONCOLOGY. Review. 40(6):671-680.
[doi:10.1200/JCO.21.01881]
Paz-Ares, LG, Ramalingam, SS, Ciuleanu, TE, Lee, JS, Urban, L, Caro, RB, Park, K, Sakai, H, Ohe, Y, Nishio, M, Audigier-Valette, C, Burgers, JA, Pluzanski, A, Sangha, R, Gallardo, C, Takeda, M, Linardou, H, Lupinacci, L, Lee, KH, Caserta, C, Provencio, M, Carcereny, E, Otterson, GA, Schenker, M, Zurawski, B, Alexandru, A, Vergnenegre, A, Raimbourg, J, Feeney, K, Kim, SW, Borghaei, H, O'Byrne, KJ, Hellmann, MD, Memaj, A, Nathan, FE, Bushong, J, Tran, P, Brahmer, JR, Reck, M (2022).

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of Thoracic Oncology. Article. 17(2):289-308.
[doi:10.1016/j.jtho.2021.09.010]
Paredes-Ruiz D, Gómez-Cuervo C, Gómez-Martín C, Sánchez-Guerrero Á, González-Olmedo J, López-López F, Bover-Larroya M, Yarza-Barrio R, Jara-Casas DD, Castelo-Laureiro A, Revilla-Ostolaza Y, Paz-Ares L, Lumbreras-Bermejo C, Díaz-Pedroche C (2022).

Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid

JOURNAL OF THROMBOSIS AND THROMBOLYSIS. Article. 53(2):1-8.
[doi:10.1007/s11239-021-02448-w]
Li, BT, Smit, EF, Goto, Y, Nakagawa, K, Udagawa, H, Mazières J, Nagasaka, M, Bazhenova, L, Saltos, AN, Felip, E, Pacheco, JM, Perol, M, Paz-Ares, L, Saxena, K, Shiga, R, Cheng, YK, Acharyya, S, Vitazka, P, Shahidi, J, Planchard, D, Jänne PA (2022).

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

NEW ENGLAND JOURNAL OF MEDICINE. Article. 386(3):241-251.
[doi:10.1056/NEJMoa2112431]
Bernardini A, Dueñas M, Martín-Soberon MC, Rubio C, Suarez-Cabrera C, Ruiz-Palomares R, Munera-Maravilla E, Lázaro S, Lodewijk I, Rueda D, Gómez-Sánchez D, Alonso-Gordoa T, Puente J, Pinto Á, González-Peramato P, Aguado C, Herrera M, López F, Martinez VMG, Morales L, Castellano D, Paramio JM, de Velasco G (2022).

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer.

Cancers. Article. 14(2).
[doi:10.3390/cancers14020378]
Arriola E, Trigo JM, Sánchez-Gastaldo A, Navarro A, Perez C, Crama L, Ponce-Aix S (2022).

Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis.

JTO Clinical and Research Reports. Article. 3(1):100266-100266.
[doi:10.1016/j.jtocrr.2021.100266]

2021

Otano I, Azpilikueta A, Glez-Vaz J, Alvarez M, Medina-Echeverz J, Cortés-Domínguez I, Ortiz-de-Solorzano C, Ellmark P, Fritzell S, Hernandez-Hoyos G, Nelson MH, Ochoa MC, Bolanos, E, Cuculescu D, Jaúregui P, Sanchez-Gregorio S, Etxeberria I, Rodriguez-Ruiz ME, Sanmamed MF, Teijeira Á, Berraondo P, Melero I (2021).

CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

Nature Communications. Article. 12(1):7296-7296.
[doi:10.1038/s41467-021-27613-w]
Riudavets, M, Bosch-Barrera, J, Cabezon-Gutierrez, L, Tain, PD, Hernandez, A, Alonso, M, Blanco, R, Galvez, E, Insa, A, Mielgo, X, Moran, T, Ponce, S, Roa, D, Sanchez, JM, Majem, M (2021).

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma

Clinical & Translational Oncology. Article. 23(12):2560-2567.
[doi:10.1007/s12094-021-02661-2]
Gonzalez-Cao, M, Casas, CM, Oramas, J, Berciano-Guerrero, MA, de la Cruz, L, Cerezuela, P, Arance, A, Munoz-Couselo, E, Espinosa, E, Puertolas, T, Beveridge, RD, Ochenduszko, S, Villanueva, MJ, Basterretxea, L, Bellido, L, Rodriguez, D, Campos, B, Montagut, C, Drozdowskyj, A, Molina, MA, Lopez-Martin, JA, Berrocal, A (2021).

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Nature Communications. Article. 12(1).
[doi:10.1038/s41467-021-26572-6]
Bouza, E, Jimenez, MM, Alemany, L, Arribas, J, Banares, R, Barragan, MB, Bouza, JME, Felip, E, Fernandez-Capetillo, O, Gracia, D, Lopez-Velez, R, Mollar, JB, Munoz, P, Paz-Ares, L, Torne, A, Tovar, J, Valencia, E, Palomo, E (2021).

Overview of virus and cancer relationships. Position paper

Revista Espanola de Quimioterapia. Review. 34(6):525-555.
[doi:10.37201/req/058.2021]
Doroshow DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, Rimm DL (2021).

Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.

Journal of Thoracic Oncology. Article. 16(12):2139-2143.
[doi:10.1016/j.jtho.2021.07.032]
De Jalon, EG, De Garibay, GR, Haug, BE, McCormack, E (2021).

CytoCy5S (TM), a compound of many structures. in vitro and in vivo evaluation of four near-infrared fluorescent substrates of nitroreductase (NTR)

DYES AND PIGMENTS. Article. 196.
[doi:10.1016/j.dyepig.2021.109553]
Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, Rodríguez-Cid J, Kowalski DM, Cheng Y, Kurata T, Awad MM, Lin J, Zhao B, Pietanza MC, Piperdi B, Garassino MC (2021).

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.

Journal of Thoracic Oncology. Article. 16(11):1883-1892.
[doi:10.1016/j.jtho.2021.06.020]
Pujol JL, Vansteenkiste J, Paz-Ares Rodríguez L, Gregorc V, Mazieres J, Awad M, Jänne PA, Chisamore M, Hossain AM, Chen Y, Beck JT (2021).

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study.

JTO Clinical and Research Reports. Article. 2(11):100234-100234.
[doi:10.1016/j.jtocrr.2021.100234]
Nakagawa K, Nadal E, Garon EB, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Paz-Ares L, Frimodt-Moller B, Zimmermann AH, Wijayawardana S, Visseren-Grul C, Reck M, RELAY study investigators (2021).

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.

CLINICAL CANCER RESEARCH. Article. 27(19):5258-5271.
[doi:10.1158/1078-0432.CCR-21-0273]
Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, Wu L, Cao L, Liu J, Zhang H, Sun H, Wang Z, Gao H, Sun Y, Li B, Hu X, Schwarzenberger P, Paz-Ares L (2021).

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407.

JTO Clinical and Research Reports. Article. 2(10):100225-100225.
[doi:10.1016/j.jtocrr.2021.100225]
Reck, M, Ciuleanu, TE, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, PJ, De Marchiy, P, Martin, C, Perol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, John, T (2021).

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

ESMO Open. Article. 6(5).
[doi:10.1016/j.esmoop.2021.100273]
Antequera D, Moneo D, Carrero L, Bartolome F, Ferrer I, Proctor G, Carro E (2021).

Salivary Lactoferrin Expression in a Mouse Model of Alzheimer's Disease.

Frontiers in Immunology. Article. 12:749468-749468.
[doi:10.3389/fimmu.2021.749468]
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, Garc?a-Campelo R, González-Larriba JL, Sánchez-Torres JM, Isla D, Viñolas N, Camps C, Insa A, Juan Ó, Massuti B, Paredes A, Artal Á, López-Brea M, Palacios J, Felip E (2021).

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.

Cancer Medicine. Article. 10(17):5878-5888.
[doi:10.1002/cam4.4135]
Blanco-Palmero VA, Rubio-Fernández M, Antequera D, Villarejo-Galende A, Molina JA, Ferrer I, Bartolome F, Carro E (2021).

Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer's Disease

Biomedicines. Article. 9(9).
[doi:10.3390/biomedicines9091094]
Falco A, de Oliveira TB, Cacicedo J, Ospina AV, Ticona MÁ, Galindo H, Pereira MD, Aguilar-Ponce JL, Rueda-Domínguez A, Soria T, Taberna M, Iglesias L, Sowley T, Mesía R, TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer) (2021).

Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice.

Cancer Management and Research. Review. 13:6689-6703.
[doi:10.2147/CMAR.S322411]
Martinez-Trufero, J., Lozano Borbalas, A., Pajares Bernad, I., Taberna Sanz, M., Ortega Izquierdo, E., Cirauqui Cirauqui, B., Rubio-Casadevall, J., Plana Serrahima, M., Ponce Ortega, J. M., Planas Toledano, I., Caballero, J., Marruecos Querol, J., Iglesias Docampo, L., Lambea Sorrosal, J., Adansa, J. C., Mesia Nin, R., Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC) (2021).

Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.

Clinical & Translational Oncology. Article. 23(8):1666-1677.
[doi:10.1007/s12094-021-02567-z]
Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Ucero ÁC, González-Barcala FJ, Salgado FJ, Pichel JG (2021).

IGF1R as a Potential Pharmacological Target in Allergic Asthma.

Biomedicines. Article. 9(8).
[doi:10.3390/biomedicines9080912]
Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B (2021).

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.

EUROPEAN JOURNAL OF CANCER. Article. 151:211-220.
[doi:10.1016/j.ejca.2021.03.011]
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V (2021).

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

LANCET ONCOLOGY. Article. 22(7):959-969.
[doi:10.1016/S1470-2045(21)00247-3]
Yarza R, Bover M, Agulló-Ortuño MT, Iglesias-Docampo LC (2021).

Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. Review. 40(1):202-202.
[doi:10.1186/s13046-021-02010-9]
Amador, M, Matias-Guiu, X, Sancho-Pardo, G, Martinez, JC, de la Torre-Montero, JC, Saiz, AP, Garrido, P, Garcia-Sanz, R, Rodriguez-Lescure, A, Paz-Ares, L (2021).

Impact of the COVID-19 pandemic on the care of cancer patients in Spain

ESMO Open. Article. 6(3).
[doi:10.1016/j.esmoop.2021.100157]
Baena J, Modrego A, Zeaiter A, Kahatt C, Alfaro V, Jimenez-Aguilar E, Mazarico JM, Paz-Ares L (2021).

Lurbinectedin in the treatment of relapsed small cell lung cancer.

Future Oncology. Article. 17(18):2279-2289.
[doi:10.2217/fon-2020-1212]
Hotta K, Nishio M, Saito H, Okamoto I, Nakahara Y, Hayashi H, Hayama M, Laud P, Jiang H, Paz-Ares L, Azuma K (2021).

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis.

International Journal of Clinical Oncology. Article. 26(6):1073-1082.
[doi:10.1007/s10147-021-01899-8]
Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G (2021).

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.

ESMO Open. Article. 6(3):100113-100113.
[doi:10.1016/j.esmoop.2021.100113]
Compte M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, Romero E, Ferrer I, Garrido-Martin EM, Enguita AB, Ochoa MC, Blanco B, Oteo M, Merino N, Nehme-Álvarez D, Hangiu O, Domínguez-Alonso C, Zonca M, Ramírez-Fernández A, Blanco FJ, Morcillo MA, Munoz, IG, Melero I, Rodriguez-Peralto JL, Paz-Ares L, Sanz L, Alvarez-Vallina L (2021).

An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity

CLINICAL CANCER RESEARCH. Article. 27(11):3167-3177.
[doi:10.1158/1078-0432.CCR-20-4625]
Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, Trigo J, Chaves M, García-Castaño A, Cruz J (2021).

SEOM clinical guidelines for the treatment of head and neck cancer (2020).

Clinical & Translational Oncology. Article. 23(5):913-921.
[doi:10.1007/s12094-020-02533-1]
Ramos-Paradas J, Hernández-Prieto S, Lora D, Sanchez E, Rosado A, Caniego-Casas T, Carrizo N, Enguita AB, Muñoz-Jimenez MT, Rodriguez B, Perez-Gonzalez U, Gómez-Sánchez D, Ferrer I, Ponce Aix S, Nuñez Buiza Á, Garrido P, Palacios J, Lopez-Rios F, Garrido-Martin EM, Paz-Ares L (2021).

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB(2) harmonization project comparing three NGS panels.

Journal for ImmunoTherapy of Cancer. Article. 9(5).
[doi:10.1136/jitc-2020-001904]
Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, Trigo J, Chaves M, García-Castaño A, Cruz-Hernández JJ (2021).

Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020).

Clinical & Translational Oncology. Correction. .(5):1001-1001.
[doi:10.1007/s12094-021-02582-0]
Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Özgüroglu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ (2021).

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.

Journal of Thoracic Oncology. Article. 16(5):860-867.
[doi:10.1016/j.jtho.2020.12.015]
Serrano-Lorenzo P, Coya ON, López-Jimenez A, Blázquez A, Delmiro A, Lucia A, Arenas J, Martín MA, COVID-19 ’12 Octubre’ Hospital Clinical Biochemistry Study Group (2021).

Plasma LDH: A specific biomarker for lung affectation in COVID-19?

Practical Laboratory Medicine. Article. 25.
[doi:10.1016/j.plabm.2021.e00226]
Ponce Aix S, Novello S, Garon EB, Nakagawa K, Nadal E, Moro-Sibilot D, Alonso Garcia M, Fabre E, Frimodt-Moller B, Zimmermann AH, Visseren-Grul CM, Reck M, RELAY investigators (2021).

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.

Cancer Treatment and Research Communications. Article. 27:100378-100378.
[doi:10.1016/j.ctarc.2021.100378]
Ruiz de Garibay G, García de Jalón E, Stigen E, Lund KB, Popa M, Davidson B, Safont MM, Rygh CB, Espedal H, Barrett TM, Haug BE, McCormack E (2021).

Repurposing (18)F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy.

THERANOSTICS. Article. 11(12):6044-6057.
[doi:10.7150/thno.55092]
Garassino, MC, Paz-Ares, L, Hui, RN, Faivre-Finn, C, Spira, A, Planchard, D, Özgüroglu M, Daniel, D, Vicente, D, Murakami, S, Langer, C, Senan, S, Spigel, D, Ryden, A, Zhang, YD, O'Brien, C, Dennis, PA, Antonia, SJ (2021).

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

Future Oncology. Article. 17(10):1165-1184.
[doi:10.2217/fon-2020-1102]
Hitt, R, Iglesias, L, Lopez-Pousa, A, Berrocal-Jaime, A, Grau, JJ, Garcia-Giron, C, Martinez-Trufero, J, Guix, M, Lambea-Sorrosal, J, del Barco-Morillo, E, Leon-Vintro, X, Cunquero-Tomas, AJ, Baste, N, Ocana, A, Cruz-Hernandez, JJ, Spanish Head Neck Canc Cooperati (2021).

Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

Clinical & Translational Oncology. Article. 23(4):764-772.
[doi:10.1007/s12094-020-02467-8]
Paz-Ares L (2021).

Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.

Journal of Thoracic Oncology. Letter. 16(4).
[doi:10.1016/j.jtho.2021.01.1608]
Ocana, J, Vivas, A, Labalde, M, Pelaez, P, Garcia, S, Garcia-Borda, J, Ferrero, E (2021).

Laparoscopic sigmoid resection for a giant colonic diverticulum - a video vignette

Colorectal Disease. Letter. 23(4):1011-1011.
[doi:10.1111/codi.15520]
Teran S, Camara Jurado M, Nuñez Sobrino JA (2021).

A Patient with an Ileocecal MiNEN and a Synchronous Squamous Non-Small-Cell Lung Cancer: Case Report and Review of the Literature.

Case Reports in Oncological Medicine. Review. 2021:8896254-8896254.
[doi:10.1155/2021/8896254]
Prieto-García E, Díaz-García CV, Agudo-López A, Pardo-Marqués V, García-Consuegra I, Asensio-Peña S, Alonso-Riaño M, Pérez C, Gómez C, Adeva J, Paz-Ares L, López-Martín JA, Agulló-Ortuño MT (2021).

Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread.

Biomedicines. Article. 9(4).
[doi:10.3390/biomedicines9040364]
Majem M, Cobo M, Isla D, Marquez-Medina D, Rodriguez-Abreu D, Casal-Rubio J, Bueno TM, Bernabé-Caro R, Parente DP, Ruiz-Gracia P, Arroyo MM, Paz-Ares L (2021).

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.

Journal of Clinical Medicine. Review. 10(7).
[doi:10.3390/jcm10071365]
Marrugal Á, Ferrer I, Gómez-Sánchez D, Quintanal-Villalonga Á, Pastor MD, Ojeda L, Paz-Ares L, Molina-Pinelo S (2021).

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Article. 22(5).
[doi:10.3390/ijms22052538]
Goldman JW, Paz-Ares L (2021).

Combination treatment options for small-cell lung cancer - Authors' reply.

LANCET ONCOLOGY. Letter. 22(3):84-84.
[doi:10.1016/S1470-2045(21)00083-8]
Yu, HA, Paz-Ares, LG, Yang, JCH, Lee, KH, Garrido, P, Park, K, Kim, JH, Lee, DH, Mao, HZ, Wijayawardana, SR, Gao, L, Hozak, RR, Chao, BH, Planchard, D (2021).

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer

CLINICAL CANCER RESEARCH. Article. 27(4):992-1002.
[doi:10.1158/1078-0432.CCR-20-1690]
Ortega-Franco A, Ackermann C, Paz-Ares L, Califano R (2021).

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.

ESMO Open. Review. 6(1):100003-100003.
[doi:10.1016/j.esmoop.2020.100003]
Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K, Visseren-Grul C, Heymach JV, Garon EB (2021).

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.

Journal of Thoracic Oncology. Article. 16(2):205-215.
[doi:10.1016/j.jtho.2020.10.006]
Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, Paz-Ares L (2021).

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.

Journal of Thoracic Oncology. Article. 16(2):289-298.
[doi:10.1016/j.jtho.2020.10.004]
Paz-Ares, L, Ciuleanu, TE, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Salman, P, Souquet, PJ, De Marchi, P, Martin, C, Perol, M, Scherpereel, A, Lu, S, John, T, Carbone, DP, Meadows-Shropshire, S, Agrawal, S, Oukessou, A, Yan, JC, Reck, M (2021).

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

LANCET ONCOLOGY. Article. 22(2):198-211.
[doi:10.1016/S1470-2045(20)30641-0]
Cobo, I, Iglesias, M, Flandez, M, Verbeke, C, del Pozo, N, Llorente, M, Lawlor, R, Luchini, C, Rusev, B, Scarpa, A, Real, FX (2021).

Epithelial Nr5a2 heterozygosity cooperates with mutant Kras in the development of pancreatic cystic lesions

JOURNAL OF PATHOLOGY. Article. 253(2):174-185.
[doi:10.1002/path.5570]
Pillai RN, Ramalingam SS, Thayu M, Lorenzini P, Alvarez Arias DA, Moy C, Hutnick N, Knoblauch R, Feng H, Kane C, Horn L, Reck M, Ponce S, LUC2001 Investigators (2021).

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).

JTO Clinical and Research Reports. Article. 2(2):100104-100104.
[doi:10.1016/j.jtocrr.2020.100104]
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigators (2021).

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

LANCET ONCOLOGY. Article. 22(1):51-65.
[doi:10.1016/S1470-2045(20)30539-8]
Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroglu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ (2021).

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

LUNG CANCER. Article. 151:30-38.
[doi:10.1016/j.lungcan.2020.11.024]

2020

Subbiah, V, Paz-Ares, L, Besse, B, Moreno, V, Peters, S, Sala, MA, López-Vilariño, JA, Fernández, C, Kahatt, C, Alfaro, V, Siguero, M, Zeaiter, A, Zaman, K, López, R, Ponce, S, Boni, V, Arrondeau, J, Delord, JP, Martínez, M, Wannesson, L, Antón, A, Valdivia, J, Awada, A, Kristeleit, R, Olmedo, ME, Rubio, MJ, Sarantopoulos, J, Chawla, SP, Mosquera-Martinez, J, D' Arcangelo M, Santoro, A, Villalobos, VM, Sands, J, Trigo, J (2020).

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

LUNG CANCER. Article. 150:90-96.
[doi:10.1016/j.lungcan.2020.10.003]
Paz-Ares, L, AstraZeneca UK Limited (2020).

Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.

BRITISH JOURNAL OF CANCER. Editorial Material. 123(Suppl 1):1-2.
[doi:10.1038/s41416-020-01068-0]
Paz-Ares, L, AstraZeneca UK Limited (2020).

Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.

BRITISH JOURNAL OF CANCER. Editorial Material. 123(Suppl 1):36-36.
[doi:10.1038/s41416-020-01073-3]
Muñoz-Unceta N, Zugazagoitia, J, Manzano, A, Jimenez-Aguilar, E, Olmedo, ME, Cacho, JD, Oliveira, J, Domine, M, Ortega-Moran, L, Aguado, C, Luna, AM, Fernandez, L, Perez, J, Font, C, Salvador, C, Corral, J, Benitez, G, Ros, S, Biosca, M, Calvo, V, Martinez, J, Sanchez-Canovas, M, Lopez, R, Sereno, M, Mielgo, X, Aparisi, F, Carmona, M, Carrion, R, Ponce-Aix, S, Soares, M, Martinez-Salas, I, Garcia-Morillo, M, Juan-Vidal, O, Blasco, A, Muñoz AJ, Paz-Ares, L, Grp Trombosis & Canc SEOM (2020).

High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

EUROPEAN JOURNAL OF CANCER. Article. 141:193-198.
[doi:10.1016/j.ejca.2020.10.002]
Borghaei, H, Langer, CJ, Paz-Ares, L, Rodríguez-Abreu, D, Halmos, B, Garassino, MC, Houghton, B, Kurata, T, Cheng, Y, Lin, JX, Pietanza, MC, Piperdi, B, Gadgeel, SM (2020).

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.

CANCER. Article. 126(22):4867-4877.
[doi:10.1002/cncr.33142]
Goldman, JW, Garassino, MC, Chen, YB, Özgüroglu M, Dvorkin, M, Trukhin, D, Statsenko, G, Hotta, K, Ji, JH, Hochmair, MJ, Voitko, O, Havel, L, Poltoratskiy, A, Losonczy, G, Reinmuth, N, Patel, N, Laud, PJ, Shire, N, Jiang, HY, Paz-Ares, L (2020).

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

LUNG CANCER. Article. 149:46-52.
[doi:10.1016/j.lungcan.2020.09.003]
Garcia-Prat, L, Perdiguero, E, Alonso-Martin, S, Dell'Orso, S, Ravichandran, S, Brooks, SR, Juan, AH, Campanario, S, Jiang, K, Hong, XT, Ortet, L, Ruiz-Bonilla, V, Flandez, M, Moiseeva, V, Rebollo, E, Jardi, M, Sun, HW, Musaro, A, Sandri, M, del Sol, A, Sartorelli, V, Muñoz-Cánoves P (2020).

FoxO maintains a genuine muscle stem-cell quiescent state until geriatric age.

NATURE CELL BIOLOGY. Article. 22(11):1307-1318.
[doi:10.1038/s41556-020-00593-7]
Martin-Broto, J, Hindi, N, Grignani, G, Martinez-Trufero, J, Redondo, A, Valverde, C, Stacchiotti, S, Lopez-Pousa, A, D'Ambrosio, L, Gutierrez, A, Perez-Vega, H, Encinas-Tobajas, V, de Alava, E, Collini, P, Peña-Chilet M, Dopazo, J, Carrasco-Garcia, I, Lopez-Alvarez, M, Moura, DS, Lopez-Martin, JA (2020).

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.

Journal for ImmunoTherapy of Cancer. Article. 8(2).
[doi:10.1136/jitc-2020-001561]
Serrano, MJ, Garrido-Navas, MC, Mochon, JJD, Cristofanilli, M, Gil-Bazo, I, Pauwels, P, Malapelle, U, Russo, A, Lorente, JA, Ruiz-Rodriguez, AJ, Paz-Ares, LG, Vilar, E, Raez, LE, Cardona, AF, Rolfo, C, Int Soc Liquid Biopsy (2020).

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

Cancer Discovery. Review. 10(11):1635-1644.
[doi:10.1158/2159-8290.CD-20-0466]
Goldman, JW, Mazieres, J, Barlesi, F, Dragnev, KH, Koczywas, M, Göskel T, Cortot, AB, Girard, N, Wesseler, C, Bischoff, H, Nadal, E, Park, K, Lu, S, Taus, A, Cobo, M, Estrem, ST, Wijayawardana, SR, Turner, K, Oakley, GJ, Hurt, KC, Chiang, AY, Hossain, AM, John, WJ, Paz-Ares, L (2020).

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.

Frontiers in Oncology. Article. 10:578756-578756.
[doi:10.3389/fonc.2020.578756]
Marquez-Rodas, I, Longo, F, Rodriguez-Ruiz, ME, Calles, A, Ponce, S, Jove, M, Rubio-Viqueira, B, Perez-Gracia, JL, Gomez-Rueda, A, Lopez-Tarruella, S, Ponz-Sarvise, M, Alvarez, R, Soria-Rivas, A, de Miguel, E, Ramos-Medina, R, Castañon E, Gajate, P, Sempere-Ortega, C, Jimenez-Aguilar, E, Aznar, MA, Calvo, A, Lopez-Casas, PP, Martin-Algarra, S, Martin, M, Tersago, D, Quintero, M, Melero, I (2020).

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.

SCIENCE TRANSLATIONAL MEDICINE. Article. 12(565).
[doi:10.1126/scitranslmed.abb0391]
Fernández-Mateos, J, Pérez-García, J, Seijas-Tamayo, R, Mesía, R, Rubió-Casadevall, J, García-Girón, C, Iglesias, L, Carral Maseda A, Adansa Klain JC, Taberna, M, Vazquez, S, Gómez, MA, del Barco, E, Ocana, A, González-Sarmiento, R, Cruz-Hernández, JJ (2020).

Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.

SCIENTIFIC REPORTS. Article. 10(1):16634-16634.
[doi:10.1038/s41598-020-72927-2]
Rolfo, C, Cardona, AF, Cristofanilli, M, Paz-Ares, L, Diaz Mochon JJ, Duran, I, Raez, LE, Russo, A, Lorente, JA, Malapelle, U, Gil-Bazo, I, Jantus-Lewintre, E, Pauwels, P, Mok, T, Serrano, MJ, ISLB (2020).

Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978].

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Correction. 154:103058-103058.
[doi:10.1016/j.critrevonc.2020.103058]
Paz-Ares, L, Vicente, D, Tafreshi, A, Robinson, A, Soto Parra H, Mazières J, Hermes, B, Cicin, I, Medgyasszay, B, Rodríguez-Cid, J, Okamoto, I, Lee, S, Ramlau, R, Vladimirov, V, Cheng, Y, Deng, X, Zhang, Y, Bas, T, Piperdi, B, Halmos, B (2020).

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.

Journal of Thoracic Oncology. Article. 15(10):1657-1669.
[doi:10.1016/j.jtho.2020.06.015]
Marabelle, A, Fakih, M, Lopez, J, Shah, M, Shapira-Frommer, R, Nakagawa, K, Chung, HC, Kindler, HL, Lopez-Martin, JA, Miller, WH, Italiano, A, Kao, S, Piha-Paul, SA, Delord, JP, McWilliams, RR, Fabrizio, DA, Aurora-Garg, D, Xu, L, Jin, F, Norwood, K, Bang, YJ (2020).

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

LANCET ONCOLOGY. Article. 21(10):1353-1365.
[doi:10.1016/S1470-2045(20)30445-9]
Remon, J, Nadal, E, Domine, M, Ruffinelli, J, Garcia, Y, Pardo, JC, Lopez, R, Cilleruelo, A, Garcia-Campelo, R, Martin, P, Juan, O, Gonzalez-Larriba, JL, Provencio, M, Olmedo, E, Ponce, S, Cumplido, D, Barenys, C, Majem, M, Massutti, B, Rodriguez-Abreu, D, Porta, R, Sala, MA, Martinez-Kareaga, M, Lianes, P, Reguart, N (2020).

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.

LUNG CANCER. Article. 147:83-90.
[doi:10.1016/j.lungcan.2020.06.034]
Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G (2020).

Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.

Biomedicine Hub. Article. 5(3):182-223.
[doi:10.1159/000511209]
Romaniello, D, Marrocco, I, Belugali Nataraj N, Ferrer, I, Drago-Garcia, D, Vaknin, I, Oren, R, Lindzen, M, Ghosh, S, Kreitman, M, Kittel, JC, Gaborit, N, Bergado Baez G, Sanchez, B, Eilam, R, Pikarsky, E, Paz-Ares, L, Yarden, Y (2020).

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.

Cancers. Article. 12(9).
[doi:10.3390/cancers12092394]
Zugazagoitia, J, Gupta, S, Liu, YT, Fuhrman, K, Gettinger, S, Herbst, RS, Schalper, KA, Rimm, DL (2020).

Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) identified using high-plex digital spatial profiling.

CLINICAL CANCER RESEARCH. Article. 26(16):4360-4368.
[doi:10.1158/1078-0432.CCR-20-0175]
Capdevila, J, Wirth, LJ, Ernst, T, Ponce Aix S, Lin, CC, Ramlau, R, Butler, MO, Delord, JP, Gelderblom, H, Ascierto, PA, Fasolo, A, Führer, D, Hütter-Krönke, ML, Forde, PM, Wrona, A, Santoro, A, Sadow, PM, Szpakowski, S, Wu, HQ, Bostel, G, Faris, J, Cameron, S, Varga, A, Taylor, M (2020).

PD-1 Blockade in Anaplastic Thyroid Carcinoma.

JOURNAL OF CLINICAL ONCOLOGY. Article. 38(23):2620-2627.
[doi:10.1200/JCO.19.02727]
Candito, A, Palacio-Torralba, J, Jiménez-Aguilar, E, Good, DW, McNeill, A, Reuben, RL, Chen, YH (2020).

Identification of tumor nodule in soft tissue: An inverse finite-element framework based on mechanical characterization.

International Journal for Numerical Methods in Biomedical Engineering. Article. 36(8).
[doi:10.1002/cnm.3369]
Yarza, R, Bover, M, Paredes, D, López-López, F, Jara-Casas, D, Castelo-Loureiro, A, Baena, J, Mazarico, JM, Folgueira, MD, Meléndez-Carmo, MA, Reyes, A, Lumbreras, C, Paz-Ares, L, Díaz-Pedroche, C, Gómez-Martín, C (2020).

SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.

EUROPEAN JOURNAL OF CANCER. Article. 135:242-250.
[doi:10.1016/j.ejca.2020.06.001]
Alessi, JV, Ricciuti, B, Jimenez-Aguilar, E, Hong, FX, Wei, ZH, Nishino, M, Plodkowski, AJ, Sawan, P, Luo, J, Rizvi, H, Carter, BW, Heymach, JV, Altan, M, Hellmann, M, Awad, M (2020).

Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status.

Journal for ImmunoTherapy of Cancer. Article. 8(2).
[doi:10.1136/jitc-2020-001007]
Cedres, S, Ponce-Aix, S, Iranzo, P, Callejo, A, Pardo, N, Navarro, A, Martinez-Marti, A, Gomez-Abecia, S, Zucchiatti, AC, Sansano, I, Enguita, AB, Miquel, JM, Viaplana, C, Dienstmann, R, Paz-Ares, L, Felip, E (2020).

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.

Clinical & Translational Oncology. Article. 22(8):1390-1398.
[doi:10.1007/s12094-019-02275-9]
Fruh, M, Panje, CM, Reck, M, Blackhall, F, Califano, R, Cappuzzo, F, Besse, B, Novello, S, Garrido, P, Felip, E, O'Brien, M, Paz Ares L, de Marinis, F, Westeel, V, De Ruysscher, D, Putora, PM (2020).

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.

LUNG CANCER. Article. 146:6-11.
[doi:10.1016/j.lungcan.2020.03.024]
Noguera-Uclés, JF, Boyero, L, Salinas, A, Cordero Varela JA, Benedetti, JC, Bernabé-Caro, R, Sánchez-Gastaldo, A, Alonso, M, Paz-Ares, L, Molina-Pinelo, S (2020).

The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients.

Cancers. Article. 12(8).
[doi:10.3390/cancers12082075]
Rolfo, C, Cardona, AF, Cristofanilli, M, Paz-Ares, L, Diaz Mochon JJ, Duran, I, Raez, LE, Russo, A, Lorente, JA, Malapelle, U, Gil-Bazo, I, Jantus-Lewintre, E, Pauwels, P, Mok, T, Serrano, MJ, ISLB (2020).

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Review. 151:102978-102978.
[doi:10.1016/j.critrevonc.2020.102978]
López-Ríos F, Paz-Ares L, Sanz J, Isla D, Pijuan L, Felip E, Gómez-Román JJ, de Castro J, Conde E, Garrido P (2020).

Actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón de célula no pequeña avanzado. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica.

Revista Espanola de Patologia. Article. 53(3):167-181.
[doi:10.1016/j.patol.2019.11.004]
Garrido, P, Conde, E, de Castro, J, Gómez-Román, JJ, Felip, E, Pijuan, L, Isla, D, Sanz, J, Paz-Ares, L, López-Ríos, F (2020).

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Clinical & Translational Oncology. Article. 22(7):989-1003.
[doi:10.1007/s12094-019-02218-4]
Paz-Ares, L, Kim, TM, Vicente, D, Felip, E, Lee, DH, Lee, KH, Lin, CC, Flor, MJ, Di Nicola, M, Alvarez, RM, Dussault, I, Helwig, C, Ojalvo, LS, Gulley, JL, Cho, BC (2020).

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.

Journal of Thoracic Oncology. Article. 15(7):1210-1222.
[doi:10.1016/j.jtho.2020.03.003]
Whisenant, JG, Torri, V, Huang, LC, Trama, A, Paz-Ares, LG, Felip, E, Pancaldi, V, De Toma, A, Tiseo, M, Garrido, P, Genova, C, Cadranel, J, Michielin, O, Dingemans, AMC, Van Meerbeeck, JP, Barlesi, F, Wakelee, HA, Peters, S, Garassino, MC (2020).

Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 38(18).
[doi:10.1200/JCO.2020.38.18_suppl.LBA111]
Lopez-Martin, JA, Arance Fernández A, Ríos-Martín, JJ, Hernández-Losa, J, Alós Hernández L, Cerezuela Fuentes P, Ortiz Reina S, Ortega Izquierdo E, Martí, RM, Soberino García J, Ferrer Fábrega B, Rodríguez Peralto JL, ABSOLUT-BRAF Study Group (2020).

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain.

TRANSLATIONAL ONCOLOGY. Article. 13(6):100750-100750.
[doi:10.1016/j.tranon.2020.100750]
Paz-Ares, L, Spira, A, Raben, D, Planchard, D, Cho, BC, Ozguroglu, M, Daniel, D, Villegas, A, Vicente, D, Hui, R, Murakami, S, Spigel, D, Senan, S, Langer, CJ, Perez, BA, Boothman, AM, Broadhurst, H, Wadsworth, C, Dennis, PA, Antonia, SJ, Faivre-Finn, C (2020).

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.

ANNALS OF ONCOLOGY. Article. 31(6):798-806.
[doi:10.1016/j.annonc.2020.03.287]
Kroeze, LI, de Voer, RM, Kamping, EJ, von Rhein, D, Jansen EAM, Hermsen MJW, Barberis MCP, Botling, J, Garrido-Martin, EM, Haller, F, Lacroix, L, Maes, B, Merkelbach-Bruse, S, Pestinger, V, Pfarr, N, Stenzinger, A, van den Heuvel, MM, Grünberg, K, Ligtenberg MJL (2020).

Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes.

JOURNAL OF MOLECULAR DIAGNOSTICS. Article. 22(6):757-769.
[doi:10.1016/j.jmoldx.2020.02.009]
Remon, J, Passiglia, F, Ahn, MJ, Barlesi, F, Forde, PM, Garon, EB, Gettinger, S, Goldberg, SB, Herbst, RS, Horn, L, Kubota, K, Lu, S, Mezquita, L, Paz-Ares, L, Popat, S, Schalper, KA, Skoulidis, F, Reck, M, Adjei, AA, Scagliotti, GV (2020).

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.

Journal of Thoracic Oncology. Review. 15(6):914-947.
[doi:10.1016/j.jtho.2020.03.006]
Tan, DSW, Leighl, NB, Riely, GJ, Yang, JCH, Sequist, LV, Wolf, J, Seto, T, Felip, E, Aix, SP, Jonnaert, M, Pan, C, Tan, EY, Ko, J, Moody, SE, Kim, DW (2020).

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

Lancet Respiratory Medicine. Article. 8(6):561-572.
[doi:10.1016/S2213-2600(19)30267-X]
Manso, L, De Velasco, G, Paz-Ares, L (2020).

Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain.

ESMO Open. Letter. 4(Suppl 2).
[doi:10.1136/esmoopen-2020-000828]
Isla, D, de Castro, J, García-Campelo, R, Lianes, P, Felip, E, Garrido, P, Paz-Ares, L, Trigo, JM (2020).

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

Clinical & Translational Oncology. Article. 22(5):759-771.
[doi:10.1007/s12094-019-02191-y]
Trigo, J, Subbiah, V, Besse, B, Moreno, V, Lopez, R, Sala, MA, Peters, S, Ponce, S, Fernandez, C, Alfaro, V, Gomez, J, Kahatt, C, Zeaiter, A, Zaman, K, Boni, V, Arrondeau, J, Martinez, M, Delord, JP, Awada, A, Kristeleit, R, Olmedo, ME, Wannesson, L, Valdivia, J, Rubio, MJ, Anton, A, Sarantopoulos, J, Chawla, SP, Mosquera-Martinez, J, D'Arcangelo, M, Santoro, A, Villalobos, VM, Sands, J, Paz-Ares, L (2020).

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

LANCET ONCOLOGY. Article. 21(5):645-654.
[doi:10.1016/S1470-2045(20)30068-1]
Moreno-Rubio, J, Ponce, S, Alvarez, R, Olmedo, ME, Falagan, S, Mielgo, X, Navarro, F, Cruz, P, Cabezón-Gutiérrez, L, Aguado, C, Colmenarejo, G, de Leglaria, MMF, Enguita, AB, Cebollero, M, Benito, A, Alemany, I, del Castillo, C, Ramos, R, de Molina, AR, Casado, E, Sereno, M (2020).

Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer

Cancer Biology & Medicine. Article. 17(2):444-457.
[doi:10.20892/j.issn.2095-3941.2019.0363]
Ruano, D, López-Martín, JA, Moreno, L, Lassaletta, A, Bautista, F, Andión, M, Hernández, C, González-Murillo, A, Melen, G, Alemany, R, Madero, L, García-Castro, J, Ramírez, M (2020).

First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors.

MOLECULAR THERAPY. Article. 28(4):1033-1042.
[doi:10.1016/j.ymthe.2020.01.019]
Chung, HC, Piha-Paul, SA, Lopez-Martin, J, Schellens, JHM, Kao, S, Miller, WH, Delord, JP, Gao, B, Planchard, D, Gottfried, M, Zer, A, Jalal, SI, Penel, N, Mehnert, JM, Matos, I, Bennouna, J, Kim, DW, Xu, L, Krishnan, S, Norwood, K, Ott, PA (2020).

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Journal of Thoracic Oncology. Article. 15(4):618-627.
[doi:10.1016/j.jtho.2019.12.109]
Ponce Aix S, Talbot, D, Govindan, R, Dols, MC, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Ong, TJ, Morgensztern, D (2020).

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.

Future Oncology. Article. 16(12):749-762.
[doi:10.2217/fon-2019-0796]
Carpio, C, Bouabdallah, R, Ysebaert, L, Sancho, JM, Salles, G, Cordoba, R, Pinto, A, Gharibo, M, Rasco, D, Panizo, C, Lopez-Martin, JA, Santoro, A, Salar, A, Damian, S, Martin, A, Verhoef, G, Van den Neste, E, Wang, M, Couto, S, Carrancio, S, Weng, A, Wang, XH, Schmitz, F, Wei, X, Hege, K, Trotter, MWB, Risueno, A, Buchholz, TJ, Hagner, PR, Gandhi, AK, Pourdehnad, M, Ribrag, V (2020).

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

BLOOD. Article. 135(13):996-1007.
[doi:10.1182/blood.2019002395]
Ready, NE, Ott, PA, Hellmann, MD, Zugazagoitia, J, Hann, CL, de Braud, F, Antonia, SJ, Ascierto, PA, Moreno, V, Atmaca, A, Salvagni, S, Taylor, M, Amin, A, Camidge, DR, Horn, L, Calvo, E, Li, A, Lin, WH, Callahan, MK, Spigel, DR (2020).

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

Journal of Thoracic Oncology. Article. 15(3):426-435.
[doi:10.1016/j.jtho.2019.10.004]
Agullo-Ortuno, MT, Garcia-Ruiz, I, Diaz-Garcia, CV, Enguita, AB, Pardo-Marques, V, Prieto-Garcia, E, Ponce, S, Iglesias, L, Zugazagoitia, J, Lopez-Martin, JA, Paz-Ares, L, Nuñez JA (2020).

Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.

CANCER CHEMOTHERAPY AND PHARMACOLOGY. Article. 85(3):525-535.
[doi:10.1007/s00280-019-04008-9]
Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Fontecedro AC, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R, results from the European Thoracic Oncology Platform (ETOP) BELIEF trial (2020).

Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

Journal of Thoracic Oncology. Article. 15(3):416-425.
[doi:10.1016/j.jtho.2019.11.023]
Mazarico Gallego JM, Herrera Juarez M, Paz-Ares, L (2020).

The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer.

Expert Opinion On Drug Safety. Article. 19(3):233-242.
[doi:10.1080/14740338.2020.1736554]
Quintanal-Villalonga, A, Ferrer, I, Guruceaga, E, Cirauqui, C, Marrugal, A, Ojeda, L, Garcia, S, Zugazagoitia, J, Munoz-Galvan, S, Lopez-Rios, F, Montuenga, L, Vicent, S, Molina-Pinelo, S, Carnero, A, Paz-Ares, L (2020).

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.

EBioMedicine. Article. 53:102683-102683.
[doi:10.1016/j.ebiom.2020.102683]
Felip, E, Ardizzoni, A, Ciuleanu, T, Cobo, M, Laktionov, K, Szilasi, M, Califano, R, Carcereny, E, Griffiths, R, Paz-Ares, L, Duchnowska, R, Garcia, MA, Isla, D, Jassem, J, Appel, W, Milanowski, J, Van Meerbeeck, JP, Wolf, J, Li, A, Acevedo, A, Popat, S (2020).

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.

EUROPEAN JOURNAL OF CANCER. Article. 127:160-172.
[doi:10.1016/j.ejca.2019.11.019]
Huber, RM, Hansen, KH, Paz-Ares Rodríguez L, West, HL, Reckamp, KL, Leighl, NB, Tiseo, M, Smit, EF, Kim, DW, Gettinger, SN, Hochmair, MJ, Kim, SW, Langer, CJ, Ahn, MJ, Kim, ES, Kerstein, D, Groen HJM, Camidge, DR (2020).

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Journal of Thoracic Oncology. Article. 15(3):404-415.
[doi:10.1016/j.jtho.2019.11.004]
Domine, M, Moran, T, Isla, D, Marti, JL, Sullivan, I, Provencio, M, Olmedo, ME, Ponce, S, Blasco, A, Cobo, M (2020).

SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019).

Clinical & Translational Oncology. Article. 22(2):245-255.
[doi:10.1007/s12094-020-02295-w]
Bousquet Mur E, Bernardo, S, Papon, L, Mancini, M, Fabbrizio, E, Goussard, M, Ferrer, I, Giry, A, Quantin, X, Pujol, JL, Calvayrac, O, Moll, HP, Glasson, Y, Pirot, N, Turtoi, A, Cañamero M, Wong, KK, Yarden, Y, Casanova, E, Soria, JC, Colinge, J, Siebel, CW, Mazieres, J, Favre, G, Paz-Ares, L, Maraver, A (2020).

Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.

JOURNAL OF CLINICAL INVESTIGATION. Article. 130(2):612-624.
[doi:10.1172/JCI126896]
Gray, JE, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, RN, Kurata, T, Chiappori, A, Lee, KH, Cho, BC, Planchard, D, Paz-Ares, L, Faivre-Finn, C, Vansteenkiste, JF, Spigel, DR, Wadsworth, C, Taboada, M, Dennis, PA, Özgüroglu M, Antonia, SJ (2020).

Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC.

Journal of Thoracic Oncology. Article. 15(2):288-293.
[doi:10.1016/j.jtho.2019.10.002]
Doebele, RC, Drilon, A, Paz-Ares, L, Siena, S, Shaw, AT, Farago, AF, Blakely, CM, Seto, T, Cho, BC, Tosi, D, Besse, B, Chawla, SP, Bazhenova, L, Krauss, JC, Chae, YK, Barve, M, Garrido-Laguna, I, Liu, SV, Conkling, P, John, T, Fakih, M, Sigal, D, Loong, HH, Buchschacher, GL, Garrido, P, Nieva, J, Steuer, C, Overbeck, TR, Bowles, DW, Fox, E, Riehl, T, Chow-Maneval, E, Simmons, B, Cui, N, Johnson, A, Eng, S, Wilson, TR, Demetri, GD, Trial Investigators (2020).

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

LANCET ONCOLOGY. Article. 21(2):271-282.
[doi:10.1016/S1470-2045(19)30691-6]
Gallardo, E, Medina, J, Sanchez, JC, Viudez, A, Grande, E, Porras, I, Ramón Y Cajal T, Trigo, J, Iglesias, L, Capdevila, J (2020).

SEOM clinical guideline thyroid cancer (2019).

Clinical & Translational Oncology. Article. 22(2):223-235.
[doi:10.1007/s12094-019-02284-8]
Majem, M, Garcia-Martinez, E, Martinez, M, Muñoz-Couselo E, Rodriguez-Abreu, D, Alvarez, R, Arance, A, Berrocal, A, de la Cruz-Merino, L, Lopez-Martin, JA (2020).

SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).

Clinical & Translational Oncology. Article. 22(2):213-222.
[doi:10.1007/s12094-019-02273-x]
Mazieres, J, Kowalski, D, Luft, A, Vicente, D, Tafreshi, A, Gumus, M, Laktionov, K, Hermes, B, Cicin, I, Rodriguez-Cid, J, Wilson, J, Kato, T, Ramlau, R, Novello, S, Reddy, S, Kopp, HG, Piperdi, B, Li, XD, Burke, T, Paz-Ares, L (2020).

Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.

JOURNAL OF CLINICAL ONCOLOGY. Article. 38(3):271-280.
[doi:10.1200/JCO.19.01348]
Marabelle, A, Le, DT, Ascierto, PA, Di Giacomo, AM, De Jesus-Acosta, A, Delord, JP, Geva, R, Gottfried, M, Penel, N, Hansen, AR, Piha-Paul, SA, Doi, T, Gao, B, Chung, HC, Lopez-Martin, J, Bang, YJ, Frommer, RS, Shah, M, Ghori, R, Joe, AK, Pruitt, SK, Diaz, LA (2020).

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

JOURNAL OF CLINICAL ONCOLOGY. Article. 38(1):1-10.
[doi:10.1200/JCO.19.02105]
Bover, M, Yarza, R, Docampo, LI (2020).

Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm.

Clinical Lung Cancer. Article. 21(1):1-5.
[doi:10.1016/j.cllc.2019.07.012]
Agullo-Ortuno, MT, Gomez-Martin, O, Ponce, S, Iglesias, L, Ojeda, L, Ferrer, I, Garcia-Ruiz, I, Paz-Ares, L, Pardo-Marques, V (2020).

Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.

Clinical Lung Cancer. Article. 21(1):75-85.
[doi:10.1016/j.cllc.2019.08.006]
Garrido-Martin, EM, Paz-Ares, L (2020).

Lung Cancer and Microbiome.

ARCHIVOS DE BRONCONEUMOLOGIA. Editorial Material. 56(1):3-4.
[doi:10.1016/j.arbres.2019.04.012]
Heinhuis, KM, Carlino, M, Joerger, M, Di Nicola, M, Meniawy, T, Rottey, S, Moreno, V, Gazzah, A, Delord, JP, Paz-Ares, L, Britschgi, C, Schilder, RJ, O'Byrne, K, Curigliano, G, Romano, E, Patah, P, Wang, R, Liu, YL, Bajaj, G, Siu, LL (2020).

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.

JAMA Oncology. Article. 6(1):1-8.
[doi:10.1001/jamaoncol.2019.3848]
Garon, EB, Scagliotti, GV, Gautschi, O, Reck, M, Thomas, M, Iglesias Docampo L, Kalofonos, H, Kim, JH, Gans, S, Brustugun, OT, Orlov, SV, Cuyun Carter G, Zimmermann, AH, Oton, AB, Alexandris, E, Lee, P, Wolff, K, Stefaniak, VJ, Socinski, MA, Pérol M (2020).

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

ESMO Open. Article. 5(1).
[doi:10.1136/esmoopen-2019-000567]

2019

Munster, P, Mita, M, Mahipal, A, Nemunaitis, J, Massard, C, Mikkelsen, T, Cruz, C, Paz-Ares, L, Hidalgo, M, Rathkopf, D, Blumenschein, G, Smith, DC, Eichhorst, B, Cloughesy, T, Filvaroff, EH, Li, SY, Raymon, H, de Haan, H, Hege, K, Bendell, JC (2019).

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.

Cancer Management and Research. Article. 11:10463-10476.
[doi:10.2147/CMAR.S208720]
Dingemans, AMC, Hendriks LEL, Berghmans, T, Levy, A, Hasan, B, Faivre-Finn, C, Giaj-Levra, M, Giaj-Levra, N, Girard, N, Greillier, L, Lantuejoul, S, Edwards, J, O'Brien, M, Reck, M, Smit, EF, Van Schil, P, Postmus, PE, Ramella, S, Lievens, Y, Gaga, M, Peled, N, Scagliotti, GV, Senan, S, Paz-Ares, L, Guckenberger, M, McDonald, F, Ekman, S, Cufer, T, Gietema, H, Infante, M, Dziadziuszko, R, Peters, S, Porta, RR, Vansteenkiste, J, Dooms, C, de Ruysscher, D, Besse, B, Novello, S (2019).

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

Journal of Thoracic Oncology. Article. 14(12):2109-2119.
[doi:10.1016/j.jtho.2019.07.025]
Conde, E, Hernandez, S, Martinez, R, Angulo, B, De Castro, J, Collazo-Lorduy, A, Jimenez, B, Muriel, A, Mate, JL, Moran, T, Aranda, I, Massuti, B, Rojo, F, Domine, M, Sansano, I, Garcia, F, Felip, E, Mancheño N, Juan, O, Sanz, J, Gonzalez-Larriba, JL, Atienza-Cuevas, L, Arriola-Arellano, E, Abdulkader, I, Garcia-Gonzalez, J, Camacho, C, Rodriguez-Abreu, D, Teixido, C, Reguart, N, Gonzalez-Piñeiro, A, Lazaro-Quintela, M, Lozano, MD, Gurpide, A, Gomez-Roman, J, Lopez-Brea, M, Pijuan, L, Salido, M, Arriola, E, Company, A, Insa, A, Esteban-Rodriguez, I, Saiz, M, Azkona, E, Alvarez, R, Artal, A, Plaza, ML, Aguiar, D, Enguita, AB, Benito, A, Paz-Ares, L, Garrido, P, Lopez-Rios, F (2019).

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

Journal of Thoracic Oncology. Article. 14(12):2120-2132.
[doi:10.1016/j.jtho.2019.07.005]
Nakagawa, K, Garon, EB, Seto, T, Nishio, M, Ponce Aix S, Paz-Ares, L, Chiu, CH, Park, K, Novello, S, Nadal, E, Imamura, F, Yoh, K, Shih, JY, Au, KH, Moro-Sibilot, D, Enatsu, S, Zimmermann, A, Frimodt-Moller, B, Visseren-Grul, C, Reck, M, RELAY Study Investigators (2019).

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

LANCET ONCOLOGY. Article. 20(12):1655-1669.
[doi:10.1016/S1470-2045(19)30634-5]
Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ (2019).

Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77].

RADIOTHERAPY AND ONCOLOGY. Correction. 141:332-332.
[doi:10.1016/j.radonc.2019.10.006]
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW, CASPIAN investigators (2019).

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

LANCET. Article. 394(10212):1929-1939.
[doi:10.1016/S0140-6736(19)32222-6]
Hellmann, MD, Paz-Ares, L, Bernabe Caro R, Zurawski, B, Kim, SW, Carcereny Costa E, Park, K, Alexandru, A, Lupinacci, L, de la Mora Jimenez E, Sakai, H, Albert, I, Vergnenegre, A, Peters, S, Syrigos, K, Barlesi, F, Reck, M, Borghaei, H, Brahmer, JR, O'Byrne, KJ, Geese, WJ, Bhagavatheeswaran, P, Rabindran, SK, Kasinathan, RS, Nathan, FE, Ramalingam, SS (2019).

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

NEW ENGLAND JOURNAL OF MEDICINE. Article. 381(21):2020-2031.
[doi:10.1056/NEJMoa1910231]
Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM (2019).

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

JCO Precision Oncology. Article. 3.
[doi:10.1200/PO.19.00171]
Sridhar, S, Paz-Ares, L, Liu, H, Shen, K, Morehouse, C, Rizvi, N, Segal, NH, Jin, XP, Zheng, YN, Narwal, R, Gupta, A, Dennis, PA, Ye, JB, Mukhopadhyay, P, Higgs, BW, Ranade, K (2019).

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.

Clinical Lung Cancer. Article. 20(6):601-608.
[doi:10.1016/j.cllc.2019.06.020]
Ciruelos, EM, Diaz, MN, Isla, MD, Lopez, R, Bernabe, R, Gonzalez, E, Cirauqui, B, Coves, J, Morales, S, Arcediano, A, Barneto, I, Cerezuela, P, Illarramendi, JJ, Morales, C, Ponce, S (2019).

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.

EUROPEAN JOURNAL OF CANCER CARE. Article. 28(6).
[doi:10.1111/ecc.13164]
Kim JW, Marquez CP, Kostyrko K, Koehne AL, Marini K, Simpson DR, Lee AG, Leung SG, Sayles LC, Shrager J, Ferrer I, Paz-Ares L, Gephart MH, Vicent S, Cochran JR, Sweet-Cordero EA (2019).

Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.

NATURE MEDICINE. Article. 25(11):1783-1795.
[doi:10.1038/s41591-019-0612-2]
Garmendia, I, Pajares, MJ, Hermida-Prado, F, Ajona, D, Bertolo, C, Sainz, C, Lavin, A, Remirez, AB, Valencia, K, Moreno, H, Ferrer, I, Behrens, C, Cuadrado, M, Paz-Ares, L, Bustelo, XR, Gil-Bazo, I, Alameda, D, Lecanda, F, Calvo, A, Felip, E, Sanchez-Cespedes, M, Wistuba, II, Granda-Diaz, R, Rodrigo, JP, Garcia-Pedrero, JM, Pio, R, Montuenga, LM, Agorreta, J (2019).

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. Article. 200(7):888-899.
[doi:10.1164/rccm.201807-1292OC]
Wolin, E, Mita, A, Mahipal, A, Meyer, T, Bendell, J, Nemunaitis, J, Munster, PN, Paz-Ares, L, Filvaroff, EH, Li, SY, Hege, K, de Haan, H, Mita, M (2019).

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

PLoS One. Article. 14(9).
[doi:10.1371/journal.pone.0221994]
Melgar-Sanchez, LM, Garcia-Ruiz, I, Pardo-Marques, V, Agullo-Ortuno, MT, Martinez-Galan, I (2019).

Influence of mineral waters on in vitro proliferation, antioxidant response and cytokine production in a human lung fibroblasts cell line.

INTERNATIONAL JOURNAL OF BIOMETEOROLOGY. Article. 63(9):1171-1180.
[doi:10.1007/s00484-019-01730-0]
Isla D, De Las Peñas R, Insa A, Marsé R, Martínez-Banaclocha N, Mut P, Morán T, Sala MÁ, Massuti B, Ortega AL, Jurado JM, Gómez-Codina J, Diz P, Artal Á, Gutiérrez V, Vázquez MF, Viñolas N, Maestu I, Camps C, Álvarez R, de Mon Soto MÁ, Ponce S, Provencio M (2019).

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

LUNG CANCER. Article. 135:161-168.
[doi:10.1016/j.lungcan.2018.11.041]
Zugazagoitia, J, Gomez-Rueda, A, Jantus-Lewintre, E, Isla, D, Camps, C, Ramos, I, Trigo, JM, Bernabe, R, Juan-Vidal, O, Sanchez-Torres, JM, Garcia-Campelo, R, Provencio, M, Felip, E, de Castro, J, Faull, I, Lanman, RB, Ponce-Aix, S, Paz-Ares, L, Garrido, P (2019).

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.

LUNG CANCER. Article. 134:72-78.
[doi:10.1016/j.lungcan.2019.05.032]
Ponce, S, Yuste, A, Esquivias, A, Leal, A, Villoria, J (2019).

A cross-sectional, comparative, syndromic description of oncological mixed pain in Medical Oncology units in Spain

SUPPORTIVE CARE IN CANCER. Article. 27(8):2921-2931.
[doi:10.1007/s00520-018-4575-5]
Ackermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R (2019).

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.

LUNG CANCER. Article. 134:245-253.
[doi:10.1016/j.lungcan.2019.06.007]
Trigo, J, Vermorken, J, Bourhis, J, Psyrri, A, Nangia, CS, Chaves-Conde, M, Del Campo, JM, Wang, BS, Gibson, N, Ehrnrooth, E, Cohen, EEW, Giglio, RE, Blajman, CR, Freue, JM, Pilnik, NG, Palazzo, FS, McGrath, M, Fureder, T, Kornek, G, Pichler, A, Bauernhofer, T, Tinchon, C, Greil, R, Burian, M, Kienzer, H, Specenier, P, Sautois, B, Debruyne, P, Graas, MP, Maes, A, Lonchay, C, Daisne, JF, Fontaine, C, Castro, G, de Oliveira, F, Pereira, RP, De Marchi, PRM, Viana, LD, Segalla, JGM, Nicolau, UR, Lazaretti, NS, Kulkarni, S, Alam, Y, Ho, C, Shenouda, G, Soulieres, D, Sultanem, K, Singh, S, Mella, PG, Campos, JAS, Holeckova, P, Prausova, J, Obermannova, R, Friborg, J, Specht, L, Elsaid, AA, Minn, H, Martin, L, Rolland, F, Ceruse, P, Calais, G, Even, C, Guigay, J, Ferte, C, Peyrade, F, Duffaud, F, Champeaux-Orange, E, Coutte, A, Clatot, F, Fournel, P, Le Moal, LB, Dietz, A, Grunwald, V, Gauler, T, Guntinas-Lichius, O, Hildebrandt, G, Kuhnt, T, Schmidt, HJ, Henke, M, Ruckert, A, Brugger, W, Rotter, N, Mahlberg, R, Karavasilis, V, Fountzilas, G, Psyrri, D, Lang, I, Boer, A, Kocsis, J, Pajkos, G, Tamas, L, Anand, AL, Sharma, A, Sharma, Voona, M, Pandy, AS, Kumar, K, Nathan, RKP, Srinivasan, V, Zade, B, Jain, M, Srinivasa, BJ, Naik, R, Mohanty, BK, Asarawala, N, Charas, T, Billan, S, Popovtzer, A, Licitra, L, Ferrari, D, Fao, P, Merlano, M, Rocca, MC, Homma, A, Fujii, H, Tahara, M, Minami, S, Fujii, M, Yokota, T, Kadowaki, S, Muro, K, Kiyota, N, Okami, K, Yagi, T, Yoshino, K, Matsumoto, K, Takahashi, S, Matsuura, K, Avitia, MAA, Riestra, HJG, van Meerten, E, Buter, J, Gelderblom, AJ, Kawecki, A, Golusinski, W, Dinis, J, Dinis, R, Ribeiro, L, Silva, R, Mansinho, H, Selezneva, I, Biakhov, M, Galiulin, R, Izmailov, A, Romanov, I, Vladimirov, V, Vinogradov, V, Mufazalov, F, Vasilevskaya, I, Baste, N, del Campo, JM, Nin, RM, Pousa, AL, de Castro, JJG, Reig, O, Vera, R, Trigo, J, Iglesias, L, Trufero, JM, Vazquez, S, Rubio, B, Ales, JE, Villar, E, Rubio, J, Escobar, Y, Soria, A, Chaves, M, Johansson, GW, Friesland, S, Tell, R, Nyman, J, Rothschild, S, Zippelius, A, Rauch, D, Usluoglu, N, Gogunska, I, Zabolotniy, D, Vinnyk, Y, Burian, O, Harrington, K, Sykes, A, Peel, D, Lester, J, Robinson, M, Srinivasan, D, Fragkandrea-Nixon, I, Junor, E, Gollins, S, Evans, M, Newbold, K, Hwang, D, Schipani, S, Rizwanullah, M, Atiq, O, Arnaoutakis, K, Bauman, J, Burtness, B, Mehra, R, Kang, H, Chung, C, Davis, T, Haddad, R, Jimeno, A, Keresztes, R, Nangia, C, Ignatius, SH, Su, YB, Overton, LC, Garrison, MA, Jeong, W, Wehbe, A, Argiris, A, Chiang, A, Morgensztern, D, Haigentz, M, Martincic, D, Porosnicu, M, LUX-HEAD & Neck 2 Investigators (2019).

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

JAMA Oncology. Article. 5(8):1170-1180.
[doi:10.1001/jamaoncol.2019.1146]
Marrugal, A, Ferrer, I, Pastor, MD, Ojeda, L, Quintanal-Villalonga, A, Carnero, A, Molina-Pinelo, S, Paz-Ares, L (2019).

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.

Cells. Article. 8(8).
[doi:10.3390/cells8080806]
Schuler, M, Paz-Ares, L, Sequist, LV, Hirsh, V, Lee, KH, Wu, YL, Lu, S, Zho, CC, Feng, JF, Ellis, SH, Samuelsen, CH, Tang, WB, Märten A, Ehrnrooth, E, Park, K, Yang, JCH (2019).

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

LUNG CANCER. Article. 133:10-19.
[doi:10.1016/j.lungcan.2019.04.006]
Sharma, P, Siefker-Radtke, A, de Braud, F, Basso, U, Calvo, E, Bono, P, Morse, MA, Ascierto, PA, Lopez-Martin, J, Brossart, P, Rohrberg, K, Mellado, B, Fischer, BS, Meadows-Shropshire, S, Saci, A, Callahan, MK, Rosenberg, J (2019).

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

JOURNAL OF CLINICAL ONCOLOGY. Article. 37(19):1608-1616.
[doi:10.1200/JCO.19.00538]
Putora, PM, Glatzer, M, De Ruysscher, D, Faivre-Finn, C, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadiuszko, R, Felip, E, Früh M, Garrido, P, Le Pechoux, C, McDonald, F, Nestle, U, Novello, S, Brien MO, Paz Ares L, Peeters, S, Pöttgen S, Ramella, S, Reck, M, Troost EGC, Van Houtte, P, Westeel, V, Widder, J, Mornex, F, Slotman, BJ (2019).

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

RADIOTHERAPY AND ONCOLOGY. Article. 135:74-77.
[doi:10.1016/j.radonc.2019.02.010]
Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N (2019).

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

LUNG CANCER. Article. 132:126-131.
[doi:10.1016/j.lungcan.2019.04.014]
Schuler, M, Tan, EH, O'Byrne, K, Zhang, L, Boyer, M, Mok, T, Hirsh, V, Yang, JCH, Lee, KH, Lu, S, Shi, YK, Kim, SW, Laskin, J, Kim, DW, Arvis, CD, Kolbeck, K, Massey, D, Marten, A, Paz-Ares, L, Park, K (2019).

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Article. 145(6):1569-1579.
[doi:10.1007/s00432-019-02862-x]
Quintanal-Villalonga, A, Ferrer, I, Molina-Pinelo, S, Paz-Ares, L (2019).

A patent review of FGFR4 selective inhibition in cancer (2007-2018).

EXPERT OPINION ON THERAPEUTIC PATENTS. Review. 29(6):429-438.
[doi:10.1080/13543776.2019.1624720]
Ponce, S, Bruna, J, Juan, O, Lopez, R, Navarro, A, Ortega, AL, Puente, J, Verger, E, Bartolome, A, Nadal, E (2019).

Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Review. 138:190-206.
[doi:10.1016/j.critrevonc.2019.03.017]
Ucero AC, Bakiri L, Roediger B, Suzuki M, Jimenez M, Mandal P, Braghetta P, Bonaldo P, Paz-Ares L, Fustero-Torre C, Ximenez-Embun P, Hernandez AI, Megias D, Wagner EF (2019).

Fra-2-expressing macrophages promote lung fibrosis in mice.

JOURNAL OF CLINICAL INVESTIGATION. Article. 129(8):3293-3309.
[doi:10.1172/JCI125366]
Quintanal-Villalonga, A, Molina-Pinelo, S, Yague, P, Marrugal, A, Ojeda-Marquez, L, Suarez, R, Ponce-Aix, S, Enguita, AB, Carnero, A, Ferrer, I, Paz-Ares, L (2019).

FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.

LUNG CANCER. Article. 131:112-121.
[doi:10.1016/j.lungcan.2019.02.007]
Levy, B, Paz-Ares, L, Bennouna, J, Felip, E, Abreu, DR, Isla, D, Barlesi, F, Molinier, O, Madelaine, J, Audigier-Valette, C, Kim, SW, Kim, HR, Ozguroglu, M, Erman, M, Badin, FB, Mekhail, TM, Scheff, R, Chisamore, MJ, Sadrolhefazi, B, Riess, JW (2019).

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Clinical Lung Cancer. Editorial Material. 20(3):407-412.
[doi:10.1016/j.cllc.2018.12.022]
Ready, N, Hellmann, MD, Awad, MM, Otterson, GA, Gutierrez, M, Gainor, JF, Borghaei, H, Jolivet, J, Horn, L, Mates, M, Brahmer, J, Rabinowitz, I, Reddy, PS, Chesney, J, Orcutt, J, Spigel, DR, Reck, M, O'Byrne, KJ, Paz-Ares, L, Hu, WH, Zerba, K, Li, XM, Lestini, B, Geese, WJ, Szustakowski, JD, Green, G, Chang, H, Ramalingam, SS (2019).

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

JOURNAL OF CLINICAL ONCOLOGY. Article. 37(12):992-1000.
[doi:10.1200/JCO.18.01042]
Reck, M, Kerr, KM, Grohe, C, Manegold, C, Pavlakis, N, Paz-Ares, L, Huber, RM, Popat, S, Thatcher, N, Park, K, Hilberg, F, Barrueco, J, Kaiser, R (2019).

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Future Oncology. Article. 15(12):1363-1383.
[doi:10.2217/fon-2018-0948]
Thatcher, N, Goldschmidt, JH, Thomas, M, Schenker, M, Pan, ZY, Paz-Ares Rodriguez L, Breder, V, Ostoros, G, Hanes, V (2019).

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.

CLINICAL CANCER RESEARCH. Article. 25(7):2088-2095.
[doi:10.1158/1078-0432.CCR-18-2702]
Nikolic, MZ, Garrido-Martin, EM, Greiffo, FR, Fabre, A, Heijink, IH, Boots, A, Greene, CM, Hiemstra, PS, Bartel, S (2019).

From the pathophysiology of the human lung alveolus to epigenetic editing: Congress 2018 highlights from ERS Assembly 3 "Basic and Translational Science."

ERJ Open Research. Article. 5(2).
[doi:10.1183/23120541.00194-2018]
Quintanal-Villalonga, A, Molina-Pinelo, S, Cirauqui, C, Ojeda-Marquez, L, Marrugal, A, Suarez, R, Conde, E, Ponce-Aix, S, Enguita, AB, Carnero, A, Ferrer, I, Paz-Ares, L (2019).

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy

Journal of Thoracic Oncology. Article. 14(4):641-655.
[doi:10.1016/j.jtho.2018.12.021]
Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D (2019).

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

RADIOTHERAPY AND ONCOLOGY. Article. 133:163-166.
[doi:10.1016/j.radonc.2018.12.014]
Diaz-Serrano, A, Sanchez-Torre, A, Paz-Ares, L (2019).

Necitumumab for the treatment of advanced non-small-cell lung cancer

Future Oncology. Article. 15(7):705-716.
[doi:10.2217/fon-2018-0594]
Manso, L, Moreno Anton F, Izarzugaza Peron Y, Delgado Mingorance JI, Borrega Garcia P, Echarri Gonzalez MJ, Martinez-Janez, N, Lopez-Gonzalez, A, Olier Garate C, Ballesteros Garcia A, Chacon Lopez-Muniz I, Ciruelos Gil E, Garcia-Saenz, JA, Paz-Ares, L (2019).

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

Breast Journal. Article. 25(2):219-225.
[doi:10.1111/tbj.13199]
Zugazagoitia, J, Ramos, I, Trigo, JM, Palka, M, Gomez-Rueda, A, Jantus-Lewintre, E, Camps, C, Isla, D, Iranzo, P, Ponce-Aix, S, Garcia-Campelo, R, Provencio, M, Franco, F, Bernabe, R, Juan-Vidal, O, Felip, E, de Castro, J, Sanchez-Torres, JM, Faul, I, Lanman, RB, Garrido, P, Paz-Ares, L (2019).

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

ANNALS OF ONCOLOGY. Article. 30(2):290-296.
[doi:10.1093/annonc/mdy512]
Levy, BP, Giaccone, G, Besse, B, Felip, E, Garassino, MC, Domine Gomez M, Garrido, P, Piperdi, B, Ponce-Aix, S, Menezes, D, MacBeth, KJ, Risueno, A, Slepetis, R, Wu, XL, Fandi, A, Paz-Ares, L (2019).

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

EUROPEAN JOURNAL OF CANCER. Article. 108:120-128.
[doi:10.1016/j.ejca.2018.11.028]
Peters, S, Dafni, U, Boyer, M, De Ruysscher, D, Faivre-Finn, C, Felip, E, Garrido, P, Girard, N, Guckenberger, M, Haanen, J, Le Pechoux, C, Mornex, F, Ozsahin, M, Paz-Ares, L, Planchard, D, Raben, D, Ramalingam, S, Reck, M, Smit, E, Stahel, R, Stenzinger, A, Swanton, C, Vallone, S, Garassino, MC (2019).

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

ANNALS OF ONCOLOGY. Editorial Material. 30(2):161-165.
[doi:10.1093/annonc/mdy553]
Puig P, Erill N, Terricabras M, Subirana I, González-García J, Asensi-Puig A, Donovan MJ, Mengual L, Agulló-Ortuño MT, Olivan M, Alcaraz A, López-Martín JA, de Torres I, Rodríguez-Peralto JL, Rodríguez-Antolín A, Morote J, González-Rumayor V (2019).

Multiple immunofluorescence assay identifies upregulation of Active ß-catenin in prostate cancer.

BMC Research Notes. Article. 12(1):68-68.
[doi:10.1186/s13104-019-4100-z]
Farago, AF, Drapkin, BJ, Lopez-Vilarino de Ramos JA, Galmarini, CM, Nunez, R, Kahatt, C, Paz-Ares, L (2019).

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

Future Oncology. Review. 15(3):231-239.
[doi:10.2217/fon-2018-0597]
Matias-Guiu X, Fuste V, Iglesias L, Balana C, Concha A, de la Cruz-Merino L, Nieto B, Pane M, Sanz J, Losa F (2019).

Consenso 2018 de la Sociedad Espanola de Anatomia Patologica y la Sociedad Espanola de Oncologia Medica sobre el diagnostico y tratamiento del cancer de origen desconocido.

Revista Espanola de Patologia. Review. 52(1):33-44.
[doi:10.1016/j.patol.2018.08.002]
Redondo, B, Moliz, C, Alonso, M, Paz-Ares, L, Praga, M, Morales, E (2019).

Cancer immunotherapy: Great expectations in the world of oncology but a cause for kidney concern

NEFROLOGIA. Letter. 39(1):94-96.
[doi:10.1016/j.nefro.2018.05.002]
Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Kung M (2019).

Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study

Pancreatology. Article. 19(1):64-72.
[doi:10.1016/j.pan.2018.10.004]

2018

Antonia, SJ, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, R, Kurata, T, Chiappori, A, Lee, KH, de Wit, M, Cho, BC, Bourhaba, M, Quantin, X, Tokito, T, Mekhail, T, Planchard, D, Kim, YC, Karapetis, CS, Hiret, S, Ostoros, G, Kubota, K, Gray, JE, Paz-Ares, L, de Castro Carpeno J, Faivre-Finn, C, Reck, M, Vansteenkiste, J, Spigel, DR, Wadsworth, C, Melillo, G, Taboada, M, Dennis, PA, Ozguroglu, M, PACIFIC Investigators (2018).

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

NEW ENGLAND JOURNAL OF MEDICINE. Article. 379(24):2342-2350.
[doi:10.1056/NEJMoa1809697]
Gandara, DR, von Pawel, J, Mazieres, J, Sullivan, R, Helland, A, Han, JY, Aix, SP, Rittmeyer, A, Barlesi, F, Kubo, T, Park, K, Goldschmidt, J, Gandhi, M, Yun, C, Yu, W, Matheny, C, He, P, Sandler, A, Ballinger, M, Fehrenbacher, L (2018).

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Journal of Thoracic Oncology. Article. 13(12):1906-1918.
[doi:10.1016/j.jtho.2018.08.2027]
Paz-Ares, L, Luft, A, Vicente, D, Tafreshi, A, Gumus, M, Mazieres, J, Hermes, B, Cay Senler F, Csoszi, T, Fulop, A, Rodriguez-Cid, J, Wilson, J, Sugawara, S, Kato, T, Lee, KH, Cheng, Y, Novello, S, Halmos, B, Li, X, Lubiniecki, GM, Piperdi, B, Kowalski, DM, KEYNOTE-407 Investigators (2018).

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 379(21):2040-2051.
[doi:10.1056/NEJMoa1810865]
Kim, ES, Kelly, K, Paz-Ares, LG, Garrido, P, Jalal, S, Mahadevan, D, Gutierrez, M, Provencio, M, Schaefer, E, Shaheen, M, Johnston, EL, Turner, PK, Kambhampati, SRP, Beckmann, R, Hossain, A, John, WJ, Goldman, JW (2018).

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study

CLINICAL CANCER RESEARCH. Article. 24(22):5543-5551.
[doi:10.1158/1078-0432.CCR-18-0651]
Gonzalez Rubio S, Montero Pastor N, Garcia, C, Almendro-Vedia, VG, Ferrer, I, Natale, P, Paz-Ares, L, Lillo, MP, Lopez-Montero, I (2018).

Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy

Frontiers in Oncology. Article. 8:514-514.
[doi:10.3389/fonc.2018.00514]
Losa F, Iglesias L, Pane M, Sanz J, Nieto B, Fuste V, de la Cruz-Merino L, Concha A, Balana C, Matias-Guiu X (2018).

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

Clinical & Translational Oncology. Review. 20(11):1361-1372.
[doi:10.1007/s12094-018-1899-z]
Patel, JD, Paz-Ares, L, Zinner, RG, Barlesi, F, Koustenis, AG, Obasaju, CK (2018).

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care

Clinical Lung Cancer. Review. 19(6):823-830.
[doi:10.1016/j.cllc.2018.05.013]
Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Domine Gomez M, Kollmeier J, Sadjadian P, Frohling KP, Huber R, Wolf M, IMPULSE study team (2018).

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

ANNALS OF ONCOLOGY. Article. 29(10):2076-2084.
[doi:10.1093/annonc/mdy326]
Schneeweiss, A, Park-Simon, TW, Albanell, J, Lassen, U, Cortes, J, Dieras, V, May, M, Schindler, C, Marme, F, Cejalvo, JM, Martinez-Garcia, M, Gonzalez, I, Lopez-Martin, J, Welt, A, Levy, C, Joly, F, Michielin, F, Jacob, W, Adessi, C, Moisan, A, Meneses-Lorente, G, Racek, T, James, I, Ceppi, M, Hasmann, M, Weisser, M, Cervantes, A (2018).

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

INVESTIGATIONAL NEW DRUGS. Article. 36(5):848-859.
[doi:10.1007/s10637-018-0562-4]
Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G (2018).

KRAS-Mutant non-small cell lung cancer: From biology to therapy

LUNG CANCER. Review. 124:53-64.
[doi:10.1016/j.lungcan.2018.07.013]
Hellmann MD, Paz-Ares L (2018).

Lung Cancer with a High Tumor Mutational Burden.

NEW ENGLAND JOURNAL OF MEDICINE. Letter. 379(11):1093-1094.
[doi:10.1056/NEJMc1808566]
Hellmann, MD, Paz-Ares, L (2018).

Dry Eye Reply

NEW ENGLAND JOURNAL OF MEDICINE. Letter. 379(11):1094-1094.
Carril-Ajuria L, Jimenez-Aguilar E, Gomez-Martin C, Diaz-Pedroche C (2018).

An unsuspected complication with immune checkpoint blockade: a case report.

Journal of Medical Case Reports. Article. 12(1):246-246.
[doi:10.1186/s13256-018-1782-0]
Gillison, ML, Blumenschein G Jr, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, KJ, Kasper, S, Vokes, EE, Even, C, Worden, F, Saba, NF, Iglesias Docampo LC, Haddad, R, Rordorf, T, Kiyota, N, Tahara, M, Monga, M, Lynch, M, Li, L, Ferris, RL (2018).

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

ONCOLOGIST. Article. 23(9):1079-1082.
[doi:10.1634/theoncologist.2017-0674]
Giaccone, G, Sanborn, RE, Waqar SN, Martinez-Marti, A, Ponce, S, Zhen, HL, Kennealey, G, Erickson-Viitanen, S, Schaefer, E (2018).

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation

Clinical Lung Cancer. Article. 19(5):567-574.
[doi:10.1016/j.cllc.2018.03.016]
Jimenez, RB, Vera, DG, Rivera-Diaz, R, Cortijo-Cascajares, S, Ballesteros, RM, Pastor, MDD (2018).

Successful subcutaneous desensitization in a patient with allergy to ixekizumab

Journal of Allergy and Clinical Immunology-In Practice. Letter. 6(5):1761-1762.
[doi:10.1016/j.jaip.2017.12.036]
Diaz-Serrano, A, Angulo, B, Dominguez, C, Pazo-Cid, R, Salud, A, Jimenez-Fonseca, P, Leon, A, Galan, MC, Alsina, M, Rivera, F, Plaza, JC, Paz-Ares, L, Lopez-Rios, F, Gomez-Martin, C (2018).

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

ONCOLOGIST. Article. 23(9):1092-1102.
[doi:10.1634/theoncologist.2017-0379]
Von Hoff, DD, Rasco, DW, Heath, EI, Munster, PN, Schellens, JHM, Isambert, N, Le Tourneau, C, O'Neill, B, Mathijssen, RHJ, Lopez-Martin, JA, Edenfiele, WJ, Martin, M, LoRusso, PM, Bray, GL, DiMartino, J, Nguyen, A, Liu, KJ, Laille, E, Bendell, JC (2018).

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

CLINICAL CANCER RESEARCH. Article. 24(17):4072-4080.
[doi:10.1158/1078-0432.CCR-17-3716]
Ferrer, I, Quintanal-Villalonga, A, Molina-Pinelo, S, Garcia-Heredia, JM, Perez, M, Suarez, R, Ponce-Aix, S, Paz-Ares, L, Carnero, A (2018).

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. Article. 37(1):195-195.
[doi:10.1186/s13046-018-0871-7]
Jimenez Aguilar E, Zugazagoitia Fraile J, Paz-Ares Rodriguez L (2018).

Necitumumab: a new option for first-line treatment of squamous cell lung cancer

Expert Opinion on Drug Metabolism & Toxicology. Article. 14(8):765-772.
[doi:10.1080/17425255.2018.1498839]
Bonomi, PD, Gandara, D, Hirsch, FR, Kerr, KM, Obasaju, C, Paz-Ares, L, Bellomo, C, Bradley, JD, Bunn PA Jr, Culligan, M, Jett, JR, Kim, ES, Langer, CJ, Natale, RB, Novello, S, Perol, M, Ramalingam, SS, Reck, M, Reynolds, CH, Smit, EF, Socinski, MA, Spigel, DR, Vansteenkiste, JF, Wakelee, H, Thatcher, N (2018).

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

ANNALS OF ONCOLOGY. Review. 29(8):1701-1709.
[doi:10.1093/annonc/mdy196]
Fehrenbacher, L, von Pawel, J, Park, K, Rittmeyer, A, Gandara, DR, Ponce Aix S, Han, JY, Gadgeel, SM, Hida, T, Cortinovis, DL, Cobo, M, Kowalski, DM, De Marinis, F, Gandhi, M, Danner, B, Matheny, C, Kowanetz, M, He, P, Felizzi, F, Patel, H, Sandler, A, Ballinger, M, Barlesi, F (2018).

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology. Article. 13(8):1156-1170.
[doi:10.1016/j.jtho.2018.04.039]
Hirsch, FR, Kerr, KM, Bunn PA Jr, Kim, ES, Obasaju, C, Perol, M, Bonomi, P, Bradley, JD, Gandara, D, Jett, JR, Langer, CJ, Natale, RB, Novello, S, Paz-Ares, L, Ramalingam, SS, Reck, M, Reynolds, CH, Smit, EF, Socinski, MA, Spigel, DR, Stinchcombe, TE, Vansteenkiste, JF, Wakelee, H, Thatcher, N (2018).

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Clinical Lung Cancer. Review. 19(4):331-339.
[doi:10.1016/j.cllc.2018.03.014]
Young, K, Paz-Ares, L, Thatcher, N, Spigel, DR, Shahidi, J, Soldatenkova, V, Grau, G, Kurek, R, Shepherd, FA (2018).

Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis

THROMBOSIS RESEARCH. Article. 167:50-56.
[doi:10.1016/j.thromres.2018.05.004]
Wu, YL, Sequist, LV, Tan, EH, Geater, SL, Orlov, S, Zhang, L, Lee, KH, Tsai, CM, Kato, T, Barrios, CH, Schuler, M, Hirsh, V, Yamamoto, N, O'Byrne, K, Boyer, M, Mok, T, Peil, B, Marten, A, Chih-Hsin Yang J, Paz-Ares, L, Park, K (2018).

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

Clinical Lung Cancer. Article. 19(4):465-479.
[doi:10.1016/j.cllc.2018.03.009]
Gridelli, C, Baas, P, Barlesi, F, Ciardiello, F, Crino, L, Felip, E, Gadgeel, S, Papadimitrakopoulou, V, Paz-Ares, L, Planchard, D, Perol, M, Hanna, N, Sgambato, A, Casaluce, F, de Marinis, F (2018).

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

Clinical Lung Cancer. Review. 19(4):301-314.
[doi:10.1016/j.cllc.2017.12.010]
Diaz-Serrano, A, Gella, P, Jimenez, E, Zugazagoitia, J, Paz-Ares Rodriguez L (2018).

Targeting EGFR in Lung Cancer: Current Standards and Developments

DRUGS. Review. 78(9):893-911.
[doi:10.1007/s40265-018-0916-4]
Ferris, RL, Blumenschein G Jr, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, KJ, Kasper, S, Vokes, EE, Even, C, Worden, F, Saba, NF, Docampo LCI, Haddad, R, Rordorf, T, Kiyota, N, Tahara, M, Lynch, M, Jayaprakash, V, Li, L, Gillison, ML (2018).

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

ORAL ONCOLOGY. Article. 81:45-51.
[doi:10.1016/j.oraloncology.2018.04.008]
Hellmann, MD, Ciuleanu, TE, Pluzanski, A, Lee, JS, Otterson, GA, Audigier-Valette, C, Minenza, E, Linardou, H, Burgers, S, Salman, P, Borghaei, H, Ramalingam, SS, Brahmer, J, Reck, M, O'Byrne, KJ, Geese, WJ, Green, G, Chang, H, Szustakowski, J, Bhagavatheeswaran, P, Healey, D, Fu, Y, Nathan, F, Paz-Ares, L (2018).

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

NEW ENGLAND JOURNAL OF MEDICINE. Article. 378(22):2093-2104.
[doi:10.1056/NEJMoa1801946]
Nagar SP, Mytelka DS, Candrilli SD, D'yachkova Y, Lorenzo M, Kasper B, Lopez-Martin JA, Kaye JA (2018).

Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France.

Sarcoma. Article. 2018:5467057-5467057.
[doi:10.1155/2018/5467057]
Reck, M, Garon, EB, Paz-Ares, L, Ponce, S, Jaime, JC, Juan, O, Nadal, E, Kiura, K, Widau, RC, He, S, Dalal, R, Lee, P, Nakagawa, K (2018).

Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results

Clinical Lung Cancer. Article. 19(3):213.
[doi:10.1016/j.cllc.2017.11.003]
Zugazagoitia J, Biosca M, Olivera J, Eugenia Olmedo M, Domine M, Nadal E, Carlos Ruffinelli J, Munoz N, Maria Luna A, Hernandez B, Martinez M, Gallego I, Martinez de Castro E, Font C, Calvo V, Martinez-Marin V, Corral J, Nogueron E, Mondejar R, Garcia Escobar I, Salvador-Coloma C, Juan O, Sanchez Canovas M, Valdivia J, Ochoa MP, Lopez Castro R, Obispo B, Pangua C, Sereno M, Fernandez Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Francisco Grau J, Soares M, Gomez A, Zenzola V, Garcia-Morillo M, Cacho D, Diaz-Serrano A, Aguado C, Ponce-Aix S, Luis Gonzalez-Larriba J, Munoz AJ, Lora D, Paz-Ares L, Manzano A (2018).

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

EUROPEAN RESPIRATORY JOURNAL. Letter. 51(5).
[doi:10.1183/13993003.02431-2017]
Nieves Sedano M, Manuel Caro Teller J, Garcia Munoz C, Fernandez Redondo D, Ponce Aix S, Menendez Orenga M, Miguel Ferrari Piquero J (2018).

Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients

Journal of BUON. Article. 23(3):647-653.
Quintanal-Villalonga A, Mediano M, Ferrer I, Melendez R, Carranza-Carranza A, Suarez R, Carnero A, Molina-Pinelo S, Paz-Ares L (2018).

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer.

Oncotarget. Article. 9(28):19945-19960.
[doi:10.18632/oncotarget.24977]
Cala, MP, Agullo-Ortuno, MT, Prieto-Garcia, E, Gonzalez-Riano, C, Parrilla-Rubio, L, Barbas, C, Diaz-Garcia, CV, Garcia, A, Pernaut, C, Adeva, J, Riesco, MC, Ruperez, FJ, Lopez-Martin, JA (2018).

Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

Journal of Cachexia Sarcopenia and Muscle. Article. 9(2):348-357.
[doi:10.1002/jcsm.12270]
Ferris, RL, Blumenschein, GR, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, K, Kasper, S, Vokes, EE, Even, C, Worden, F, Saba, NF, Docampo, L, Haddad, RI, Rordorf, T, Kiyota, N, Tahara, M, Lynch, M, Li, L, Gillison, M (2018).

Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. Meeting Abstract. 100(5):1317-1317.
[doi:10.1016/j.ijrobp.2017.12.300]
Mezquita, L, Auclin, E, Ferrara, R, Charrier, M, Remon, J, Planchard, D, Ponce, S, Ares, LP, Leroy, L, Audigier-Valette, C, Felip, E, Zeron-Medina, J, Garrido, P, Brosseau, S, Zalcman, G, Mazieres, J, Caramela, C, Lahmar, J, Adam, J, Chaput, N, Soria, JC, Besse, B (2018).

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

JAMA Oncology. Article. 4(3):351-357.
[doi:10.1001/jamaoncol.2017.4771]
Block, MS, Vierkant, RA, Rambau, PF, Winham, SJ, Wagner, P, Traficante, N, Toloczko, A, Tiezzi, DG, Taran, FA, Sinn, P, Sieh, W, Sharma, R, Rothstein, JH, Ramon Y Cajal T, Paz-Ares, L, Oszurek, O, Orsulic, S, Ness, RB, Nelson, G, Modugno, F, Menkiszak, J, McGuire, V, McCauley, BM, Mack, M, Lubinski, J, Longacre, TA, Li, Z, Lester, J, Kennedy, CJ, Kalli, KR, Jung, AY, Johnatty, SE, Jimenez-Linan, M, Jensen, A, Intermaggio, MP, Hung, J, Herpel, E, Hernandez, BY, Hartkopf, AD, Harnett, PR, Ghatage, P, Garcia-Bueno, JM, Gao, B, Fereday, S, Eilber, U, Edwards, RP, de Sousa, CB, de Andrade, JM, Chudecka-Glaz, A, Chenevix-Trench, G, Cazorla, A, Brucker, SY, Alsop, J, Whittemore, AS, Steed, H, Staebler, A, Moysich, KB, Menon, U, Koziak, JM, Kommoss, S, Kjaer, SK, Kelemen, LE, Karlan, BY, Huntsman, DG, Hogdall, E, Gronwald, J, Goodman, MT, Gilks, B, Garcia, MJ, Fasching, PA, de Fazio, A, Deen, S, Chang-Claude, J, Candido Dos Reis FJ, Campbell, IG, Brenton, JD, Bowtell, DD, Benitez, J, Pharoah PDP, Kobel, M, Ramus, SJ, Goode, EL, Australian Ovarian Cancer Study Group (2018).

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

MAYO CLINIC PROCEEDINGS. Article. 93(3):307-320.
[doi:10.1016/j.mayocp.2017.10.023]
Ciuleanu, T, Socinski, MA, Obasaju, C, Luft, AV, Szczesna, A, Szafranski, W, Ramlau, R, Balint, B, Molinier, O, Depenbrock, H, Nanda, S, Paz-Ares, L, Thatcher, N (2018).

Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer

Clinical Lung Cancer. Article. 19(2):130.
[doi:10.1016/j.cllc.2017.10.004]
Quintanal-Villalonga, A, Ojeda-Marquez, L, Marrugal, A, Yague, P, Ponce-Aix, S, Salinas, A, Carnero, A, Ferrer, I, Molina-Pinelo, S, Paz-Ares, L (2018).

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction

SCIENTIFIC REPORTS. Article. 8(1):2394-2394.
[doi:10.1038/s41598-018-20570-3]
Carretero-Gonzalez A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepulveda JM, Lopez-Martin JA, Paz-Ares L, de Velasco G (2018).

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.

Oncotarget. Article. 9(9):8706-8715.
[doi:10.18632/oncotarget.24283]
Martin-Liberal, J, Lopez-Pousa, A, Martinez-Trufero, J, Martin-Broto, J, Cubedo, R, Lavernia, J, Redondo, A, Lopez-Martin, JA, Mulet-Margalef, N, Sanjuan, X, Tirado ÒM, Garcia-del-Muro, X (2018).

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study

TARGETED ONCOLOGY. Article. 13(1):81-87.
[doi:10.1007/s11523-017-0539-9]
Socinski, MA, Obasaju, C, Gandara, D, Hirsch, FR, Bonomi, P, Bunn, PA, Kim, ES, Langer, CJ, Natale, RB, Novello, S, Paz-Ares, L, Perol, M, Reck, M, Ramalingam, SS, Reynolds, CH, Spigel, DR, Wakelee, H, Thatcher, N (2018).

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Journal of Thoracic Oncology. Review. 13(2):165-183.
[doi:10.1016/j.jtho.2017.11.111]
Genova, C, Socinski, MA, Hozak, RR, Mi, G, Kurek, R, Shahidi, J, Paz-Ares, L, Thatcher, N, Rivard, CJ, Varella-Garcia, M, Hirsch, FR (2018).

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

Journal of Thoracic Oncology. Article. 13(2):228-236.
[doi:10.1016/j.jtho.2017.11.109]
Arriola, E, García Gómez R, Diz, P, Majem, M, Martínez Aguillo M, Valdivia, J, Paredes, A, Sanchez-Torres, JM, Peralta Muñoz S, Barneto, I, Gutierrez, V, Andrade Santiago JM, Aparisi, F, Isla, D, Ponce, S, Vicente Baz D, Artal, A, Amador, M, Provencio, M (2018).

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

BMC CANCER. Article. 18(1):106-106.
[doi:10.1186/s12885-018-4004-7]
Molina-Pinelo, S, Salinas, A, Moreno-Mata, N, Ferrer, I, Suarez, R, Andres-Leon, E, Rodriguez-Paredes, M, Gutekunst, J, Jantus-Lewintre, E, Camps, C, Carnero, A, Paz-Ares, L (2018).

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer

Oncotarget. Article. 9(4):4395-4410.
[doi:10.18632/oncotarget.10611]
Conde, E, Caminoa, A, Dominguez, C, Calles, A, Walter, S, Angulo, B, Sanchez, E, Alonso, M, Jimenez, L, Madrigal, L, Hernando, F, Sanz-Ortega, J, Jimenez, B, Garrido, P, Paz-Ares, L, de Castro, J, Hernandez, S, Lopez-Rios, F (2018).

Aligning digital CD8(+) scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma

HISTOPATHOLOGY. Article. 72(2):270-284.
[doi:10.1111/his.13346]
Zugazagoitia, J, Rueda, D, Carrizo, N, Enguita, AB, Gomez-Sanchez, D, Diaz-Serrano, A, Jimenez, E, Merida, A, Calero, R, Lujan, R, De Miguel, E, Gamez, P, Diaz-Hellin, V, Nuñez JA, Iglesias, L, Ferrer, I, Paz-Ares, L, Ponce-Aix, S (2018).

Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments

Clinical Lung Cancer. Article. 19(1):65.
[doi:10.1016/j.cllc.2017.06.008]
Iglesias Docampo LC, Arrazubi Arrula V, Baste Rotllan N, Carral Maseda A, Cirauqui, BC, Escobar, Y, Lambea Sorrosal JJ, Pastor Borgoñón M, Rueda, A, Cruz Hernández JJ (2018).

SEOM clinical guidelines for the treatment of head and neck cancer (2017)

Clinical & Translational Oncology. Article. 20(1):75-83.
[doi:10.1007/s12094-017-1776-1]
Westover, D, Zugazagoitia, J, Cho, BC, Lovly, CM, Paz-Ares, L (2018).

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

ANNALS OF ONCOLOGY. Review. 29(suppl_1):10-19.
[doi:10.1093/annonc/mdx703]
Middleton, G, Gridelli, C, De Marinis, F, Pujol, JL, Reck, M, Ramlau, R, Parente, B, Pieters, T, Visseren-Grul, CM, San Antonio, B, John, WJ, Zimmermann, AH, Chouaki, N, Paz-Ares, L (2018).

Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

CURRENT MEDICAL RESEARCH AND OPINION. Article. 34(5):865-871.
[doi:10.1080/03007995.2018.1439462]
Serke, M, Gandara, D, von Pawel, J, Sullivan, R, Aslaug, H, Han, JY, Aix, SP, Rittmeyer, A, Barlesi, F, Kubo, T, Park, K, Goldschmidt, J, Gandhi, M, Yun, C, Yu, W, Matheny, C, He, P, Sandler, A, Ballinger, M, Fehrenbacher, L (2018).

Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: results from the randomized Ph III OAK study

Oncology Research and Treatment. Meeting Abstract. 41:16-16.
Kasper, S, Gillison, ML, Blumenschein, G, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, K, Vokes, EE, Even, C, Worden, F, Saba, NF, Docampo, LCI, Haddad, R, Rordorf, T, Kiyota, N, Makoto, T, Lynch, M, Kopit, J, Ferris, RL (2018).

Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy

Oncology Research and Treatment. Meeting Abstract. 41:96-96.
Quintanal-Villalonga A, Paz-Ares L, Ferrer I, Molina-Pinelo S (2018).

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications (vol 2016, 9214056, 2016)

DISEASE MARKERS. Correction. 2018:3714684-3714684.
[doi:10.1155/2018/3714684]
Carballal S, Maisterra S, López-Serrano A, Gimeno-García AZ, Vera MI, Marín-Garbriel JC, Díaz-Tasende J, Márquez L, Álvarez MA, Hernández L, De Castro L, Gordillo J, Puig I, Vega P, Bustamante-Balén M, Acevedo J, Peñas B, López-Cerón M, Ricart E, Cuatrecasas M, Jimeno M, Pellisé M, EndoCAR group of the Spanish Gastroenterological Association and Spanish Digesti (2018).

Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD

GUT. Article. 67(1):70-78.
[doi:10.1136/gutjnl-2016-312332]
Marrugal, A, Ojeda, L, Paz-Ares, L, Molina-Pinelo, S, Ferrer, I (2018).

Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer (vol 2016, pg 12, 2016)

DISEASE MARKERS. Correction. 2018:1404780-1404780.
[doi:10.1155/2018/1404780]
Munoz-Unceta, N, Burgueno, I, Jimenez, E, Paz-Ares, L (2018).

Durvalumab in NSCLC: latest evidence and clinical potential.

Therapeutic Advances in Medical Oncology. Review. 10.
[doi:10.1177/1758835918804151]

2017

Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC (2017).

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth; Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant; to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker; Analyses

JOURNAL OF CLINICAL ONCOLOGY. Article. 35(36):4027-4034.
[doi:10.1200/JCO.2017.73.9250]
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crino L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE (2017).

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced; Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized,; Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

JOURNAL OF CLINICAL ONCOLOGY. Article. 35(35):3924-3933.
[doi:10.1200/JCO.2017.74.3062]
Verdugo-Sivianes EM, Navas L, Molina-Pinelo S, Ferrer I, Quintanal-Villalonga A, Peinado J, Garcia-Heredia JM, Felipe-Abrio B, Muñoz-Galvan S, Marin JJ, Montuenga L, Paz-Ares L, Carnero A (2017).

Coordinated downregulation of Spinophilin and the catalytic subunits of; PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer

Oncotarget. Article. 8(62):105196-105210.
[doi:10.18632/oncotarget.22111]
Martín Algarra S, Soriano V, Fernández-Morales L, Berciano-Guerrero MÁ, Mujika K, Manzano JL, Puértolas Hernández T, Soria A, Rodríguez-Abreu D, Espinosa Arranz E, Medina Martínez J, Márquez-Rodas I, Rubió-Casadevall J, Ortega ME, Jurado García JM, Lecumberri Biurrun MJ, Palacio I, Rodríguez de la Borbolla Artacho M, Altozano JP, Castellón Rubio VE, García A, Luna P, Ballesteros A, Fernández O, López Martín JA, Berrocal A, Arance A (2017).

Dabrafenib plus trametinib for compassionate use in metastatic melanoma:; A STROBE-compliant retrospective observational postauthorization study

MEDICINE. Article. 96(52).
[doi:10.1097/MD.0000000000009523]
Arnold D, Fuchs C, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I (2017).

Meta-analysis of individual patient safety data from six randomized,; placebo-controlled trials with the antiangiogenic VEGFR2-binding; monoclonal antibody ramucirumab

ANNALS OF ONCOLOGY. Review. 28(12):2932-2942.
[doi:10.1093/annonc/mdx514]
de la Fuente-Bartolomé M, Moreno-Bargueiras A, Osorio-Silla I, Martínez-Pueyo JI, de la Cruz-Vigo F, Gutiérrez-Ashling L (2017).

Localizacion intratiroidea de glandulas paratiroides. Presentacion atipica del sindrome de neoplasia endocrina multiple tipo 1.

Cirugia y Cirujanos. Abstract of Published Item. 85 Suppl 1:68-71.
[doi:10.1016/j.circir.2016.10.020]
Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, Martinez-Trufero J, Lopez-Martin JA, Correa R, Cruz J, Lopez-Pousa A, Santos A, García Del Muro X, Martin-Broto J (2017).

Malignant bone tumors (other than Ewing's): clinical practice guidelines; for diagnosis, treatment and follow-up by Spanish Group for Research on; Sarcomas (GEIS)

CANCER CHEMOTHERAPY AND PHARMACOLOGY. Article. 80(6):1113-1131.
[doi:10.1007/s00280-017-3436-0]
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroglu M, PACIFIC Investigators (2017).

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung; Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 377(20):1919-1929.
[doi:10.1056/NEJMoa1709937]
Quintanal-Villalonga Á, Carranza-Carranza A, Meléndez R, Ferrer I, Molina-Pinelo S, Paz-Ares L (2017).

Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell; Carcinoma Patients With Lymph Node Involvement

Clinical Lung Cancer. Article. 18(6):667.
[doi:10.1016/j.cllc.2017.05.008]
Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M (2017).

A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or; Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line; Treatment for Extensive-Stage Small-Cell Lung Cancer

Clinical Lung Cancer. Article. 18(6):615.
[doi:10.1016/j.cllc.2017.05.007]
Garrido P, Sánchez M, Belda Sanchis J, Moreno Mata N, Artal Á, Gayete Á, Matilla González JM, Galbis Caravajal JM, Isla D, Paz-Ares L, Seijo LM (2017).

Reflections on the Implementation of Low-Dose Computed Tomography; Screening in Individuals at High Risk of Lung Cancer in Spain

ARCHIVOS DE BRONCONEUMOLOGIA. Article. 53(10):568-573.
[doi:10.1016/j.arbres.2017.03.004]
Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Carter GC, Alexandris E, Garon EB (2017).

Treatment outcomes by histology in REVEL: A randomized phase III trial; of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

LUNG CANCER. Article. 112:126-133.
[doi:10.1016/j.lungcan.2017.05.021]
Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Perol M (2017).

Outcomes in patients with aggressive or refractory disease from REVEL: A; randomized phase III study of docetaxel with ramucirumab or placebo for; second-line treatment of stage IV non-small-cell lung cancer

LUNG CANCER. Article. 112:181-187.
[doi:10.1016/j.lungcan.2017.07.038]
Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K (2017).

Phase 1 study of intravenous administration of the chimeric adenovirus; enadenotucirev in patients undergoing primary tumor resection

Journal for ImmunoTherapy of Cancer. Article. 5(1):71-71.
[doi:10.1186/s40425-017-0277-7]
Garrido, P, Olmedo, ME, Gomez, A, Ares, LP, Lopez-Rios, F, Rosa-Rosa, JM, Palacios, J (2017).

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences

Therapeutic Advances in Medical Oncology. Review. 9(9):589-597.
[doi:10.1177/1758834017719829]
Langer CJ, Paz-Ares LG, Wozniak AJ, Gridelli C, de Marinis F, Pujol JL, San Antonio B, Chen J, Liu J, Oton AB, Visseren-Grul C, Scagliotti GV (2017).

Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance; Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective; Analyses From 2 Phase III Studies

Clinical Lung Cancer. Article. 18(5):489-496.
[doi:10.1016/j.cllc.2017.04.003]
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E (2017).

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for; Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell; Lung Cancer (BIRCH)

JOURNAL OF CLINICAL ONCOLOGY. Article. 35(24):2781-2789.
[doi:10.1200/JCO.2016.71.9476]
Kim, DW, Tiseo, M, Ahn, MJ, Reckamp, KL, Hansen, KH, Kim, SW, Huber, RM, West, HL, Groen, HJM, Hochmair, MJ, Leighl, NB, Gettinger, SN, Langer, CJ, Rodriguez, LGPA, Smit, EF, Kim, ES, Reichmann, W, Haluska, FG, Kerstein, D, Camidge, DR (2017).

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma; Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter; Phase II Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 35(22):2490-2498.
[doi:10.1200/JCO.2016.71.5904]
Prieto-García E, Díaz-García CV, García-Ruiz I, Agulló-Ortuño MT (2017).

Epithelial-to-mesenchymal transition in tumor progression

MEDICAL ONCOLOGY. Review. 34(7):122-122.
[doi:10.1007/s12032-017-0980-8]
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate 026 Investigators (2017).

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 376(25):2415-2426.
[doi:10.1056/NEJMoa1613493]
Wehler T, Thomas M, Schumann C, Bosch-Barrera J, Viñolas Segarra N, Dickgreber NJ, Dalhoff K, Sebastian M, Corral Jaime J, Alonso M, Hynes SM, Lin J, Hurt K, Bence Lin A, Calvo E, Paz-Ares L (2017).

A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618,; administered in combination with pemetrexed and cisplatin in patients; with advanced nonsquamous non-small cell lung cancer

LUNG CANCER. Article. 108:212-216.
[doi:10.1016/j.lungcan.2017.03.001]
Agullo-Ortuno, MT, Diaz, CE, Gonzalez-Coloma, A, Reina, M (2017).

Structure-Dependent Cytotoxic Effects of Eremophilanolide Sesquiterpenes

Natural Product Communications. Article. 12(5):663-665.
Isla, D., Majem, M., Vinolas, N., Artal, A., Blasco, A., Felip, E., Garrido, P., Remon, J., Baquedano, M., Borras, J. M., Die Trill, M., Garcia-Campelo, R., Juan, O., Leon, C., Lianes, P., Lopez-Rios, F., Molins, L., Planchuelo, M. A., Cobo, M., Paz-Ares, L., Trigo, J. M., de Castro, J. (2017).

A consensus statement on the gender perspective in lung cancer

Clinical & Translational Oncology. Review. 19(5):527-535.
[doi:10.1007/s12094-016-1578-x]
González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A (2017).

A definition for aggressive disease in patients with HER-2 negative; metastatic breast cancer: an expert consensus of the Spanish Society of; Medical Oncology (SEOM)

Clinical & Translational Oncology. Review. 19(5):616-624.
[doi:10.1007/s12094-016-1571-4]
Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez Lorenzo ML, Plazas JG, Custodio A, Hernández R, Garrido M, García T, Echavarría I, Cano JM, Rodríguez Palomo A, Mangas M, Macías Declara I, Ramchandani A, Visa L, Viudez A, Buxó E, Díaz-Serrano A, López C, Azkarate A, Longo F, Castañón E, Sánchez Bayona R, Pimentel P, Limón ML, Cerdá P, Álvarez Llosa R, Serrano R, Lobera MP, Alsina M, Hurtado Nuño A, Gómez-Martin C (2017).

Prognostic significance of performing universal HER2 testing in cases of; advanced gastric cancer

Gastric Cancer. Article. 20(3):465-474.
[doi:10.1007/s10120-016-0639-8]
Nutu OA, Brandáriz L, Pérez Carreras M, García-Borda J, Perea J (2017).

Rectal neuroendocrine tumor with an exceptional behaviour

Gastroenterologia y Hepatologia. Letter. 40(5):351-352.
[doi:10.1016/j.gastrohep.2016.03.009]
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA, BELIEF collaborative group (2017).

Erlotinib and bevacizumab in patients with advanced non-small-cell lung; cancer and activating EGFR mutations (BELIEF): an international,; multicentre, single-arm, phase 2 trial

Lancet Respiratory Medicine. Article. 5(5):435-444.
[doi:10.1016/S2213-2600(17)30129-7]
Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP (2017).

Translational research in neuroendocrine tumors: pitfalls and; opportunities

ONCOGENE. Review. 36(14):1899-1907.
[doi:10.1038/onc.2016.316]
Zugazagoitia J, Díaz A, Jimenez E, Nuñez JA, Iglesias L, Ponce-Aix S, Paz-Ares L (2017).

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the; Clinical Development of Dacomitinib

Frontiers in Medicine. Review. 4:36-36.
[doi:10.3389/fmed.2017.00036]
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group (2017).

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients; with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing; First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat; Good versus VeriStrat Poor. The European Thoracic Oncology Platform; (ETOP) EMPHASIS-lung Trial

Journal of Thoracic Oncology. Article. 12(4):752-762.
[doi:10.1016/j.jtho.2016.12.017]
Herraiz I, Simón E, Toldos Ó, Rodríguez Y, Gómez-Arriaga PI, Galindo A (2017).

Angiogenesis-related biomarkers (sFlt-1/PlGF) in placental mesenchymal; dysplasia

Journal of Maternal-Fetal & Neonatal Medicine. Article. 30(8):958-961.
[doi:10.1080/14767058.2016.1192600]
Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, Cubillo A, Teruel CF, Calderero IL, Siguero M, Bohan P, Calvo E (2017).

Phase I clinical and pharmacokinetic study of PM01183 (a; tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine; in patients with advanced solid tumors

INVESTIGATIONAL NEW DRUGS. Article. 35(2):198-206.
[doi:10.1007/s10637-016-0410-3]
Quintela-Fandino M, Lluch A, Manso LM, Calvo I, Cortes J, García-Saenz JA, Gil JM, Martinez-Jañez N, González-Martín A, Adrover E, De Andres R, Viñas G, Llombart Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas-Simon S, Carrato A, Lopez A, Escudero MJ, Campo R, Carrasco EM, Palacios J, Mulero F, Colomer R (2017).

F-18-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in; Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized; Trial

CLINICAL CANCER RESEARCH. Article. 23(6):1432-1441.
[doi:10.1158/1078-0432.CCR-16-0738]
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr (2017).

First-line ceritinib versus platinum-based chemotherapy in advanced; ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised,; open-label, phase 3 study

LANCET. Article. 389(10072):917-929.
[doi:10.1016/S0140-6736(17)30123-X]
Wagner, A. J., Kindler, H., Gelderblom, H., Schoffski, P., Bauer, S., Hohenberger, P., Kopp, H. -G., Lopez-Martin, J. A., Peeters, M., Reichardt, P., Qin, A., Nippgen, J., Ilaria, R. L., Rutkowski, P. (2017).

A phase II study of a human anti-PDGFR alpha monoclonal antibody; (olaratumab, IMC-3G3) in previously treated patients with metastatic; gastrointestinal stromal tumors

ANNALS OF ONCOLOGY. Article. 28(3):541-546.
[doi:10.1093/annonc/mdw659]
Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L (2017).

Biological therapies in nonsmall cell lung cancer

EUROPEAN RESPIRATORY JOURNAL. Review. 49(3).
[doi:10.1183/13993003.01520-2016]
Marín-Gabriel JC, Díaz-Tasende J, Rodríguez-Muñoz S, Del Pozo-García AJ, Ibarrola-Andrés C (2017).

Colonic endoscopic full-thickness resection (EFTR) with the; over-the-scope device (FTRD): a short case series

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. Article. 109(3):230-233.
[doi:10.17235/reed.2017.4259/2016]
Agudo-López A, Prieto-García E, Alemán J, Pérez C, Díaz-García CV, Parrilla-Rubio L, Cabrera S, Navarro-Ranninger C, Cortés-Funes H, López-Martín JA, Agulló-Ortuño MT (2017).

Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human; melanoma cell lines and synergism with cis-Platin

Molecular Cancer. Article. 16(1):45-45.
[doi:10.1186/s12943-017-0618-7]
Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I (2017).

Strategies to design clinical studies to identify predictive biomarkers; in cancer research

CANCER TREATMENT REVIEWS. Review. 53:79-97.
[doi:10.1016/j.ctrv.2016.12.005]
Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N, PanGenEU Study Investigators (2017).

Reduced risk of pancreatic cancer associated with asthma and nasal; allergies

GUT. Article. 66(2):314.
[doi:10.1136/gutjnl-2015-310442]
Manso Sanchez, L., Moreno Anton, F., Izarzugaza Peron, Y., Delgado Mingorance, I., Borrega Garcia, P., Echarri Gonzalez, M. J., Martinez Janez, N., Lopez Gonzalez, A., Olier Garate, C., Ballesteros Garcia, A., Chacon Lopez-Muniz, I., Ciruelos Gil, E. M., Garcia Saenz, J. A., Paz-Ares Rodriguez, L. (2017).

High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P6-07-21]
Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T (2017).

Results From the Phase III Randomized Trial of Onartuzumab Plus; Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV; Non-Small-Cell Lung Cancer: METLung

JOURNAL OF CLINICAL ONCOLOGY. Article. 35(4):412-420.
[doi:10.1200/JCO.2016.69.2160]
Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV (2017).

Meta-analysis examining impact of age on overall survival with; pemetrexed for the treatment of advanced non-squamous non-small cell; lung cancer

LUNG CANCER. Article. 104:45-51.
[doi:10.1016/j.lungcan.2016.12.007]
De Castro J, Gonzalez-Larriba JL, Vazquez S, Massuti B, Sanchez-Torres JM, Domine M, Garrido P, Calles A, Artal A, Collado R, Garcia R, Sereno M, Majem M, Macias JA, Juan O, Gomez-Codina J, Hernandez B, Lazaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Munoz J, Diz P, Mendez M, Rosillo F, Paz-Ares L, Cardona JV, Isla D (2017).

Long-term survival in advanced non-squamous NSCLC patients treated with; first-line bevacizumab-based therapy

Clinical & Translational Oncology. Article. 19(2):219-226.
[doi:10.1007/s12094-016-1527-8]
Mestres JA, iMolins AB, Martínez LC, López-Muñiz JI, Gil EC, de Juan Ferré A, Del Barco Berrón S, Pérez YF, Mata JG, Palomo AG, Gregori JG, Pardo PG, Mañas JJ, Hernández AL, de Dueñas EM, Jáñez NM, Murillo SM, Bofill JS, Auñón PZ, Sanchez-Rovira P (2017).

Defining the optimal sequence for the systemic treatment of metastatic; breast cancer

Clinical & Translational Oncology. Article. 19(2):149-161.
[doi:10.1007/s12094-016-1520-2]
Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K (2017).

Afatinib versus gefitinib in patients with EGFR mutation-positive; advanced non-small-cell lung cancer: overall survival data from the; phase IIb LUX-Lung 7 trial

ANNALS OF ONCOLOGY. Article. 28(2):270-277.
[doi:10.1093/annonc/mdw611]
Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limón ML, Garcia-Carbonero R (2017).

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with; supportive care, in a randomized, controlled trial of patients with; metastatic colorectal cancer from Spain: results of a subgroup analysis; of the phase 3 RECOURSE trial

Clinical & Translational Oncology. Article. 19(2):227-235.
[doi:10.1007/s12094-016-1528-7]
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, Paz-Ares L (2017).

Lung cancer: current therapies and new targeted treatments

LANCET. Review. 389(10066):299-311.
[doi:10.1016/S0140-6736(16)30958-8]
Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A (2017).

Leakage decrease detected by dynamic susceptibility-weighted; contrast-enhanced perfusion MRI predicts survival in recurrent; glioblastoma treated with bevacizumab

Clinical & Translational Oncology. Article. 19(1):51-57.
[doi:10.1007/s12094-016-1502-4]
Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K (2017).

Treatment Rationale and Study Design for the RELAY Study: A Multicenter,; Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo; in Patients With Epidermal Growth Factor Receptor Mutation-Positive; Metastatic Non-Small-Cell Lung Cancer

Clinical Lung Cancer. Article. 18(1):96-99.
[doi:10.1016/j.cllc.2016.05.023]
Gillison, ML, Blumenschein, G, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, KJ, Kasper, S, Vokes, EE, Even, C, Worden, F, Saba, NF, Docampo, LCI, Haddad, R, Rordorf, T, Kiyota, N, Tahara, M, Lynch, M, Kopit, J, Ferris, RL (2017).

Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory; Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and; Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and; Updated Safety and Efficacy

Asia-Pacific Journal of Clinical Oncology. Meeting Abstract. 13:144-144.
Oza AM, Selle F, Davidenko I, Korach J, Mendiola C, Pautier P, Chmielowska E, Bamias A, DeCensi A, Zvirbule Z, González-Martín A, Hegg R, Joly F, Zamagni C, Gadducci A, Martin N, Robb S, Colombo N (2017).

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed; Ovarian Cancer ROSiA Single-Arm Phase 3B Study

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 27(1):50-58.
[doi:10.1097/IGC.0000000000000836]
Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, Majem M, Lorigan P, Gandhi L, Gutierrez ME, Nepert D, Corral J, Ares LP (2017).

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate; Lorvotuzumab Mertansine (IMGN901) in Combination With; Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With; Extensive-Stage Disease

Clinical Lung Cancer. Article. 18(1):68-76.
[doi:10.1016/j.cllc.2016.09.002]
Popat, S, Ardizzoni, A, Ciuleanu, T, Dols, MC, Laktionov, K, Szilasi, M, Califano, R, Costa, EC, Griffiths, R, Paz-Ares, L, Szczylik, C, Jaime, JC, Isla, D, Jassem, J, Appel, W, van Meerbeeck, J, Wolf, J, Jiang, J, Molife, LR, Felip, E (2017).

Nivolumab in Patients With Previously TreatedMetastatic Squamous; Non-Small Cell Lung Cancer (NSCLC): Results of A European Single-Arm,; Phase II Trial (CHECKMATE 171) Including Patients Aged >= 70 Years or; With Poor Performance Status

Asia-Pacific Journal of Clinical Oncology. Meeting Abstract. 13:149-150.
Arnold, D, Fuchs, CS, Tabernero, J, Ohtsu, A, Zhu, AX, Garon, EB, Paz-Ares, L, Baron, AD, Okusaka, T, Yoshino, T, Yoon, HH, Das, M, Ferry, D, Zhang, Y, Lin, Y, Binder, P, Sashegyi, A, Chau, I (2017).

Meta-analysis of individual patient safety data from six randomized,; placebo-controlled trials with the antiangiogenic VEGFR2-binding; monoclonal antibody ramucirumab

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Barcena, C, Rojas, K, Lema, L, Sanchez, LM, Rios, J, Garcia-Martin, R, Maroto, A, Rodriguez-Peralto, JL, Gil, EMC, Mendiola, DC, Paz-Ares, L (2017).

Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade; serous ovarian cancer: Variation with neoadjuvant chemotherapy and; prognostic value

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Kueng, M, Guillen-Ponce, C, Herrero, FR, Plazas, JG, Lopez-Martin, JA, Benavides, M (2017).

PANOVA: a phase II study of TTFields (150 kHz) with concomitant standard; chemotherapy for front-line advanced pancreatic adenocarcinoma: Updated; efficacy results

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
[doi:10.1093/annonc/mdx369.141]
Lopez-Martin, JA, Cala, M, Prieto-Garcia, E, Riano, CG, Diaz-Garcia, CV, Garcia, A, Marques, VP, Pascualena, FR, Garcia-Ruiz, I, Pernaut, C, Otero, I, Rubio, LP, Riesco, MC, Alfonso, JA, Barbas, C, Agullo-Ortuno, MT (2017).

Metabolomics in cancer cachexia

ANNALS OF ONCOLOGY. Meeting Abstract. 28.

2016

Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N (2016).

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Journal of Thoracic Oncology. Review. 11(12):2066-2081.
[doi:10.1016/j.jtho.2016.08.138]
Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F (2016).

SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)

Clinical & Translational Oncology. Article. 18(12):1179-1186.
[doi:10.1007/s12094-016-1577-y]
Iwata, H., Rubovszky, G., Loibl, S., Ciruelos, E., Campone, M., Juric, D., Rugo, H., Mayer, I., Conte, P. F., Kaufman, B., Inoue, K., Tesch, H., Li, Y-S., Mingorance, I. D., Ryvo, L., Iwase, H., Longin, A-S., Mills, D., Wilke, C., Andre, F. (2016).

A phase III study of alpelisib and fulvestrant for hormone; receptor-positive (HR1), human epidermal growth factor receptor; 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after; aromatase inhibitor (AI) therapy (SOLAR-1)

ANNALS OF ONCOLOGY. Meeting Abstract. 27(9).
Hidalgo, M., Gil, M., Garcia-Carbonero, R., Alvarez, R., Laquente, B., Moreno, R., De Martino, A., Alemany, R., Capella, G., Blasi, E., Viaplana, I., Cascallo, M., Salazar, R. (2016).

First-in-human dose-escalation study of VCN-01, a selective oncolytic; adenovirus with hyaluronidase activity in patients with advanced or; metastatic cancer

EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 69(1):99-100.
[doi:10.1016/S0959-8049(16)32895-7]
Park, K, Tan, EH, Zhang, L, Hirsh, V, O'Byrne, K, Boyer, M, Yang, JCH, Mok, T, Lee, KH, Lu, S, Shi, Y, Kim, SW, Laskin, J, Kim, DW, Laurie, SA, Kolbeck, K, Fan, J, Dodd, N, Marten, A, Paz-Ares, L (2016).

Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR; mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from; LUX-Lung 7 (LL7)

ANNALS OF ONCOLOGY. Meeting Abstract. 27.
Pericay, Carles, Rivera, Fernando, Gomez-Martin, Carlos, Nunez, Inmaculada, Cassinello, Alejo, Rodrigo Imedio, Esteban (2016).

Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma

Cancer Medicine. Review. 5(12):3464-3474.
[doi:10.1002/cam4.941]
Ferris, R. L., Blumenschein, Jr., G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., Gillison, M. L. (2016).

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

NEW ENGLAND JOURNAL OF MEDICINE. Article. 375(19):1856-1867.
[doi:10.1056/NEJMoa1602252]
Sevilla, I, Segura, A, Capdevila, J, Lopez, C, Garcia-Carbonero, R, Grande, E, GETNE (Spanish Group of NeuroEndocrine Tumors) (2016).

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program

BMC CANCER. Article. 16(1):858-858.
[doi:10.1186/s12885-016-2901-1]
Barlesi, F, Steins, M, Horn, L, Ready, N, Felip, E, Borghaei, H, Spigel, DR, Arrieta, O, Antonia, S, Fayette, J, Rizvi, N, Crino, L, Reck, M, Eberhardt, WE, Hellman, M, Geese, WJ, Li, A, Healey, D, Brahmer, J, Paz-Ares, L (2016).

LONG-TERM OUTCOMES WITH NIVOLUMAB VESRSUS DOCETAXEL IN PATIENTS WITH; ADVANCED NSCLC: CHECKMATE 017 AND CHECKMATE 057 2-YEAR UPDATE

Asia-Pacific Journal of Clinical Oncology. Meeting Abstract. 12:115-116.
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J (2016).

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(aEuro)

ANNALS OF ONCOLOGY. Article. 27(11):2082-2089.
[doi:10.1093/annonc/mdw402]
Arance AM, Berrocal A, Lopez-Martin JA, de la Cruz-Merino L, Soriano V, Martín Algarra S, Alonso L, Cerezuela P, La Orden B, Espinosa E (2016).

Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience

Clinical & Translational Oncology. Article. 18(11):1147-1157.
[doi:10.1007/s12094-016-1498-9]
Colomer, R., Ciruelos, E., De la Haba, J., Martin, M., De Salas-Cansado, M., Munoz-Molina, B., Albanell, J. (2016).

COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB,; TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO; ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB,; TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN

VALUE IN HEALTH. Meeting Abstract. 19(7):740-740.
[doi:10.1016/j.jval.2016.09.2249]
García-Alfonso P, Feliú J, García-Carbonero R, Grávalos C, Guillén-Ponce C, Sastre J, García-Foncillas J (2016).

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

Clinical & Translational Oncology. Review. 18(11):1072-1081.
[doi:10.1007/s12094-016-1499-8]
Simonelli, M, Sepulveda, J, Brandes, A, Soria, JC, Edenfield, J, Moreno, V, Perez-Larraya, JG, Britten, C, Cloughesy, TF, Garcia, MM, Balana, C, Hagner, P, Li, Y, Wei, X, Gandhi, A, Pourdehnad, M, Martin, JAL, Santoro, A, Shih, K (2016).

A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE; SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER; CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME; (GBM) AND OTHER BRAIN TUMORS

NEURO-ONCOLOGY. Meeting Abstract. 18:24-24.
Albanell, J., Ciruelos, E., De la Haba, J., Martin, M., Munoz-Molina, B., De Salas-Cansado, M., Colomer, R. (2016).

ESTIMATED COSTS OF LOCOREGIONAL AND METASTATIC RECURRENCES IN PATIENTS; WITH HER2+BREAST CANCER IN SPAIN

VALUE IN HEALTH. Meeting Abstract. 19(7):729-729.
[doi:10.1016/j.jval.2016.09.2190]
Perez M, Peinado-Serrano J, Garcia-Heredia JM, Felipe-Abrio I, Tous C, Ferrer I, Martin-Broto J, Saez C, Carnero A (2016).

Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)

Oncotarget. Article. 7(41):67033-67046.
[doi:10.18632/oncotarget.11475]
Borghaei H, Brahmer J, Horn L, Ready N, Steins M, Felip E, Paz-Ares L, Xx X, Barlesi F, Antonia S, Fayette J, Rizvi N, Crino L, Reck M, Erich Eberhardt WE, Hellmann M, Desai K, Li A, Healey D, Spigel D, Mathias C (2016).

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.

Journal of Thoracic Oncology. Article. 11(10S).
[doi:10.1016/j.jtho.2016.08.106]
Andre, F., Kaufman, B., Juric, D., Ciruelos, E., Iwata, H., Mayer, I. A., Conte, P., Rugo, H. S., Loibl, S., Rubovszky, G., Tesch, H., Inoue, K., Lu, Y-S., Ryvo, L., Longin, A-S., Mills, D., Wilke, C., Germa, C., Campone, M. (2016).

A phase III study of alpelisib and fulvestrant in men and postmenopausal; women with hormone receptor-positive (HR plus ), human epidermal growth; factor receptor 2-negative (HER2-) advanced breast cancer (BC); progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw365.90]
Aix SP, Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Chih-Hsin Yang J, Märten A, Paz-Ares L (2016).

P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC.

Journal of Thoracic Oncology. Article. 11(10S).
[doi:10.1016/j.jtho.2016.08.056]
Cascales Garcia, M. A., Colmenero, M., Rodriguez Antolin, A., Samper Ots, P. M., Valero, J., Gonzalez Sansegundo, C., Cabrera, J. A., Gomez Veiga, F., Couselo, M. L., Garcia Gomez, B., Hernando Arteche, A., Ponce Diaz-Reixa, J., Rubio, C., Rodriguez Cabrera, M., Martin-Arriscado, C., Lora, D., Paz-Ares, L. G., Cabeza Rodriguez, M. D. L. A. (2016).

Measuring Quality of Life in Low-Risk Prostate Cancer Treated With; Surgery, External Beam Radiation Therapy, or Brachytherapy. CAPCIRAB; Project: A Prospective, Multicentric Cohort Study

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. Meeting Abstract. 96(2):277-277.
Kasper, S., van Cutsem, E., Ciardello, F., Ychou, M., Seitz, J. -F, Hofheinz, R. -D, Arriaga, Y. E., Verma, U., Garcia-Carbonero, R., Grothey, A., Miriyala, A., Kalmus, J., Kappeler, C., Falcone, A., Zaniboni, A. (2016).

Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial

Oncology Research and Treatment. Meeting Abstract. 39(3):94-95.
Manso Sanchez, L. M., Moreno Anton, F., Izarzugaza Peron, Y., Delgado Mingorance, J. I., Borrega, P., Echarri Gonzalez, M. J., Martinez, N., Lopez Gonzalez, A., Olier, C., Ballesteros Garcia, A., Chacon, I., Ciruelos, E., Garcia-Saenz, J. A., Paz-Ares, L. (2016).

Single arm, multicentre, non-randomized open-label trial to evaluate the; safety of eribulin in third line chemotherapy in patients with; HER2-negative metastatic or locally advanced breast cancer previously; treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw365.25]
Azuara, D., Garcia-Carbonero, R., Garcia Alfonso, P., Santos-Vivas, C., Navarro, V., Varela, M., Carrato, A., Elez, E., Cano, M. T., Losa, F., Montagut, C., Massuti Sureda, B., Manzano, J. L., Vieitez, J., Valladares-Ayerbes, M., Sanjuan, X., Capella, G., Tabernero, J., Aranda, E., Salazar, R. (2016).

Extended genotyping of RAS/BRAF for improved selection of metastatic CRC patients to anti-EGFR therapy: Comparison of three platforms

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw363.5]
Van Cutsem, E., Garcia-Carbonero, R., Pastorino, A., Zaniboni, A., Falcone, A., Amellal, N., Benedetti, F., Mayer, R., Ohtsu, A., Tabernero, J. (2016).

RECOURSE trial: Performance status at discontinuation in patients; receiving trifluridine/tipiracil (TAS-102)

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw370.63]
Riesco-Martinez, M. C., Diaz-Serrano, A., Gomez-Martin, C., Adeva Alfonso, J., Sabater Cabrera, E., Garcia-Carbonero, R. (2016).

The role of antiangiogenic therapy in advanced gastro-esophageal cancer:; a systematic review and meta-analysis

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw371.20]
Garcia-Carbonero, R., Van Cutsem, E., Ciardiello, F., Ychou, M., Seitz, J-F., Hofheinz, R. D., Arriaga, Y., Verma, U., Grothey, A., Miriyala, A., Kalmus, J., Kappeler, C., Falcone, A., Zaniboni, A. (2016).

Subgroup analysis of patients with metastatic colorectal cancer (mCRC); treated with regorafenib (REG) in the phase 3b CONSIGN trial who had; progression-free survival (PFS) > 4 months (m)

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw370.54]
Garcia-Carbonero, R., Boni, V., Duran, I., Gil, M., Espinosa, M., Salazar, R., Cubillo, A., Jurado, M., Champion, B., Alvis, S., Fisher, K., Beadle, J., Pover, G., McElwaine-Johnn, H., Ellis, C., Blanc, C., Calvo, E. (2016).

A mechanism of action study of intra-tumoral or intravenous dosing of enadenotucirev, an oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma undergoing resection of primary tumor

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw378.41]
Capdevila, J., Teule, A., Barriuso, J., Castellano, D., Lopez, C., Manzano, J. L., Alonso, V., Garcia-Carbonero, R., Dotor, E., Matos, I., Custodio, A., Casanovas, O., Salazar, R. (2016).

Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients; with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs):; EVERLAR study

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw369.29]
Ciuleanu, T. -E., Bodoky, G., Garcia-Carbonero, R., Alfonso, P. Garcia, Van Cutsem, E., Muro, K., Mytelka, D., Lipkovich, O., Ferry, D., Sashegyi, A., Nasroulah, F., Tabernero, J. (2016).

Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) plus FOLFIRI vs placebo (PBO) plus FOLFIRI

ANNALS OF ONCOLOGY. Meeting Abstract. 27(6).
[doi:10.1093/annonc/mdw370.140]
Vergote, I., Von Moos, R., Manso, L., Sessa, C. (2016).

INNOVATE: A PILOT STUDY OF TTFIELDS CONCOMITANT WITH WEEKLY PACLITAXEL FOR RECURRENT OVARIAN CARCINOMA

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Meeting Abstract. 26(3):868-868.
Rodríguez Garzotto A, Díaz-García CV, Agudo-López A, Prieto García E, Ponce S, López-Martín JA, Paz-Ares L, Iglesias L, Agulló-Ortuño MT (2016).

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

MEDICAL ONCOLOGY. Article. 33(10):105-105.
[doi:10.1007/s12032-016-0824-y]
Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M., Ehlen, T., Jayson, G., Johnson, N., Swart, A. M., Verheijen, R., McCluggage, W. G., Perrin, T., Panici, P. L. Benedetti, Kenter, G. G., Casado, A., Mendiola, C., Stuart, G. C. E., Reed, N. S., Kehoe, S. (2016).

META-ANALYSIS OF THE RANDOMIZED EORTC AND CHORUS NEOADJUVANT VERSUS; PRIMARY DEBULKING TRIALS IN ADVANCED TUBO-OVARIAN CANCER

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Meeting Abstract. 26(3):24-25.
Korach, J., Colombo, N., Mendiola, C., Selle, F., Martin, N., Robb, S., Oza, A. (2016).

OUTCOME ACCORDING TO RESIDUAL DISEASE (SURGEON'S REPORT VERSUS PRE-CHEMOTHERAPY IMAGING) IN BEVACIZUMAB-TREATED OVARIAN CANCER PATIENTS: ANALYSIS OF THE ROSIA STUDY

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Meeting Abstract. 26(3):746-748.
Lonardi, S., Cohn, A. L., Yoshino, T., Obermannova, R., Bodoky, G., Prausova, J., Garcia-Carbonero, R., Ciuleanu, T., Garcia-Alfonso, P., Portnoy, D. C., Van Cutsem, E., Yamazaki, K., Clingan, P. R., Polikoff, J., Gao, L., Yang, L., Chang, S., Ferry, D., Nasroulah, F., Tabernero, J. (2016).

Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

ANNALS OF ONCOLOGY. Meeting Abstract. 27(4).
[doi:10.1093/annonc/mdw335.4]
Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N (2016).

Clinicopathologic Features of Advanced Squamous NSCLC

Journal of Thoracic Oncology. Review. 11(9):1411-1422.
[doi:10.1016/j.jtho.2016.05.024]
Brandariz Gil L, Fernández de Miguel T, Perea J (2016).

Rigler triad in gallstone ileus

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. Editorial Material. 108(9):581-582.
Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P (2016).

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

ANNALS OF ONCOLOGY. Article. 27(9):1719-1725.
[doi:10.1093/annonc/mdw249]
Vazquez-Sequeiros E, Baron TH, Pérez-Miranda M, Sánchez-Yagüe A, Gornals J, Gonzalez-Huix F, de la Serna C, Gonzalez Martin JA, Gimeno-Garcia AZ, Marra-Lopez C, Castellot A, Alberca F, Fernandez-Urien I, Aparicio JR, Legaz ML, Sendino O, Loras C, Subtil JC, Nerin J, Perez-Carreras M, Diaz-Tasende J, Perez G, Repiso A, Vilella A, Dolz C, Alvarez A, Rodriguez S, Esteban JM, Juzgado D, Albillos A, Spanish Group for FCSEMS in Pancreas Collections (2016).

Evaluation of the short- and long-term effectiveness and safety of fully covered self-expandable metal stents for drainage of pancreatic fluid collections: results of a Spanish nationwide registry

GASTROINTESTINAL ENDOSCOPY. Article. 84(3):450-450.
[doi:10.1016/j.gie.2016.02.044]
Walter, Stefan, Beltran-Sanchez, Hiram, Regidor, Enrique, Gomez-Martin, Carlos, Luis del-Barrio, Jose, Gil-de-Miguel, Angel, Subramanian, S. V., Gil-Prieto, Ruth (2016).

No evidence of morbidity compression in Spain: a time series study based on national hospitalization records

International Journal of Public Health. Article. 61(7):729-738.
[doi:10.1007/s00038-016-0829-5]
Sanchez-Gastaldo A, Gonzalez-Exposito R, Garcia-Carbonero R (2016).

Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors

TARGETED ONCOLOGY. Review. 11(4):479-487.
[doi:10.1007/s11523-016-0419-8]
Toll A, Fernández LC, Pons T, Groesser L, Sagrera A, Carrillo-de Santa Pau E, Vicente A, Baselga E, Vázquez M, Beltrán S, Pisano DG, Rueda D, Gut M, Pujol RM, Hafner C, Gut I, Valencia A, Real FX (2016).

Somatic Embryonic FGFR2 Mutations in Keratinocytic Epidermal Nevi

JOURNAL OF INVESTIGATIVE DERMATOLOGY. Letter. 136(8):1718-1721.
[doi:10.1016/j.jid.2016.03.040]
Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR (2016).

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

ANNALS OF ONCOLOGY. Article. 27(8):1573-1579.
[doi:10.1093/annonc/mdw214]
Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J (2016).

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status

Clinical & Translational Oncology. Article. 18(8):805-812.
[doi:10.1007/s12094-015-1444-2]
Donat, M., Alonso, S., Pereira, F., Ferrero, E., Carrion, L., Acin-Gandara, D., Moreno, E. (2016).

Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation

TRANSPLANTATION PROCEEDINGS. Article. 48(6):1968-1977.
[doi:10.1016/j.transproceed.2016.04.002]
Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L (2016).

Current Challenges in Cancer Treatment

CLINICAL THERAPEUTICS. Review. 38(7):1551-1566.
[doi:10.1016/j.clinthera.2016.03.026]
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E (2016).

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

LANCET ONCOLOGY. Article. 17(7):883-895.
[doi:10.1016/S1470-2045(16)30098-5]
Martin-Broto, Javier, Lopez Pousa, Antonio, de las Penas, Ramon, Garcia del Muro, Xavier, Gutierrez, Antonio, Martinez-Trufero, Javier, Cruz, Josefina, Alvarez, Rosa, Cubedo, Ricardo, Redondo, Andres, Maurel, Joan, Carrasco, Juan A., Lopez-Martin, Jose A., Sala, Angeles, Andres Meana, Jose, Ramos, Rafael, Martinez-Serra, Jordi, Lopez-Guerrero, Jose A., Sevilla, Isabel, Balana, Carmen, Vaz, Angeles, De Juan, Ana, Alemany, Regina, Poveda, Andres (2016).

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

JOURNAL OF CLINICAL ONCOLOGY. Article. 34(19):2294-2294.
[doi:10.1200/JCO.2015.65.3329]
Nakajima, Takako, Tabernero, Josep, Van Cutsem, Eric, Obermannova, Radka, Bodoky, Gyorgy, Prausova, Jana, Garcia-Carbonero, Rocio, Ciuleanu, Tudor, Garcia Alfonso, Pilar, Portnoy, David, Cohn, Allen, Yamazaki, Kentaro, Clingan, Phil, Yoshino, Takayuki, Lonardi, Sara, Yang, Ling, Nasroulah, Federico (2016).

Subgroup analysis in RAISE: a phase III study of FOLFIRI plus ramucirumab or placebo in patients with advanced mCRC

ANNALS OF ONCOLOGY. Meeting Abstract. 27(7).
[doi:10.1093/annonc/mdw468]
Barriuso, Jorge, Benavent, Marta, Lamarca, Angela, Bernal, Elsa, Pastrian, Laura Guerra, Heredia, Victoria, Miguel, Maria, Garcia-Calderon, Clara Beatriz, Alvarez-Escola, Cristina, Castell, Jose, Custodio, Ana, Burgos, Emilio, Feliu, Jaime, Garcia-Carbonero, Rocio, Mendiola, Marta (2016).

External validation of lysyl oxidase-like 2 (LOXL2) as a novel prognostic marker for gastro-entero-pancreatic neuroendocrine tumors (GEP-NET)

CANCER RESEARCH. Meeting Abstract. 76(14).
[doi:10.1158/1538-7445.AM2016-3488]
Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Joerg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann, Gueorguieva, Ivelina, Desaiah, Durisala, Lahn, Michael M., Al Blunt, Benhadji, Karim A., Tabernero, Josep (2016).

A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib plus gemcitabine (GG) or gemcitabine plus placebo (GP) in patients with unresectable pancreatic cancer (PC)

CANCER RESEARCH. Meeting Abstract. 76(14).
[doi:10.1158/1538-7445.AM2016-CT068]
Riesco-Martínez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K, Wong WW, Chan KK (2016).

Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer

Journal of Oncology Practice. Article. 12(6):574-723.
[doi:10.1200/JOP.2015.008730]
Van Cutsem, E., Ciardiello, F., Ychou, M., Seitz, J. -F., Hofheinz, R., Arriaga, Y., Garcia-Carbonero, R., Grothey, A., Miriyala, A., Kalmus, J., Kappeler, C., Falcone, A., Zaniboni, A. (2016).

Analysis of patients >= 75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)

ANNALS OF ONCOLOGY. Meeting Abstract. 27(2):106-106.
Diaz-Serrano A, Riesco-Martinez MC, Garcia-Carbonero R (2016).

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer

Expert Review of Anticancer Therapy. Review. 16(6):585-595.
[doi:10.1080/14737140.2016.1182430]
Cedres, S., Ponce-Aix, S., Pardo-Aranda, N., Navarro-Mendivil, A., Martinez-Marti, A., Zugazagoitia, J., Sansano, I., Montoro, M. A., Enguita, A., Felip, E. (2016).

Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

LUNG CANCER. Article. 96:1-6.
[doi:10.1016/j.lungcan.2016.03.001]
Rivera, F., Gallego, J., Guillen-Ponce, C., Benavides, M., Lopez-Martin, J., Kueng, M. (2016).

PANOVA: a pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma

ANNALS OF ONCOLOGY. Meeting Abstract. 27(2):37-37.
Vergnenegre A, Massuti B, de Marinis F, Carcereny E, Felip E, Do P, Sanchez JM, Paz-Arez L, Chouaid C, Rosell R, Spanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French (2016).

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC

Journal of Thoracic Oncology. Article. 11(6):801-807.
[doi:10.1016/j.jtho.2016.02.004]
Tabernero, J., Robert, J. Mayer, Ohtsu, A., Yoshino, T., Garcia-Carbonero, R., Pastorino, A., Peeters, M., Winkler, R., Makris, L., Wahba, M., Zaniboni, A., Shimada, Y., Yamazaki, K., Komatsu, Y., Hochster, H., Lenz, H. -J., Falcone, A., Tran, B., Van Cutsem, E. (2016).

RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment

ANNALS OF ONCOLOGY. Meeting Abstract. 27(2):111-111.
Yoshino, T., Obermannov, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T. -E., Portnoy, D., Tae, W. Kim, Hsu, Y., Yang, L., Ferry, D., Nasroulah, F., Tabernero, J. (2016).

Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial

ANNALS OF ONCOLOGY. Meeting Abstract. 27(2):113-113.
Perez, Marco, Lucena-Cacace, Antonio, Miguel Marin-Gomez, Luis, Padillo-Ruiz, Javier, Jose Robles-Frias, Maria, Saez, Carmen, Garcia-Carbonero, Rocio, Carnero, Amancio (2016).

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Oncotarget. Article. 7(22):33111-33124.
[doi:10.18632/oncotarget.8880]
Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M (2016).

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance

PLoS One. Article. 11(5).
[doi:10.1371/journal.pone.0155840]
Bellet, Meritxell, Gray, Kathryn P., Francis, Prudence A., Lang, Istvan, Ciruelos, Eva, Lluch, Ana, Angel Climent, Miguel, Catalan, Gustavo, Avella, Antoni, Bohn, Uriel, Gonzalez-Martin, Antonio, Ferrer, Roser, Catalan, Roberto, Azaro, Analia, Rajasekaran, Agnita, Morales, Josefa, Vazquez, Josep, Fleming, Gini F., Price, Karen N., Regan, Meredith M. (2016).

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

JOURNAL OF CLINICAL ONCOLOGY. Article. 34(14):1584-89.
[doi:10.1200/JCO.2015.61.2259]
Ribi, Karin, Luo, Weixiu, Bernhard, Jurg, Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perello, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Meredith M., Fleming, Gini F. (2016).

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 34(14):1601-122.
[doi:10.1200/JCO.2015.64.8675]
Perea J, Arriba M, Rueda D, Sánchez R, García JL, Pérez J, Rodríguez Y, González-Sarmiento R, Urioste M (2016).

Comment on `Wild-type APC prediction of poor prognosis in microsatellite-stable proximal colorectal cancer differs according to the age of onset'

BRITISH JOURNAL OF CANCER. Editorial Material. 114(10).
[doi:10.1038/bjc.2016.53]
Ferrer I, Verdugo-Sivianes EM, Castilla MA, Melendez R, Marin JJ, Muñoz-Galvan S, Lopez-Guerra JL, Vieites B, Ortiz-Gordillo MJ, De León JM, Praena-Fernandez JM, Perez M, Palacios J, Carnero A (2016).

Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors

ONCOGENE. Article. 35(21):2777-2788.
[doi:10.1038/onc.2015.341]
Arriba M, García JL, Inglada-Pérez L, Rueda D, Osorio I, Rodríguez Y, Álvaro E, Sánchez R, Fernández T, Pérez J, Hernández JM, Benítez J, González-Sarmiento R, Urioste M, Perea J (2016).

DNA copy number profiling reveals different patterns of chromosomal instability within colorectal cancer according to the age of onset

MOLECULAR CARCINOGENESIS. Article. 55(5):705-716.
[doi:10.1002/mc.22315]
Park, Keunchil, Tan, Eng-Huat, O'Byrne, Ken, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Wan, Arvis, Catherine Dubos, Kolbeck, Arvis Karl, Laurie, Scott A., Tsai, Chun-Ming, Shahidi, Mehdi, Kim, Miyoung, Massey, Dan, Zazulina, Victoria, Paz-Ares, Luis (2016).

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

LANCET ONCOLOGY. Article. 17(5):577-589.
[doi:10.1016/S1470-2045(16)30033-X]
Laimito KR, Gámez-Pozo A, Sepúlveda J, Manso L, López-Vacas R, Pascual T, Fresno Vara JA, Ciruelos E (2016).

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases

eCancerMedicalScience. Article. 10:632-632.
[doi:10.3332/ecancer.2016.632]
Quintanal Á, Poveda R, Meléndez R, Ojeda-Márquez L, Marrugal Á, Velasco MG, Ferrer I, Carnero A, Paz-Ares L, Molina-Pinelo S (2016).

20P Context-dependent role of FGFR4 in lung tumorogenesis.

Journal of Thoracic Oncology. Article. 11(4 Suppl).
[doi:10.1016/S1556-0864(16)30134-4]
Marrugal A, Márquez LO, Quintanal Á, Molina-Pinelo S, Ferrer I, Carnero A, Paz-Ares L (2016).

19P Comparative effectiveness analysis of HSP90 inhibitors in non-small cell lung cancer.

Journal of Thoracic Oncology. Article. 11(4 Suppl).
[doi:10.1016/S1556-0864(16)30133-2]
Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Thatcher N, Hirsch F (2016).

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

Journal of Thoracic Oncology. Article. 11(4 Suppl).
[doi:10.1016/S1556-0864(16)30326-4]
Park K, Tan EH, Zhang L, Hirsh V, O'Byrne K, Boyer M, Yang J, Mok T, Kim M, Paz-Ares L (2016).

140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations.

Journal of Thoracic Oncology. Article. 11(4 Suppl).
[doi:10.1016/S1556-0864(16)30250-7]
Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A (2016).

SEOM guidelines for the treatment of gastric cancer 2015 (vol 17, pg 996, 2015)

Clinical & Translational Oncology. Correction. 18(4):426-426.
[doi:10.1007/s12094-016-1491-3]
Kempf E, Rousseau B, Besse B, Paz-Ares L (2016).

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

European Respiratory Review. Review. 25(139):71-76.
[doi:10.1183/16000617.0071-2015]
Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L (2016).

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials

ANNALS OF ONCOLOGY. Article. 27(3):423-429.
[doi:10.1093/annonc/mdv593]
Jover, R, Zapater, P, Bujanda, L, Hernandez, V, Cubiella, J, Pellise, M, Ponce, M, Ono, A, Lanas, A, Seoane, A, Marin-Gabriel, JC, Chaparro, M, Cacho, G, Herreros-De-Tejada, A, Fernandez-Diez, S, Peris, A, Nicolas-Perez, D, Murcia, O, Castells, A, Quintero, E, COLONPREV Study Investigators (2016).

Endoscopist characteristics that influence the quality of colonoscopy

ENDOSCOPY. Article. 48(3):241-247.
[doi:10.1055/s-0042-100185]
Saura, C., Isakoff, S. J., Calvo, I., Patt, D., Andersen, J., Gonzalez-Martin, A., Fisher, J., Ciruelos, E., Gil-Gil, M., De la Pena, L., Choi, Y., Jia, S., Singel, S., Patel, P. H., Baselga, J., Oliveira, M. (2016).

FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple negative breast cancer (TNBC)

CANCER RESEARCH. Meeting Abstract. 76(4).
[doi:10.1158/1538-7445.SABCS15-OT1-03-09]
Ciruelos, E., Gonzalez, E., Lluch, A., Garrigos, L., Quiroga, V., Anton, A., Pascual, T., Montano, A., Angulo, M. dM, Camara, M. dC, Amigo, Y., Carrasco, E., Casas, A. (2016).

Phase III clinical trial to evaluate patient's preference for subcutaneous (SC) versus intravenous (IV) trastuzumab administration in patients with HER2 positive, advanced breast cancer (ABC) under IV trastuzumab treatment for at least 4 months and without disease progression. ChangHER-SC study (GEICAM/2012-07)

CANCER RESEARCH. Meeting Abstract. 76(4).
[doi:10.1158/1538-7445.SABCS15-OT3-01-03]
Prat, A., Ortega, V., Pare, L., Galvan, P., Oliveira, M., Nuciforo, P., Lluch, A., Morales, S., Amillano, K., Lopez, R., Gonzalez, R., Manso, L., Martinez, J., Llombart, A., de la Pena, L., di Cosimo, S., Rubio, I. T., Harbeck, N., Baselga, J., Cortes, J. (2016).

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

CANCER RESEARCH. Meeting Abstract. 76(4).
[doi:10.1158/1538-7445.SABCS15-P3-07-66]
Pascual-Martinez, T., Apellaniz-Ruiz, M., Pernaut, C., Cueto-Felgueroso, C., Villalba, P., Alvarez, C., Manso, L., Rodriguez-Antona, C., Ciruelos, E. M. (2016).

Pharmacogenetic study of exemestane and everolimus in metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors

CANCER RESEARCH. Meeting Abstract. 76(4).
[doi:10.1158/1538-7445.SABCS15-P3-07-40]
Bidard, F-C, Peeters, D., Fehm, T., Nole, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J. A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., Fernandez de Lascoiti, A., de Mattos-Arruda, L., Ignatiadis, M., van Laere, S. J., Meier-Stiegen, F., Sandri, M-T, Vidal-Martinez, J., Politaki, E., Consoli, F., Bottini, A., Diaz-Rubio, E., Krell, J., Dawson, S-J, Raimondi, C., Rutten, A., Janni, W., Munzone, E., Caranana, V., Agelaki, S., Almici, C., Dirix, L., Solomayer, E., Zorzino, L., Reis-Filho, J. S., Squifflet, P., Pantel, K., Belie, N., Sleijfers, S., Pierga, J-Y, Michiels, S. (2016).

Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis

CANCER RESEARCH. Meeting Abstract. 76(4).
[doi:10.1158/1538-7445.SABCS15-P2-08-08]
Arce-Salinas C, Riesco-Martinez MC, Hanna W, Bedard P, Warner E (2016).

Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature

JOURNAL OF CLINICAL ONCOLOGY. Review. 34(4):21-24.
[doi:10.1200/JCO.2013.49.8899]
Amor S, Iglesias-de la Cruz MC, Ferrero E, García-Villar O, Barrios V, Fernandez N, Monge L, García-Villalón AL, Granado M (2016).

Peritumoral adipose tissue as a source of inflammatory and angiogenic factors in colorectal cancer

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. Article. 31(2):365-375.
[doi:10.1007/s00384-015-2420-6]
Zugazagoitia J, Ponce S, Paz-Ares L (2016).

Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?

Translational lung cancer research. Editorial Material. 5(1):95-97.
[doi:10.3978/j.issn.2218-6751.2015.08.05]
Grande, Enrique, Castellano, Daniel E., Custodio, Ana B., Garcia-Carbonero, Rocio, Gonzalez, Encarnacion, Lopez-Lopez, Carlos, Munarriz, Javier, Sevilla, Isabel, Teule, Alexandre, Vinuales, Marta Benavent, Alonso, Teresa, Borau, Pablo Gajate, Palacios, Jose, Capdevila, Jaume (2016).

A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 34(4, S).
[doi:10.1200/jco.2016.34.4_suppl.tps479]
Marín-Gabriel JC, Fernández-Esparrach G, Díaz-Tasende J, Herreros de Tejada A (2016).

Colorectal endoscopic submucosal dissection from a Western perspective: Today's promises and future challenges

World journal of gastrointestinal endoscopy. Article. 8(2):40-55.
[doi:10.4253/wjge.v8.i2.40]
Valentín F, Guarinos C, Juárez M, Rodríguez-Soler M, Serradesanferm A, Rodriguez-Moranta F, Nicolas-Perez D, Bujanda L, Herraiz M, De-Castro L, Fernández-Bañares F, Herreros-de-Tejada A, Martínez F, Aguirre E, Ferrández Á, Díaz-Tasende J, Piñol V, Paya A, Egoavil C, Alenda C, Castells A, Jover R, Cubiella J (2016).

Endoscopic surveillance in patients with multiple (10-100) colorectal polyps

ENDOSCOPY. Article. 48(1):56-61.
[doi:10.1055/s-0034-1392515]
De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R (2016).

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

SUPPORTIVE CARE IN CANCER. Review. 24(1):499-507.
[doi:10.1007/s00520-015-2948-6]
Goldman JW, Shi P, Reck M, Paz-Ares L, Koustenis A, Hurt KC (2016).

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Clinical Lung Cancer. Article. 17(1):80-84.
[doi:10.1016/j.cllc.2015.08.003]
Taboada-Mostajo N, Rubio-González E, Bernal-Tirapo J, Garcia-Gutierrez V (2016).

Acute appendicitis caused by a migrated biliary endoprothesis

CIRUGIA ESPANOLA. Editorial Material. 94(1):3-3.
[doi:10.1016/j.ciresp.2015.06.006]
Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ (2016).

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients

Journal of Gynecologic Oncology. Article. 27(1).
[doi:10.3802/jgo.2016.27.e7]
Manneh R, Castellano D, Caso O, Loinaz C, Jiménez J, Estenoz J, Calatayud M, Sepúlveda JM, García-Carbonero R (2016).

Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case

Case Reports in Oncology. Article. 9(1):255-261.
[doi:10.1159/000445940]
Garcia-Carbonero, R, Sorbye, H, Baudin, E, Raymond, E, Wiedenmann, B, Niederle, B, Sedlackova, E, Toumpanakis, C, Anlauf, M, Cwikla, JB, Caplin, M, O'Toole, D, Perren, A, all other Vienna Consensus Conference participants (2016).

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

NEUROENDOCRINOLOGY. Article. 103(2):186-194.
[doi:10.1159/000443172]
Riesco-Martínez MC, Parrilla-Rubio L, Enguita-Valls AB, Delgado-Márquez AM, Ruste SA, López-Martín JA (2016).

A unique case of distant skin metastasis from chondroid chordoma.

JAAD case reports. Article. 2(1):63-66.
[doi:10.1016/j.jdcr.2015.11.014]
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT, Vienna Consensus Conference participants (2016).

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

NEUROENDOCRINOLOGY. Article. 103(2):153-171.
[doi:10.1159/000443171]
Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Perol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C (2016).

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

ESMO Open. Article. 1(6).
[doi:10.1136/esmoopen-2016-000118]
Quintanal-Villalonga A, Paz-Ares L, Ferrer I, Molina-Pinelo S (2016).

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications

DISEASE MARKERS. Review. 2016:9214056-9214056.
[doi:10.1155/2016/9214056]
Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, Ruszniewski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A, Vienna Consensus Conference participants (2016).

ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms

NEUROENDOCRINOLOGY. Article. 103(2):139-143.
[doi:10.1159/000443166]
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K, Vienna Consensus Conference participants (2016).

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

NEUROENDOCRINOLOGY. Article. 103(2):172-185.
[doi:10.1159/000443167]
Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D, Vienna Consensus Conference participants (2016).

ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)

NEUROENDOCRINOLOGY. Article. 103(2):144-152.
[doi:10.1159/000443165]
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R, Vienna Consensus Conference participants (2016).

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

NEUROENDOCRINOLOGY. Article. 103(2):125-138.
[doi:10.1159/000443170]
Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P, Vienna Consensus Conference participants (2016).

ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

NEUROENDOCRINOLOGY. Article. 103(2):119-124.
[doi:10.1159/000443168]
Gonzalez-Martin, Antonio, Alba, Emilio, Ciruelos, Eva, Cortes, Javier, Llombart, Antonio, Lluch, Ana, Andres, Raquel, Alvarez, Isabel, Manuel Aramenda, Jose, Ayala de la Pena, Francisco, Barnadas, Agusti, Batista, Norberto, Calvo, Lourdes, Galve, Elena, Garcia-Palomo, Andres, Angel Garcia-Saenz, Jose, de la Haba, Juan, Lopez, Rafael, Lopez-Vivanco, Guillermo, Martinez-Janez, Noelia, Martinez de Duenas, Eduardo, Plazaola, Arrate, Rodriguez-Lescure, Alvaro, Ruiz, Manuel, Sanchez-Rovira, Pedro, Santaballa, Ana, Angel Segui, Miguel, Tusquets, Ignasi, Zamora, Pilar, Martin, Miguel (2016).

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile

CURRENT CANCER DRUG TARGETS. Article. 16(5):415-428.
[doi:10.2174/1568009615666150817121731]
Barriuso, J., Benavent, M., Lamarca, A., Bernal, E., Guerra-Pastrian, L., Heredia, V, Miguel, M., Garcia-Calderon, C. B., Alvarez-Escola, C., Castell, J., Custodio, A., Burgos, E., Feliu, J., Carbonero R, Garcia, Mendiola, M. (2016).

Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort

NEUROENDOCRINOLOGY. Meeting Abstract. 103(1):44-44.
Marrugal Á, Ojeda L, Paz-Ares L, Molina-Pinelo S, Ferrer I (2016).

Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer

DISEASE MARKERS. Review. 2016:2138627-2138627.
[doi:10.1155/2016/2138627]
Brandariz, L, Alegre, C, Rueda, D, Arriba, M, Alonso, L, Nutu, A, Rodriguez, Y, Pajares, JA, Ferrero, E, Garcia-Borda, J, Perea, J (2016).

New Perspectives in Multiple Primary Colorectal Cancer: A Surgical Approach

DIGESTION. Article. 94(2):57-65.
[doi:10.1159/000448279]

2015

Manso, Luis, Garcia Palomo, Andres, Perez Carrion, Ramon, Cassinello, Javier, Gallegos Sancho, Isabel, Chacon Lopez-Muniz, Ignacio, Olier, Clara, Fernandez-Aramburo, Antonio, Llorca, Cristina, Gonzalez, Xavier, Llorente, Rosa, Torregrosa, Dolores, Alvarez, Inaki, Galve, Elena, Bueno, Coralia, Garau, Isabel, Garcia, Maria Jose, Gonzalez-Santiago, Santiago, Ballesteros, Ana Isabel, Blanco, Esperanza, Galan, Antonio, Gonzalez, Sonia, Perello, Antonia, Cortes-Funes, Hernan, Gravalos, Cristina (2015).

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study

ANTICANCER RESEARCH. Article. 35(12):6941-6950.
Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P (2015).

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

CANCER AND METASTASIS REVIEWS. Review. 34(4):823-842.
[doi:10.1007/s10555-015-9598-5]
Albanell, J., Ciruelos, E., Colomer, R., De la Haba, J., Martin, M., De Salas-Cansado, M., Munoz-Molina, B., Tournier, C., Thuresson, P., Schleich, W., MORSE Hlth Technology Assessment, Global Pricing Market Access (2015).

ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2(+) BREAST CANCER IN SPAIN: A COST OFFSETS STUDY

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. Meeting Abstract. 117(2, SI):42-42.
Paz-Ares, Luis, Hirsh, Vera, Zhang, Li, de Marinis, Filippo, Yang, James Chih-Hsin, Wakelee, Heather A., Seto, Takashi, Wu, Yi-Long, Novello, Silvia, Juhasz, Erszebet, Aren, Osvaldo, Sun, Yan, Schmelter, Thomas, Ong, Teng Jin, Pena, Carol, Smit, Egbert F., Mok, Tony S. (2015).

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

Journal of Thoracic Oncology. Article. 10(12):1745-1753.
[doi:10.1097/JTO.0000000000000693]
Cortes, Javier, Dieras, Veronique, Ro, Jungsil, Barriere, Jerome, Bachelot, Thomas, Hurvitz, Sara, Le Rhun, Emilie, Espie, Marc, Kim, Sung-Bae, Schneeweiss, Andreas, Sohn, Joo Hyuk, Nabholtz, Jean-Marc, Kellokumpu-Lehtinen, Pirkko-Liisa, Taguchi, Julie, Piacentini, Federico, Ciruelos, Eva, Bono, Petri, Ould-Kaci, Mahmoud, Roux, Flavien, Joensuu, Heikki (2015).

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

LANCET ONCOLOGY. Article. 16(16):1700-1710.
[doi:10.1016/S1470-2045(15)00373-3]
Berrocal A, Arance A, Espinosa E, Castaño AG, Cao MG, Larriba JL, Martín JA, Márquez I, Soria A, Algarra SM (2015).

SEOM guidelines for the management of Malignant Melanoma 2015

Clinical & Translational Oncology. Article. 17(12):1030-1035.
[doi:10.1007/s12094-015-1450-4]
Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R (2015).

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

Clinical & Translational Oncology. Article. 17(12):972-981.
[doi:10.1007/s12094-015-1434-4]
Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A (2015).

Seom guidelines for the treatment of gastric cancer 2015

Clinical & Translational Oncology. Article. 17(12):996-1004.
[doi:10.1007/s12094-015-1456-y]
Guillen-Ponce, C., Serrano, R., Sanchez-Heras, A. B., Teule, A., Chirivella, I., Martin, T., Martinez, E., Morales, R., Robles, L. (2015).

Clinical guideline seom: hereditary colorectal cancer

Clinical & Translational Oncology. Article. 17(12):962-971.
[doi:10.1007/s12094-015-1439-z]
Garcia-Saenz JA, Bermejo B, Estevez LG, Palomo AG, Gonzalez-Farre X, Margeli M, Pernas S, Servitja S, Rodriguez CA, Ciruelos E (2015).

SEOM clinical guidelines in early-stage breast cancer 2015

Clinical & Translational Oncology. Article. 17(12):939-945.
[doi:10.1007/s12094-015-1427-3]
Thomas, M., Zurlo, A., Carter, R., Aix, S. Ponce, Knorrenschild, J. Riera, Navarro Mendivil, A., Domine, M., Kollmeier, J., Huber, R. M., Wolf, M. (2015).

Immunomodulatory switch maintenance therapy to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study

ANNALS OF ONCOLOGY. Meeting Abstract. 26(8):6-6.
Calvo, Emiliano, Lopez-Martin, Jose, Bendell, Johanna, Eder, Joseph P., Taylor, Matthew, Ott, Patrick A., Pietanza, M. Catherine, Horn, Leora, Jaeger, Dirk, de Braud, Filippo, Morse, Michael A., Ascierto, Paolo A., Le, Dung T., Amin, Asim, Evans, Jeff, Simon, Jason S., Lin, Chen-Sheng, Christensen, Olaf, Antonia, Scott J. (2015).

NIVOLUMAB (NIVO) MONOTHERAPY OR IN COMBINATION WITH IPILIMUMAB (IPI) FOR TREATMENT OF RECURRENT SMALL CELL LUNG CANCER (SCLC)

Asia-Pacific Journal of Clinical Oncology. Meeting Abstract. 11(4, SI):118-118.
Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J (2015).

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

BREAST CANCER RESEARCH AND TREATMENT. Article. 154(2):351-357.
[doi:10.1007/s10549-015-3616-8]
Antonia, S. J., Bendell, J., Taylor, M., Calvo, E., Jaeger, D., de Braud, F., Ott, P. A., Pietanza, M. C., Horn, L., Le, D. T., Morse, M. A., Lopez-Martin, J. A., Ascierto, P. A., Christensen, O., Grosso, J. F., Simon, J., Lin, C., Eder, J. P. (2015).

Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

ANNALS OF ONCOLOGY. Meeting Abstract. 26(6):74-75.
Canal Lopez, A., Rueda, D., Atanasio, P., Diaz-Rodriguez, E., Martinez, J. (2015).

PHARMACOLOGICAL INHIBITION OF MET DESTROYS MULTIPLE MYELOMA CLONOGENIC TUMOR CELL

HAEMATOLOGICA. Meeting Abstract. 100(4):61-61.
Canal Lopez, A., Rueda, D., Martinez, L. J. (2015).

HEALTHY BONE MARROW STROMAL CELLS INDUCE APOPTOSIS OF CELLS OF MYELOMA COOPERATING WITH ANTIMYELOMA DRUGS

HAEMATOLOGICA. Meeting Abstract. 100(4):63-64.
Segui, Nuria, Mina, Leonardo B., Lazaro, Conxi, Sanz-Pamplona, Rebeca, Pons, Tirso, Navarro, Matilde, Bellido, Fernando, Lopez-Doriga, Adriana, Valdes-Mas, Rafael, Pineda, Marta, Guino, Elisabet, Vidal, August, Luis Soto, Jose, Caldes, Trinidad, Duran, Mercedes, Urioste, Miguel, Rueda, Daniel, Brunet, Joan, Balbin, Milagros, Blay, Pilar, Iglesias, Silvia, Garre, Pilar, Lastra, Enrique, Beatriz Sanchez-Heras, Ana, Valencia, Alfonso, Moreno, Victor, Angel Pujana, Miguel, Villanueva, Alberto, Blanco, Ignacio, Capella, Gabriel, Surralles, Jordi, Puente, Xose S., Valle, Laura (2015).

Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair

Gastroenterology. Article. 149(3):563-566.
[doi:10.1053/j.gastro.2015.05.056]
Sonnenblick, Amir, Francis, Prudence A., Azim, Jr., Hatem A., de Azambuja, Evandro, Nordenskjold, Bo, Gutierez, Jorge, Quinaux, Emmanuel, Mastropasqua, Mauro G., Ameye, Lieveke, Anderson, Michael, Lluch, Ana, Gnant, Michael, Goldhirsch, Aron, Di Leo, Angelo, Barnadas, Agusti, Cortes-Funes, Hernan, Piccart, Martine, Crown, John (2015).

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

EUROPEAN JOURNAL OF CANCER. Article. 51(12):1481-1489.
[doi:10.1016/j.ejca.2015.03.018]
Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Lee, Dae Ho, Liu, Yunpeng, Yoh, Kiyotaka, Zhou, Jian-Ying, Shi, Xiaojin, Webster, Alan, Jiang, Haiyi, Mok, Tony S. K. (2015).

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

LANCET ONCOLOGY. Article. 16(8):990-998.
[doi:10.1016/S1470-2045(15)00121-7]
Martínez-Díaz RA, Ibáñez-Escribano A, Burillo J, Heras Lde L, Prado GD, Agulló-Ortuño MT, Julio LF, González-Coloma A (2015).

Trypanocidal, trichomonacidal and cytotoxic components of cultivated Artemisia absinthium Linnaeus (Asteraceae) essential oil

MEMORIAS DO INSTITUTO OSWALDO CRUZ. Article. 110(5):693-699.
[doi:10.1590/0074-02760140129]
Ramon y Cajal, Teresa, Chirivella, Isabel, Miranda, Josefa, Teule, Alexandre, Izquierdo, Angel, Balmana, Judith, Beatriz Sanchez-Heras, Ana, Llort, Gemma, Fisas, David, Lope, Virginia, Hernandez-Agudo, Elena, Jose Juan-Fita, Maria, Tena, Isabel, Robles, Luis, Guillen-Ponce, Carmen, Perez-Segura, Pedro, Sol Luque-Molina, Mari, Hernando-Polo, Susana, Salinas, Monica, Brunet, Joan, Dolores Salas-Trejo, Maria, Barnadas, Agusti, Pollan, Marina (2015).

Mammographic density and breast cancer in women from high risk families

BREAST CANCER RESEARCH. Article. 17:93-93.
[doi:10.1186/s13058-015-0604-1]
Dueñas M, Martínez-Fernández M, García-Escudero R, Villacampa F, Marqués M, Saiz-Ladera C, Duarte J, Martínez V, Gómez MJ, Martín ML, Fernández M, Castellano D, Real FX, Rodriguez-Peralto JL, De La Rosa F, Paramio JM (2015).

PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors

MOLECULAR CARCINOGENESIS. Article. 54(7):566-576.
[doi:10.1002/mc.22125]
Gamez-Pozo, Angelo, Berges-Soria, Julia, Arevalillo, Jorge M., Nanni, Paolo, Lopez-Vacas, Rocio, Navarro, Hilario, Grossmann, Jonas, Castaneda, Carlos A., Main, Paloma, Diaz-Almiron, Mariana, Espinosa, Enrique, Ciruelos, Eva, Fresno Vara, Juan Angel (2015).

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

CANCER RESEARCH. Article. 75(11):2243-2253.
[doi:10.1158/0008-5472.CAN-14-1937]
Ghanem, I., Blazquez, M., Higuera, O., Lema, L., Rodriguez, N., Gomez-Martin, C., Mata, A., Lora, D., Custodio, A., Feliu, J. (2015).

Which is the best first approach for liver-only synchronic metastasis rectal cancer?

ANNALS OF ONCOLOGY. Meeting Abstract. 26(4).
[doi:10.1093/annonc/mdv233.324]
Carlos Marin-Gabriel, Jose, Martos-Vizcaino, Esperanza, Diaz-Tasende, Jose, Alonso-Riano, Marina, Perez-Carreras, Mercedes, Rodriguez-Munoz, Sarbelio, del-Pozo-Garcia, Andres J., Colina-Ruizdelgado, Francisco, Castellano-Tortajada, Gregorio (2015).

Endoscopic submucosal dissection (ESD) of antral subepithelial lesion suspected of malignancy

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. Article. 107(6):380-383.
Martin, Miguel, Gonzalez-Rivera, Milagros, Morales, Serafin, de la Haba-Rodriguez, Juan, Gonzalez-Cortijo, Lucia, Manso, Luis, Albanell, Joan, Gonzalez-Martin, Antonio, Gonzalez, Sonia, Arcusa, Angels, de la Cruz-Merino, Luis, Rojo, Federico, Vidal, Maria, Galvan, Patricia, Aguirre, Elena, Morales, Cristina, Ferree, Sean, Pompilio, Kristen, Casas, Maribel, Caballero, Rosalia, Goicoechea, Uxue, Carrasco, Eva, Michalopoulos, Steven, Hornberger, John, Prat, Aleix (2015).

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

CURRENT MEDICAL RESEARCH AND OPINION. Article. 31(6):1129-1137.
[doi:10.1185/03007995.2015.1037730]
Marrupe, D., Rueda, D., Lopez, J., Rodriguez, D., Garcia, S., Diego, C., Alijo, F., Barrio, M. J., Lopez, M. P., Mendez, M., Quiben, R. (2015).

Mutation detection rate among patients with adenomatous polyposis

ANNALS OF ONCOLOGY. Meeting Abstract. 26(4).
[doi:10.1093/annonc/mdv233.222]
Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-Miguel MA, Díaz-García CV, Cortijo-Cascajares S, Cortes-Funes H, Agulló-Ortuño MT (2015).

Risk factors associated with Clostridium difficile infection in adult oncology patients

SUPPORTIVE CARE IN CANCER. Article. 23(6):1569-1577.
[doi:10.1007/s00520-014-2506-7]
Garcia Alfonso, P., Ortiz, M. J., Duran, G., Falco, E., Munoz, A., Garcia-Paredes, B., Salgado, M., Lopez-Ladron, A., Vieitez de Prado, J. M., Valladares, M., Salud, A., Guillen-Ponce, C., Lopez, R., Robles, L., Juarez, A., Serrano, S., Montagut, C., Zanui, M., Gil Raga, M., La Casta, A., Benavides, M., Aranda, E. (2015).

Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab

ANNALS OF ONCOLOGY. Meeting Abstract. 26(4).
[doi:10.1093/annonc/mdv233.269]
Gil-Gil, Miguel J., Bellet, M., Morales, S., Ojeda, B., Manso, L., Mesia, C., Garcia-Martinez, E., Martinez-Janez, N., Mele, M., Llombart, A., Pernas, S., Villagrasa, P., Blasco, C., Baselga, J. (2015).

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study

BREAST CANCER RESEARCH AND TREATMENT. Article. 151(3):597-606.
[doi:10.1007/s10549-015-3415-2]
Ares, Gustavo Ruiz, Ciruelos, Eva, Mansodata, Luis (2015).

The need for post-mastectomy radiotherapy in patients with IBC

Nature Reviews Clinical Oncology. Letter. 12(6).
[doi:10.1038/nrclinonc.2015.13-c1]
Pineda M, González-Acosta M, Thompson BA, Sánchez R, Gómez C, Martínez-López J, Perea J, Caldés T, Rodríguez Y, Landolfi S, Balmaña J, Lázaro C, Robles L, Capellá G, Rueda D (2015).

Detailed characterization of MLH1 p.D41H and p.N710D variants coexisting in a Lynch syndrome family with conserved MLH1 expression tumors

CLINICAL GENETICS. Article. 87(6):543-548.
[doi:10.1111/cge.12467]
Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V (2015).

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 33(14):1564-1564.
[doi:10.1200/JCO.2014.57.1794]
Jerusalem, Guy, Mariani, Gabriella, Ciruelos, Eva M., Martin, Miguel, Tjan-Heijnen, Vivianne C. G., Neven, Patrick, Gregori, Joaquin Gavila, Michelotti, Andrea, Montemurro, Filippo, Lang, Istvan, Mardiak, Josef, Naume, Bjoem, Camozzi, Maura, Lorizzo, Katia, Brenski, Dariusz, Conte, Pierfranco (2015).

Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior nonsteroidal AI (NSAIs): Ballet study (CRAD001YIC04)

CANCER RESEARCH. Meeting Abstract. 75(9).
[doi:10.1158/1538-7445.SABCS14-P5-19-02]
Cortes, Javier, Vrdoljak, Eduard, Puglisi, Fabio, Marschner, Norbert, Gligorov, Joseph, Zielinski, Christoph, Villanueva, Cristian, Romieu, Gilles, Lang, Istvan, Ciruelos, Eva, Veyret, Corinne, Fontana, Andrea, Oestergaard, Mikkel, de Ducla, Sabine, Freudensprung, Ulrich, von Minckwitz, Gunter (2015).

Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)

CANCER RESEARCH. Meeting Abstract. 75(9).
[doi:10.1158/1538-7445.SABCS14-P3-06-08]
Cortes, Javier, Dieras, Veronique, Ro, Jungsil, Barriere, Jerome, Bachelot, Thomas, Hurvitz, Sara, Le Rhun, Emilie, Espie, Marc, Kim, Sung-Bae, Schneeweiss, Andreas, Sohn, Joo Hyuk, Nabholtz, Jean-Marc, Kellokumpu-Lehtinen, Pirkko-Liisa, Taguchi, Julie, Piacentini, Federico, Ciruelos, Eva, Bono, Petri, Ould-Kaci, Mahmoud, Roux, Flavien, Joensuu, Heikki (2015).

Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

CANCER RESEARCH. Meeting Abstract. 75(9).
Gavila, Joaquin, Bermejo, Begona, Rodriguez-Lescure, Alvaro, Lao Romera, Juan, Manso, Luis, Brunet, Joan, Munoz, Eva, Santisteban, Marta, Rodriguez, Cesar A., Santaballa, Ana, de la Haba, Juan, Sanchez-Rovira, Pedro, Ruiz-Borrego, Manuel, Angel Garcia-Saenz, Jose, Cortes, Javier, Llombart, Antonio (2015).

TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T)

CANCER RESEARCH. Meeting Abstract. 75(9).
[doi:10.1158/1538-7445.SABCS14-P5-19-21]
Llombart, Antonio, Cortes, Javier, Ciruelos, Eva, Gonzalez, Xavier, de la Pena, Lorena, Villagrasa, Patricia, Bernedo, Elena, Moreno, Katya, Meya, Susanne, Baselga, Jose (2015).

A phase II, randomized study of T-DM1 versus T-DM1 plus short induction with docetaxel in first line treatment for locally advanced or metastatic HER2+breast cancer (SOLTI-1203)

CANCER RESEARCH. Meeting Abstract. 75(9).
[doi:10.1158/1538-7445.SABCS14-OT3-1-08]
Martin, Miguel, Gonzalez-Rivera, Milagros, Morales, Serafin, de la Haba, Juan, Gonzalez-Cortijo, Lucia, Manso, Luis, Albanell, Joan, Gonzalez-Martin, Antonio, Gonzalez, Sonia, Arcusa, Angels, de la Cruz-Merino, Luis, Rojo, Federico, Vidal, Maria, Goicoechea, Uxue, Galvan, Patricla, Caballero, Rosalia, Carrasco, Eva, Michalopoulos, Steven, Hornberger, John, Prat, Aleix (2015).

Prospective study of the impact of the Prosigna (TM) assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study

CANCER RESEARCH. Meeting Abstract. 75(9).
[doi:10.1158/1538-7445.SABCS14-P6-08-10]
Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R, Spanish Lung Cancer Group (2015).

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

JAMA Oncology. Article. 1(2):149-157.
[doi:10.1001/jamaoncol.2014.257]
Manso, L., Moreno, F., Marquez, R., Castelo, B., Arcediano, A., Arroyo, M., Ballesteros, A. I., Calvo, I., Echarri, M. J., Enrech, S., Gomez, A., Gonzalez del Val, R., Lopez-Miranda, E., Martin-Angulo, M., Martinez-Janez, N., Olier, C., Zamora, P. (2015).

Use of bevacizumab as a first-line treatment for metastatic breast cancer

Current Oncology. Article. 22(2):51-60.
[doi:10.3747/co.22.2210]
Garcia-Gonzalez, Xandra, Cortejoso, Lucia, Garcia, Maria I., Garcia-Alfonso, Pilar, Robles, Luis, Gravalos, Cristina, Gonzalez-Haba, Eva, Marta, Pellicer, Sanjurjo, Maria, Lopez-Fernandez, Luis A. (2015).

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer

Oncotarget. Article. 6(8):6422-6430.
[doi:10.18632/oncotarget.3289]
Cedres, Susana, Ponce-Aix, Santiago, Zugazagoitia, Jon, Sansano, Irene, Enguita, Ana, Navarro-Mendivil, Alejandro, Martinez-Marti, Alex, Martinez, Pablo, Felip, Enriqueta (2015).

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

PLoS One. Article. 10(3).
[doi:10.1371/journal.pone.0121071]
Paz-Ares, Luis, Mezger, Joerg, Ciuleanu, Tudor E., Fischer, Juergen R., von Pawel, Joachim, Provencio, Mariano, Kazarnowicz, Andrzej, Losonczy, Gyoergy, de Castro, Jr., Gilberto, Szczesna, Aleksandra, Crino, Lucio, Reck, Martin, Ramlau, Rodryg, Ulsperger, Ernst, Schumann, Christian, Miziara, Jose Elias A., Lessa, Alvaro E., Dediu, Mircea, Balint, Beatrix, Depenbrock, Henrik, Soldatenkova, Victoria, Kurek, Raffael, Hirsch, Fred R., Thatcher, Nick, Socinski, Mark A., INSPIRE Investigators (2015).

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

LANCET ONCOLOGY. Article. 16(3):328-337.
[doi:10.1016/S1470-2045(15)70046-X]
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J (2015).

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 372(8):724-734.
[doi:10.1056/NEJMoa1413513]
Kamieniak MM, Rico D, Milne RL, Muñoz-Repeto I, Ibáñez K, Grillo MA, Domingo S, Borrego S, Cazorla A, García-Bueno JM, Hernando S, García-Donas J, Hernández-Agudo E, Y Cajal TR, Robles-Díaz L, Márquez-Rodas I, Cusidó M, Sáez R, Lacambra-Calvet C, Osorio A, Urioste M, Cigudosa JC, Paz-Ares L, Palacios J, Benítez J, García MJ (2015).

Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

Molecular Oncology. Article. 9(2):422-436.
[doi:10.1016/j.molonc.2014.09.010]
Díaz-García CV, Agudo-López A, Pérez C, Prieto-García E, Iglesias L, Ponce S, Rodríguez Garzotto A, Rodríguez-Peralto JL, Cortés-Funes H, López-Martín JA, Agulló-Ortuño MT (2015).

Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer

TUMOR BIOLOGY. Article. 36(2):1199-1206.
[doi:10.1007/s13277-014-2729-8]
Salvador, J., Manso, L., de la Haba, J., Jaen, A., Ciruelos, E., de Villena, M. C., Gil, M., Murias, A., Galan, A., Jara, C., Bayo, J., Baena, J. M., Casal, J., Mel, J. R., Blancas, I., Sanchez Rvira, P. (2015).

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Clinical & Translational Oncology. Article. 17(2):160-166.
[doi:10.1007/s12094-014-1210-x]
Francis, Prudence A., Regan, Meredith M., Fleming, Gini F., Lang, Istvan, Ciruelos, Eva, Bellet, Meritxell, Bonnefoi, Herve R., Climent, Miguel A., Da Prada, Gian Antonio, Burstein, Harold J., Martino, Silvana, Davidson, Nancy E., Geyer, Jr., Charles E., Walley, Barbara A., Coleman, Robert, Kerbrat, Pierre, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Rabaglio-Poretti, Manuela, Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Colleoni, Marco, Viale, Giuseppe, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., SOFT Investigators, Int Breast Canc Study Grp (2015).

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 372(5):436-446.
[doi:10.1056/NEJMoa1412379]
Riesco Martinez, Maria Carmen, Pernaut Sanchez, Cristina, Adeva Alfonso, Jorge, Gomez-Martin, Carlos, Lema, Laura, Diaz Luis, Robles, Parrilla Rubio, Lucia, Blazquez Arroyo, Maria, Merida Garcia, Antonio, Lopez-Martin, Jose A. (2015).

Association between inflammatory markers and prognosis in resected pancreatic cancer (PC).

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 33(3, S).
Gomez-Martin, Carlos, Pazo Cid, Roberto A., Salud, Antonieta, Salud, Antonieta, Fonseca, Paula J., Leon, Ana, Galan, MaCarmen, Visa, Laura, Rivera, Fernando, Alsina, Maria, Plaza, Carlos, Angulo, Barbara, Hernandez Prieto, Susana, Dominguez, Carolina, Rodriguez Garcia, Margarita, Del Valle, Elena, Fernandez, Soledad, Rojo, Federico, Cuatrecasas, Miriam, Lopez-Rios, Fernando (2015).

Detection of actionable oncogene drivers alterations in HER2-amplified gastric cancer by next generation sequencing

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 33(3, S).
[doi:10.1200/jco.2015.33.3_suppl.67]
Perea J, Cano JM, Rueda D, García JL, Inglada L, Osorio I, Arriba M, Pérez J, Gaspar M, Fernández-Miguel T, Rodríguez Y, Benítez J, González-Sarmiento R, Urioste M (2015).

Classifying early-onset colorectal cancer according to tumor location: new potential subcategories to explore

American Journal of Cancer Research. Article. 5(7):2308-2308.
Aguilar, Guadalupe, Albiol, Santiago, Alcaide, Julia, Alonso, Martina, Alonso, Vicente, Andreu, Montserrat, Aparicio, Jorge, Arias de la Vega, Fernando, Arrivi, Antonio, Ramon Ayuso, Juan, Bohn, Uriel, Bouzas, Rosa, Maria Cano, Juana, Castanon, Carmen, Castells, Antoni, Cerda, Paula, Cerezo, Laura, Conill, Carles, Cuatrecasas, Miriam, Nieves del Pozo, Ma, Ignacio Delgado, Jose, Enriquez-Navascues, Jose M., Escudero, Pilar, Espin, Eloy, Estevan, I, Rafael, Falco, Esther, Farre, Jose, Feliu, Jaime, Fernandez-Martos, Carlos, Isabel Ferrer, Ana, Gallego, Rosa, Galvez, Elisa, Garcia de Albeniz, Xabier, Garcia Olmo, Damian, Garcia-Carbonero, Rocio, Gomez Dorronsoro, Marisa, Gomez Martin, Carlos, Gonzalez Moreno, Santiago, Hernandez, Ana, Iraola, Amparo, Jimenez, Esther, Cecilio Jimenez, Manuel, Jurado, Ismael, Leno, Ruben, Leon, Ana, Martin, Elena, Martin, Marta, Maurel, Joan, Carlos Mendez, Jose, Mendez, Ramiro, Palma, Pablo, Pardo, Fernando, Pereira, Fernando, Perez-Altozano, Javier, Perez, Elisabet, Rodriguez, Javier, Isabel Ruiz-Casado, Ana, Sabater, Luis, Sarria, Luis, Segura, Angel, Sevilla, Isabel, Tobena, Maria, Torres, Esperanza, Viudez, Antonio, Zanui, Montserrat, Zorrilla, Miriam (2015).

Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Espanol Multidisciplinar en Cancer Digestivo (GEMCAD)

Colorectal Cancer. Review. 4(2):97-112.
[doi:10.2217/CRC.15.9]
Tolaney, Sara, Burris, Howard, Gartner, Elaina, Mayer, Ingrid A., Saura, Cristina, Maurer, Matthew, Ciruelos, Eva, Garcia, Agustin A., Campana, Frank, Wu, Bin, Xu, Yi, Jiang, Jason, Winer, Eric, Krop, Ian (2015).

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer

BREAST CANCER RESEARCH AND TREATMENT. Article. 149(1):151-161.
[doi:10.1007/s10549-014-3248-4]
Olmos VP, Ramos Gallo MJ, Rebollo MA, Ortega DB, Docampo LI, Romera-Villegas A, Díaz EG, Martín AM (2015).

Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM.

MEDICINA CLINICA. Article. 144 Suppl 1:3-15.
[doi:10.1016/S0025-7753(15)30012-9]
Agulló-Ortuño MT, Díaz-García CV, Agudo-López A, Pérez C, Cortijo A, Paz-Ares L, López-Ríos F, Pozo F, de Castro J, Cortés-Funes H, López Martín JA (2015).

Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Article. 141(1):43-53.
[doi:10.1007/s00432-014-1787-z]

2014

Berrocal, Alfonso, Arance, Ana, Lopez Martin, Jose Antonio, Soriano, Virtudes, Munoz, Eva, Alonso, Lorenzo, Espinosa, Enrique, Lopez Criado, Pilar, Valdivia, Javier, Martin Algarra, Salvador, Spanish Melanoma Grp (2014).

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program

MELANOMA RESEARCH. Article. 24(6):577-583.
[doi:10.1097/CMR.0000000000000108]
Ramalingam, Suresh S., Jaenne, Pasi A., Mok, Tony, O'Byrne, Kenneth, Boyer, Michael J., Von Pawel, Joachim, Pluzanski, Adam, Shtivelband, Mikhail, Iglesias Docampo, Lara, Bennouna, Jaafar, Zhang, Hui, Liang, Jane Q., Doherty, Jim P., Taylor, Ian, Mather, Cecile B., Goldberg, Zelanna, O'Connell, Joseph, Paz-Ares, Luis (2014).

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

LANCET ONCOLOGY. Article. 15(12):1369-1378.
[doi:10.1016/S1470-2045(14)70452-8]
Alvarez Hernández C, Vich Pérez P, Brusint B, Cuadrado Rouco C, Díaz García N, Robles Díaz L (2014).

Actualización del cáncer de mama en Atención Primaria (III/V).

Medicina de Familia-SEMERGEN. Abstract of Published Item. 40(8):460-472.
[doi:10.1016/j.semerg.2014.04.006]
García-Escobar I, Parrilla L, Ortega LM, Castellanos D, Pallarés MA, Cortés-Funés H (2014).

Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.

Molecular and Clinical Oncology. Article. 2(6):923-926.
[doi:10.3892/mco.2014.362]
D'Avola, Delia, Lopez-Franco, Esperanza, Harper, Pauline, Fontanellas, Antonio, Grosios, Nadina, Henrichson, Ann, Salmon, Florence, Abecia, Sara, Paneda, Astrid, Paz, Maria, Urdaneta, Matilde, Cornet, Maria Eugenia, Municio, Maria del Mar, Ruiz, Juan, Troconiz, Inaki, Kaeppel, Christine, von Kalle, Christof, Schmidt, Manfred, Petry, Harald, Sangro, Bruno, de Salamanca, Rafael Enriquez, Prieto, Jesus, Gonzalez-Aseguinolaza, Gloria (2014).

Phase 1 clinical trial of liver directed gene therapy with rAAV5/2-PBGD in acute intermittent porphyria: safety data

HUMAN GENE THERAPY. Meeting Abstract. 25(11):36-36.
Romero, I., Lopez-Guerrero, J. A., Del Campo, J. M., Churruca, C., Lainez, N., Redondo, A., Calvo, E., Herrero, A., Bover, I., Santaballa, A., Garcia-Martinez, E., Caballero, C., Sanchez-Heras, B., Ojeda, B., Romeo, M., Mendiola, C., Casado, A., Martinez, J., Girones, R., Poveda, A. (2014).

CLINICAL DIFFERENCES AMONG STAGE IC OVARIAN CARCINOMA: A GEICO PROSPECTIVE EARLY STAGE DATABASE ANALYSIS

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Meeting Abstract. 24(9, 4):341-342.
Rodriguez-Garzotto, A., Agullo-Ortuno, M. T., Ponce, S., Diaz-Garcia, C. V., Agudo-Lopez, A., Perez, C., Prieto-Garcia, E., Cortes-Funes, H., Iglesias, L. (2014).

Search for new blood biomarkers for response to antiangiogenic therapy in non-small cell lung cancer patients

EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 50(6):111-111.
[doi:10.1016/S0959-8049(14)70470-8]
Von Hoff, D. D., Isambert, N., Lopez-Martin, J., Munster, P. N., Rasco, D. W., Bendell, J. C., Schellens, J. H. M., Tomaro, J., Sarmiento, R., Liu, K., Nguyen, A., Bray, G. L., Hatty, S. R., DiMartino, J. F., Le Tourneau, C. (2014).

Phase 1B study of CC-486 (oral azacitidine) in tumors associated with a viral etiology

EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 50(6):179-179.
[doi:10.1016/S0959-8049(14)70677-X]
Zugazagoitia, Jon, Perez-Segura, Pedro, Manzano, Arancha, Blanco, Ignacio, Vega, Ana, Custodio, Ana, Teule, Alex, Fachal, Laura, Martinez, Beatriz, Gonzalez-Sarmiento, Rogelio, Jesus Cruz-Hernandez, Juan, Chirivella, Isabel, Garces, Vicente, Garre, Pilar, Romero, Atocha, Caldes, Trinidad, Diaz-Rubio, Eduardo, de la Hoya, Miguel (2014).

Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

BREAST CANCER RESEARCH AND TREATMENT. Article. 148(2):415-421.
[doi:10.1007/s10549-014-3167-4]
Gamez-Pozo, Angelo, Perez Carrion, Ramon M., Manso, Luis, Crespo, Carmen, Mendiola, Cesar, Lopez-Vacas, Rocio, Berges-Soria, Julia, Alvarez Lopez, Isabel, Margeli, Mireia, Bayo Calero, Juan L., Gonzalez Farre, Xavier, Santaballa, Ana, Ciruelos, Eva M., Afonso, Ruth, Lao, Juan, Catalan, Gustavo, Alvarez Gallego, Jose V., Miramon Lopez, Jose, Salvador Bofill, Francisco J., Ruiz Borrego, Manuel, Espinosa, Enrique, Vara, Juan A. Fresno, Zamora, Pilar (2014).

The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy

PLoS One. Article. 9(10).
[doi:10.1371/journal.pone.0109611]
von Minckwitz, Gunter, Puglisi, Fabio, Cortes, Javier, Vrdoljak, Eduard, Marschner, Norbert, Zielinski, Christoph, Villanueva, Cristian, Romieu, Gilles, Lang, Istvan, Ciruelos, Eva, De laurentiis, Michele, Veyret, Corinne, de Ducla, Sabine, Freudensprung, Ulrich, Srock, Stefanie, Gligorov, Joseph (2014).

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

LANCET ONCOLOGY. Article. 15(11):1269-1278.
[doi:10.1016/S1470-2045(14)70439-5]
Llombart-Cussac, Antonio, Pivot, Xavier, Biganzoli, Laura, Cortes-Funes, Hernan, Pritchard, Kathleen I., Pierga, Jean-Yves, Smith, Ian, Thomssen, Christoph, Srock, Stefanie, Sampayo, Miguel, Cortes, Javier (2014).

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial

BREAST. Article. 23(5):656-662.
[doi:10.1016/j.breast.2014.06.017]
Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S (2014).

The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

Journal of Thoracic Disease. Review. 6(Suppl 5):526-536.
[doi:10.3978/j.issn.2072-1439.2014.01.27]
Sotelo, Miguel J., Angel Garcia-Saenz, Jose, Manso, Luis, Moreno, Fernando, Ciruelos, Eva, Callata, Hector R., Mendiola, Cesar, Cabezas, Santiago, Ghanem, Ismael, Diaz-Rubio, Eduardo (2014).

Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer

Journal of Cancer Research and Therapeutics. Article. 10(4):967-972.
[doi:10.4103/0973-1482.138017]
Garcia Martin, R. M., Ponce Aix, S., Riveiro, E., Enguita Valls, A. B. (2014).

The detection of EML4-ALK fusion oncogen in non-small cell lung cancer by Immunohistochemistry (IHC) assay with two different antibodies

VIRCHOWS ARCHIV. Meeting Abstract. 465(1):375-375.
Ciruelos Gil, Eva Maria (2014).

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer

CANCER TREATMENT REVIEWS. Review. 40(7):862-871.
[doi:10.1016/j.ctrv.2014.03.004]
Cusumano, P. G., Generali, D., Ciruelos, E., Manso, L., Ghanem, I., Lifrange, E., Jerusalem, G., Klaase, J., de Snoo, F., Stork-Sloots, L., Dekker-Vroling, L., Holzik, M. Lutke (2014).

European inter-institutional impact study of MammaPrint

BREAST. Article. 23(4):423-428.
[doi:10.1016/j.breast.2014.02.011]
Pagani, Olivia, Regan, Meredith M., Walley, Barbara A., Fleming, Gini F., Colleoni, Marco, Lang, Istvan, Gomez, Henry L., Tondini, Carlo, Burstein, Harold J., Perez, Edith A., Ciruelos, Eva, Stearns, Vered, Bonnefoi, Herve R., Martino, Silvana, Geyer, Jr., Charles E., Pinotti, Graziella, Puglisi, Fabio, Crivellari, Diana, Ruhstaller, Thomas, Winer, Eric P., Rabaglio-Poretti, Manuela, Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Bernhard, Juerg, Luo, Weixiu, Ribi, Karin, Viale, Giuseppe, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Francis, Prudence A., TEXT SOFT Investigators Int Breast (2014).

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 371(2):107-118.
[doi:10.1056/NEJMoa1404037]
Cortejoso L, García MI, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández LA (2014).

Validación de polimorfismos genéticos asociados a toxicidad al tratamiento quimioterápico en pacientes de cáncer colorrectal.

FARMACIA HOSPITALARIA. Abstract of Published Item. 38(4):283-290.
[doi:10.7399/fh.2014.38.4.1121]
Pagani, Olivia, Regan, Meredith M., Walley, Barbara, Fleming, Gini F., Colleoni, Marco, Lang, Istvan, Gomez, Henry Leonidas, Tondini, Carlo, Burstein, Harold J., Perez, Edith A., Ciruelos, Eva, Stearns, Vered, Bonnefoi, Herve R., Martino, Silvana, Geyer, Charles E., Rabaglio-Poretti, Manuela, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Francis, Prudence A., SOFT, TEXT Investigators, Int Breast Canc Study Grp (2014).

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(18, S).
Ciruelos, Eva, Pascual, Tomas, Arroyo Vozmediano, Maria Luisa, Blanco, Marta, Manso, Luis, Parrilla, Lucia, Munoz, Cesar, Vega, Estela, Jackelin Calderon, Monica, Sancho, Blanca, Cortes-Funes, Hernan (2014).

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer

BREAST. Review. 23(3):201-208.
[doi:10.1016/j.breast.2014.01.016]
García Del Muro X, Gallardo E, García Carbonero I, Laínez N, José Méndez M, Maroto P, Ochoa de Olza M, Puente J, Reynes G, Rubio J, Santander C, Suárez C, Vázquez Estévez S, Castellano D (2014).

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

CANCER CHEMOTHERAPY AND PHARMACOLOGY. Review. 73(6):1095-1107.
[doi:10.1007/s00280-014-2413-0]
Escudier, Bernard, Gruenwald, Viktor, Ravaud, Alain, Ou, Yen-Chuan, Castellano, Daniel, Lin, Chia-Chi, Gschwend, Juergen E., Harzstark, Andrea, Beall, Sarah, Pirotta, Nicoletta, Squires, Matthew, Shi, Michael, Angevin, Eric (2014).

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

CLINICAL CANCER RESEARCH. Article. 20(11):3012-3022.
[doi:10.1158/1078-0432.CCR-13-3006]
Jose, Lopez-Martin, Wee, Ma Wen, Christos, Karapetis, Peter, Balcke, Hagan, Kennecke, Michael, Stahl, Michele, Milella, Francis, Nugent, Diane, Prager, Brian, Lu, Stefano, Ferrara, Darryl, Penenberg, Daniel, Von Hoff (2014).

NAB-PACLITAXEL PLUS GEMCITABINE VS GEMCITABINE ALONE FOR PATIENTS WITH METASTATIC PANCREATIC CANCER: INFLUENCE OF PRIMARY PANCREATIC TUMOR LOCATION ON EFFICACY AND TREATMENT EXPOSURE IN THE MPACT PHASE III TRIAL

ANNALS OF ONCOLOGY. Meeting Abstract. 25(2):28-28.
[doi:10.1093/annonc/mdu165.26]
Abad, A., Massuti, B., Gravalos, C., Escudero, P., Guillen-Ponce, C., Layos, L., Gomez, M. A., Safont, M. J., Gallego, J., Sastre, J., Pericay, C., Duenas, R., Lopez-Lopez, C., Losa, F., Valladares, M., Gonzalez-Flores, E., Yuste, A., Robles, L., Saenz, A., Cano, T., Carrato, A., Aranda, E. (2014).

PANITUMUMAB PLUS FOLFOX4 OR PANITUMUMAB PLUS FOLFIRI IN SUBJECTS WITH WILD-TYPE KRAS (EXON 2) COLORECTAL CANCER AND MULTIPLE OR UNRESECTABLE LIVER-LIMITED METASTASES: DATA FROM THE RANDOMIZED, PHASE II PLANET STUDY

ANNALS OF ONCOLOGY. Meeting Abstract. 25(2):8-8.
[doi:10.1093/annonc/mdu164.6]
Rodriguez Garzotto, Analia Adele, Agullo Ortuno, M. Teresa, Ponce Aix, Santiago, Diaz Garcia, Vanesa, Agudo-Lopez, Alba, Perez, Carlos, Cortes-Funes, Hernan, Iglesias, Lara (2014).

Trends in blood gene expression in non-small cell lung cancer patients treated with bevacizumab

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Pollan, Marina, Chirivella, Isabel, Miranda, Josefa, Teule, Alex, Izquierdo, Angel, Balmana, Judith, Beatriz Sanchez-Heras, Ana, Llort, Gemma, Lope, Virginia, Hernandez, Elena, Juan Fita, Maria Jose, Tena, Isabel, Robles, Luis, Guillen-Ponce, Carmen, Perez-Segura, Pedro, Sol Luque-Molina, Mari, Hernando Polo, Susana, Blanco, Ignacio, Brunet, Joan, Ramon y Cajal, Teresa (2014).

Mammographic density and breast cancer in women from high-risk families.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.1525]
Rodriguez Garzotto, Analia Adela, Merida Garcia, Antonio, Munoz Unceta, Nerea, Galera Lopez, Maria del Mar, Angeles Orellana, Maria, Cortijo Cascajares, Susana, Iglesias, Lara, Cortes-Funes, Hernan, Agullo Ortuno, M. Teresa (2014).

Clostridium difficile infection in hospitalized cancer patients

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Ponce Aix, Santiago, Blazquez, Maria, Iglesias, Lara, Nunez, Juan A., Zugazagoltla, Jon, Munoz, Cesar, Parrilla, Lucia, Pernaut, Cristina, Otero, Irene, Andres, Eva, Cortes-Funes, Hernan (2014).

Pemetrexed (Pem) in combination with cisplatin (CP) or rarboplatin (CB) for stage IV NSCLC: A single -institution experience.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Ponce Aix, Santiago, Zugazagoitia, Jon, Gonzalez Marquez, Pilar Isabel, Torres Nieto, Maria Angeles, Magasent Blesa, Joan, Mielgo, Xabler, Gonzalez Paz, Carmen, Quiben, Rosa, Garcia Llano, Juan Luis, Perez Agua, Carmen, Resano, Pilar, Calzas, Julia, Garcia, Lourdes, Diaz Munoz, Victor M., Iglesias, Lara, Nunez, Juan A., Garcia Martin, Rosa M., Cortes-Funes, Hernan, Rodriguez Peralto, Jose Luis, Enguita Valls, Ana Belen (2014).

Systematic determination of EGFR mutation (m) and immunohistocliemistry (IHC) of ALK trauslocalion (t) status in patients (p) with newly non-small cell lung cancer (NSCLC)

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Corral Jaime, Jesus, Paz-Ares, Luis, Provencio, Mariano, Bennouna, Jaafar, Ponce-Aix, Santiago, Plummer, Ruth, Delord, Jean-Pierre, Isambert, Nicolas, Manuel Trigo, Jose, Belli, Riccardo, Brienza, Silvano, Zanna, Claudio, Purcea, Daniela, Calvo, Virginia, Alonso, Miriam, Senellart, Helene, Hiret, Sandrine, Marti, Alex Martinez, Felip, Enriqueta (2014).

The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Piulats Rodriguez, Jose Maria, Ochoa de Olza, Maria, Codes, Manuel, Lopez-Martin, Jose A., Berrocal, Alfonso, Garcia, Margarita, Gurpide, Alfonso, Homet, Blanca, Martin-Algarra, Salvador (2014).

Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Dorta, Miriam, Manuel Sepulveda, Juan, Hernandez-Lain, Aurelio, Velasco, Guillermo, Manneh, Ray, Ruano, Yolanda (2014).

The frequency and impact of ROS1 rearrangement on clinical outcomes in CAM

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.2093]
Celiz, Pamela, Pinto, Alvaro, Puente, Javier, Manneh, Ray, Gonzalez Larriba, Jose Luis, Grande, Enrique, Alonso, Teresa, Manuel Sepulveda, Juan, Rodriguez, Alfredo, Castellano, Daniel E. (2014).

Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.e16074]
Arroyo Maria, Biazquez, Loma, Laura, Diaz Luis, Robles, Lopez-Martin, Jose A., Gomez-Martin, Carlos, Adeva Alfonso, Jorge, Gravalos Castro, Cristina, Riesco Martinez, Maria Carmen, Diaz Serrano, Asuncion, Munoz, Cesar, Parrilla, Lucia, Irene, Otero, Gustavo, Ruiz, Belen Enguita, Ana, Gamez, Antonio, Cortes-Funes, Heman (2014).

Surgical therapy of lung metastases from colorectal carcinoma: A single institution retrospective study

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.e14572]
Bachelot, Thomas Denis, Ciruelos, Eva, Peretz-Yablonski, Tamar, Puglisi, Fabio, Schneeweiss, Andreas, Campone, Mario, Coudert, Bruno P., Kaufman, Bella, Wardley, Andrew M., Bastiere-Truchot, Lydie, Freudensprung, Ulrich, Restuccia, Eleonora, Miles, David (2014).

First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.548]
Bellet, Meritxell, Gray, Kathryn P., Francis, Prudence A., Lang, Istvan, Ciruelos, Eva, Lluch, Ana, Climent, Miguel Angel, Catalan, Gustavo, Costa, Roser Ferrer, Catalan, Roberto, Rajasekaran, Agnita, Morales, Josefa, Vazquez, Josep, Fleming, Gini F., Price, Karen N., Regan, Meredith M., SOFT-EST Investigators, SOLTI (2014).

Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR plus ) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.585]
Perez-Segura, Pedro, Manneh Kopp, Ray, Ceballos, Isaac, Garcia, Almudena, Benavides, Manuel, Fuster, Jose, Angeles Vaz, M., Maria Cano, Juana, Pablo Berros, Jose, Covela, Marta, Moreno, Victor, Quintanar Verduguez, Maria Teresa, Maria Garcia-Bueno, Jose, Fernandez, Isaura, Gallego Rubio, Oscar, Ramirez, Patricia, Espinos, Jaime, Gonzalez, Sonia, del Barco, Sonia, Ros, Silverio (2014).

GEINOFOTE: Safety and activity analysis of the use of fotemustine (FT) in different schedules in progressive high-grade glioina (HGG) in Spain.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.2055]
Garcia del Muro, Xavier, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Martin Broto, Javier, Cubedo, Ricardo, Lavernia, Javier, Redondo, Andres, Lopez-Martin, Jose A., Mulet-Margalef, Nuria, Sanjuan, Xavier, Tirado, Oscar M. (2014).

Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Iglesias, Lara, Castelo, Beatriz, Alvarez, Ruth, Garcia Adrian, Silvia, Nunez, Juan A., Ghanem, Ismael, San Juan del Moral, Alberto, Diaz Serrano, Asuncion, Redondo, Andres, Cortes-Funes, Hernan (2014).

Head and neck cancer in the elderly: Survival and toxicity with biochemoradiation therapy.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.e17054]
Martin Broto, Javier, Martinez-Serra, Jorge, Ramos, Rafael, Antonio Lopez-Guerrero, Jose, Bague, Silvia, Martinez, Carmen, Alvarez, Ramiro, Garcia del Muro, Xavier, De Las Penas, Ramon, Gutierrez, Antonio, Martinez-Trufero, Javier, Cruz, Josefina, Poveda, Andres, Maria Alvarez, Rosa, Cubedo, Ricardo, Redondo, Andrs, Maurel, Juan Oppor, Angeles Sala, Maria, Lopez-Martin, Jose A., Lopez-Pousa, Antonio (2014).

Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin-A GEIS study.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Oskay-Ozcelik, Gulten, Keller, Maren, Lorusso, Domenica, Pignata, Sandro, Joly, Florence, Berton-Rigaud, Dominique, Maciejewski, Michal, Jedryka, Marcin, Vergote, Ignace, Lambrechts, Sandrina, Casado, Antonio, Mendiola, Cesar, Achimas, Patrick, Reimer, Daniel Uwe, Zeimet, Alain G., Hindenburg, Hans-Joachim, Richter, Rolf, Sehouli, Jalid (2014).

Expression III: Final results of an international survey in eight European countries with 1,830 patients-What are the differences in expectations from their doctors and therapy management of patients with primary and recurrent ovarian cancer? (NOGGO/ENGOT-ov4 study).

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.5579]
Pagani, Olivia, Regan, Meredith M., Walley, Barbara, Fleming, Gini F., Colleoni, Marco, Lang, Istvan, Gomez, Henry Leonidas, Tondini, Carlo, Burstein, Harold J., Perez, Edith A., Ciruelos, Eva, Stearns, Vered, Bonnefoi, Nerve R., Martino, Silvana, Geyer, Charles E., Rabaglio-Poretti, Manuela, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Francis, Prudence A., SOFT Text Investigators, Int Breast Canc Study Grp (2014).

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
Grande, Enrique, Guillen-Ponce, Carmen, Vieitez de Prado, Jose Maria, Reboredo, Margarita, Duran, Gema, Massuti Sureda, Bartolomeu, Layos, Laura, Salud, Antonia, Faico, Esther, Alonso, Vicente, Garcia Alfonso, Pilar, Jose Ortiz, Maria, Sastre, Javier, Rivera, Fernando, Gallego, Javier, Robles, Luis, Gonzalez Astorga, Beatriz, Dotor, Emma, Carreto, Alfredo, Aranda, Enrique (2014).

Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(15, S).
[doi:10.1200/jco.2014.32.15_suppl.tps3651]
Ciruelos E, Jackisch C (2014).

Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer

Expert Review of Anticancer Therapy. Review. 14(5):511-521.
[doi:10.1586/14737140.2014.883922]
Gianni, Luca, Eiermann, Wolfgang, Semiglazov, Vladimir, Lluch, Ana, Tjulandin, Sergei, Zambetti, Milvia, Moliterni, Angela, Vazquez, Federico, Byakhov, Mikhail J., Lichinitser, Mikhail, Climent, Miguel Angel, Ciruelos, Eva, Ojeda, Belen, Mansutti, Mauro, Bozhok, Alla, Magazzu, Domenico, Heinzmann, Dominik, Steinseifer, Jutta, Valagussa, Pinuccia, Baselga, Jose (2014).

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

LANCET ONCOLOGY. Article. 15(6):640-647.
[doi:10.1016/S1470-2045(14)70080-4]
D'Avola, Delia, Lopez-Franco, Esperanza, Harper, Pauline, Fontanellas, Antonio, Grosios, Nadina, Sangro, Bruno, Henrichson, Ann, Salmon, Florence, Abecia, Sara, Paneda, Astrid, Paz, Maria, Eugenia Cornet, Maria, Del Municio, Maria, Troconiz, Inaki, Kaeppel, Christine, Ruiz, Juan, von Kalle, Christof, Schmidt, Manfred, Petry, Harald, Enriquez de Salamanca, Rafael, Prieto, Jesus, Gonzalez-Aseguinolaza, Gloria (2014).

Phase 1 Clinical Trial of Liver Directed Gene Therapy With rAAV5-PBGD in Acute Intermittent Porphyria: Preliminary Safety Data

MOLECULAR THERAPY. Meeting Abstract. 22(1):7-7.
Angevin, Eric, Tabernero, Josep, Elez, Elena, Cohen, Steven J., Bahleda, Rastilav, van Laethem, Jean-Luc, Ottensmeier, Christian, Lopez-Martin, Jose A., Clive, Sally, Joly, Florence, Ray-Coquard, Isabelle, Dirix, Luc, Machiels, Jean-Pascal, Steven, Neil, Reddy, Manjula, Hall, Brett, Puchalski, Thomas A., Bandekar, Rajesh, de Velde, Helgi van, Tromp, Brenda, Vermeulen, Jessica, Kurzrock, Razelle (2014).

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

CLINICAL CANCER RESEARCH. Article. 20(8):2192-2204.
[doi:10.1158/1078-0432.CCR-13-2200]
Perez, Carlos, Vanesa Diaz-Garcia, C., Agudo-Lopez, Alba, del Solar, Virginia, Cabrera, Silvia, Teresa Agullo-Ortuno, M., Navarro-Ranninger, Carmen, Aleman, Jose, Lopez-Martin, Jose A. (2014).

Evaluation of novel trans-sulfonamide platinum complexes against tumor cell lines

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. Article. 76:360-368.
[doi:10.1016/j.ejmech.2014.02.022]
Martin-Algarra, S., Fernandez-Figueras, M. T., Lopez-Martin, J. A., Santos-Briz, A., Arance, A., Lozano, M. D., Berrocal, A., Rios-Martin, J. J., Espinosa, E., Rodriguez-Peralto, J. L. (2014).

Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & Translational Oncology. Article. 16(4):362-373.
[doi:10.1007/s12094-013-1090-5]
Ponce Aix, S., Zugazagoitia, J., Blazquez Arroyo, M., Ruiz Ares, G., Nunez Sobrino, J. A., Iglesias Docampo, L. C., Manneh Kopp, R. A., Garcia Martin, R. M., Rodriguez Peralto, J. L., Enguita Valls, A. B. (2014).

SYSTEMATIC DETERMINATION OF EGFR MUTATION (M) AND IMMUNOHISTOCHEMISTRY (IHC) OF ALK TRANSLOCATION (T) STATUS IN PATIENTS (P) WITH NEWLY NON SMALL CELL LUNG CANCER (NSCLC)

Journal of Thoracic Oncology. Meeting Abstract. 9(4, 1):9-9.
Cedres, S., Ponce, S., Zugazagoitia, J., Navarro, A., Martinez, A., Martinez, P., Salva, F., Munoz, C., Ruiz Ares, G., Felip, E. (2014).

POSITRON EMISSION TOMOGRAPHY (PET) AS A PROGNOSTIC FACTOR IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Journal of Thoracic Oncology. Meeting Abstract. 9(4, 1):51-51.
Bracarda, Sergio, Castellano, Daniel, Procopio, Giuseppe, Sepulveda, Juan M., Sisani, Michele, Verzoni, Elena, Schmidinger, Manuela (2014).

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies

Expert Opinion On Drug Safety. Review. 13(4):497-510.
[doi:10.1517/14740338.2014.888413]
Rodriguez Garzotto, A., Cortijo, S., Pernaut, C., Otero, I., Ruiz Ares, G., Parrilla, L., Blazquez Arroyo, M., Zugazagoitia, J., Ponce Aix, S. (2014).

DIFFERENT EFFICACY BETWEEN TWO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) FOR CHEMOTHERAPY-INDUCED ANAEMIA (CIA) TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC): A SINGLE CENTER EXPERIENCE

Journal of Thoracic Oncology. Meeting Abstract. 9(4, 1):48-48.
Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J (2014).

Phase II clinical trial of PM00104 (Zalypsis (R)) in urothelial carcinoma patients progressing after first-line platinum-based regimen

CANCER CHEMOTHERAPY AND PHARMACOLOGY. Article. 73(4):857-867.
[doi:10.1007/s00280-014-2419-7]
Molina-Pinelo, Sonia, Gutierrez, Gabriel, Dolores Pastor, Maria, Hergueta, Marta, Moreno-Bueno, Gema, Garcia-Carbonero, Rocio, Nogal, Ana, Suarez, Rocio, Salinas, Ana, Pozo-Rodriguez, Francisco, Lopez-Rios, Fernando, Teresa Agullo-Ortuno, Maria, Ferrer, Irene, Perpina, Asuncion, Palacios, Jose, Carnero, Amancio, Paz-Ares, Luis (2014).

MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer

PLoS One. Article. 9(3).
[doi:10.1371/journal.pone.0090524]
Vermorken, J. B., Peyrade, F., Krauss, J., Mesia, R., Remenar, E., Gauler, T. C., Keilholz, U., Delord, J. P., Schafhausen, P., Erfan, J., Bruemmendorf, T. H., Iglesias, L., Bethe, U., Hicking, C., Clement, P. M. (2014).

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

ANNALS OF ONCOLOGY. Article. 25(3):682-688.
[doi:10.1093/annonc/mdu003]
Andres, R., Pajares, I., Balmana, J., Llort, G., Ramon y Cajal, T., Chirivella, I., Aguirre, E., Robles, L., Lastra, E., Perez-Segura, P., Bosch, N., Yaguee, C., Lerma, E., Godino, J., Miramar, M. D., Moros, M., Astier, P., Saez, B., Vidal, M. J., Arcusa, A., Ramon y Cajal, S., Calvo, M. T., Tres, A. (2014).

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)

Clinical & Translational Oncology. Article. 16(3):280-284.
[doi:10.1007/s12094-013-1070-9]
Wiechno, Pawel, Somer, Bradley G., Mellado, Begona, Chlosta, Piotr L., Cervera Grau, Jose Manuel, Castellano, Daniel, Reuter, Christoph, Stockle, Michael, Kamradt, Jorn, Pikiel, Joanna, Duran, Ignacio, Wedel, Steffen, Callies, Sophie, Andre, Valerie, Hurt, Karla, Brown, Jacqueline, Lahn, Michael, Heinrich, Bernhard (2014).

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

EUROPEAN UROLOGY. Article. 65(3):516-520.
[doi:10.1016/j.eururo.2013.10.039]
Faivre S, Castellano D, Strosberg J, González E, Salazar R (2014).

Pancreatic NETs: where do we stand now?

CANCER AND METASTASIS REVIEWS. Review. 33(1):361-366.
[doi:10.1007/s10555-013-9466-0]
Albanell, Joan, Ciruelos, Eva M., Lluch, Ana, Munoz, Montserrat, Rodriguez, Cesar A. (2014).

Trastuzumab in small tumours and in elderly women

CANCER TREATMENT REVIEWS. Review. 40(1):41-47.
[doi:10.1016/j.ctrv.2013.04.002]
Climent Duran, Miguel Angel, Perez-Valderrama, Begona, Fernandez Parra, Eva, Mellado, Begona, Domenech, Montserrat, Fernandez Calvo, Ovidio, Anido, Urbano, Hernando Polo, Susana, Angel Arranz, Jose, Caballero, Cristina, Ochoa de Olza, Maria, Castellano, Daniel E. (2014).

Phase II study of weekly cabazitaxel for ``unfit'' metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis (SOGUG-CABASEM trial)

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(4, S).
Gonzalez Maeso, Iria, Castellano, Daniel E., Campos Balea, Begona, Esteban, Emilio, Perez Arnillas, Quionia, Villalobos Leon, M. Laura, Munarriz, Javier, Rubio, Gustavo, Cumplido Buron, Jose David, Garcia Sanchez, Jose, Martin, Almudena, Maria Garcia-Bueno, Jose, Reyes Garcia, Ana, Perez-Valderrama, Begona, Anido Herranz, Urbano, Bellmunt, Joaquim (2014).

Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(4, S).
Gonzalez-Grajera, Belen, Puente, Javier, Garcia Carbonero, Iciar, Mohedano, Nicolas, Lopez Criado, M. Pilar, Arranz Arija, Jose Angel, Gonzalez del Alba, Aranzazu, Fernandez Calvo, Ovidio, Villalobos, Maria L., Chirivella, Isabel, Grande, Enrique, Castellano, Daniel E. (2014).

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure to one cisplatin-based systemic therapy in clinical practice.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(4, S).
[doi:10.1200/jco.2014.32.4_suppl.332]
Hernando Polo, Susana, Gonzalez del Alba, Aranzazu, Perez-Valderrama, Begona, Villa Guzman, Jose Carlos, Angel Climent, Miguel, Lainez, Nuria, Font, Albert, Duran, Ignacio, Mellado, Begona, Castellano, Daniel, Garcia-Donas, Jesus, Antonio Virizuela, Juan, Leon, Luis, del Mar LLorente, Maria, Domenech, Montserrat, Morales, Rafael, Gallardo, Enrique, Puente, Javier, Macia, Sonia, Bellmunt, Joaquim (2014).

Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)-Interim analysis on safety.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(4, S).
[doi:10.1200/jco.2014.32.4_suppl.359]
Rodriguez-Moreno, Jf., Esteban, Emilio, Javier Leandro-Garcia, Luis, Castellano, Daniel E., Gonzalez del Alba, Aranzazu, Angel Climent, Miguel, Angel Arranz, Jose, Gallardo, Enrique, Puente, Javier, Bellmunt, Joaquim, Mellado, Begona, Martinez, Esther, Moreno, Fernando, Font, Albert, Robledo, Mercedes, Hernando Polo, Susana, Garcia-Donas, Jesus, Rodriguez-Antona, Cristina (2014).

Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(4, S).
[doi:10.1200/jco.2014.32.4_suppl.537]
Prior, Celia, Luis Perez-Gracia, Jose, Garcia-Donas, Jesus, Rodriguez-Antona, Cristina, Guruceaga, Elizabeth, Esteban, Emilio, Suarez, Cristina, Castellano, Daniel, Gonzalez del Alba, Aranzazu, Dolores Lozano, Maria, Carles, Joan, Angel Climent, Miguel, Angel Arranz, Jose, Gallardo, Enrique, Puente, Javier, Bellmunt, Joaquim, Gurpide, Alfonso, Maria Lopez-Picazo, Jose, Gonzalez Hernandez, Alvaro, Mellado, Begona, Martinez, Esther, Moreno, Fernando, Font, Albert, Calvo, Alfonso (2014).

Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

PLoS One. Article. 9(1).
[doi:10.1371/journal.pone.0086263]
Casanovas, Oriol, Capdevila, Jaume, Barriuso, Jorge, Teule, Alex, Castellano, Daniel E., Luis Manzano, Jose, Lopez, Carlos, Alonso, Vicente, Garcia Carbonero, Rocio, Dotor, Emma, Martinez, Alba, Salazar, Ramon (2014).

Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 32(3, S).
[doi:10.1200/jco.2014.32.3_suppl.484]
Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I (2014).

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 32(2):76-76.
[doi:10.1200/JCO.2012.48.5268]
Rodriguez Garzotto A, Heine O, Turner M, Rebollo Laserna F, Lorenz A (2014).

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.

Journal of Blood Medicine. Article. 5:43-48.
[doi:10.2147/JBM.S57887]
Oh, William K., McDermott, David, Porta, Camillo, Levy, Antonin, Elaidi, Reza, Scotte, Florian, Hawkins, Robert, Castellano, Daniel, Bellmunt, Joaquim, Rha, Sun Young, Sun, Jong-Mu, Nathan, Paul, Feinberg, Bruce A., Scott, Jeffrey, McDermott, Ray, Ahn, Jin-Hee, Wagstaff, John, Chang, Yen-Hwa, Ou, Yen-Chuan, Donnellan, Paul, Huang, Chao-Yuan, McCaffrey, John, Chiang, Po-Hui, Chuang, Cheng-Keng, Korves, Caroline, Neary, Maureen P., Diaz, Jose R., Mehmud, Faisal, Duh, Mei Sheng (2014).

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

INTERNATIONAL JOURNAL OF ONCOLOGY. Article. 44(1):5-16.
[doi:10.3892/ijo.2013.2181]

2013

Del Barco, S., Ciruelos, E., Tusquets, I., Ruiz, M., Barnadas, A. (2013).

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

Clinical & Translational Oncology. Article. 15(12):1011-1017.
[doi:10.1007/s12094-013-1084-3]
Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ (2013).

Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial

EUROPEAN UROLOGY. Article. 64(6):994-1002.
[doi:10.1016/j.eururo.2012.11.032]
De Dosso, Sara, Grande, Enrique, Barriuso, Jorge, Castellano, Daniel, Tabernero, Josep, Capdevila, Jaume (2013).

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation

CANCER AND METASTASIS REVIEWS. Review. 32(3-4, SI):465-477.
[doi:10.1007/s10555-013-9421-0]
Castellano, Daniel, Capdevila, Jaume, Sastre, Javier, Alonso, Vicente, Llanos, Marta, Garcia-Carbonero, Rocio, Manzano Mozo, Jose Luis, Sevilla, Isabel, Duran, Ignacio, Salazar, Ramon (2013).

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

EUROPEAN JOURNAL OF CANCER. Article. 49(18):3780-3787.
[doi:10.1016/j.ejca.2013.06.042]
Meneses JC, Avila Martínez RJ, Ponce S, Zuluaga M, Bartolomé A, Ga´mez P (2013).

Treatment of non-small cell lung carcinoma in early stages

CIRUGIA ESPANOLA. Review. 91(10):625-632.
[doi:10.1016/j.ciresp.2013.01.007]
Massuti, Bartomeu, Cobo, Manuel, Rodriguez-Paniagua, Manuel, Ballesteros, Isabel, Moran, Teresa, Arrabal, Ricardo, Gonzalez Larriba, Jose Luis, Barneto, Isidoro, Pun, Yat Wah, Castro Carpeno, Javier D., Iglesias, Lara, Baamonde, Carlos, Angel Munoz, Miguel, Lopez-Vivanco, Guillermo, Rivas De Andres, Jj, Isla, Dolores, Lopez, Rafael, De Las Penas, Ramon, Rodriguez, Delvis, Lopez De Castro, Pedro, Artal, Angel, Esteban Gonzalez, Emilio, Hernando Trancho, Florentino, Provencio, Mariano, Valdivia, J., Diaz Agero, Prudencio, Martin De Nicolas, Jose Luis, Pereira, Eva, Miguel Sanchez, Jose, Rosell, Rafael (2013).

FIRST ANALYSIS OF TOXICITY AND TREAMENT COMPLIANCE IN CUSTOMIZED POSTOPERATIVE CHEMOTHERAPY BASED ON BRCA1 LEVELS AFTER NSCLC RESECTION: SCAT (SPANISH CUSTOMIZED ADJUVANT THERAPY) TRIAL. SPANISH LUNG CANCER GROUP/GECP

Journal of Thoracic Oncology. Meeting Abstract. 8(2):300-301.
Ponce Aix, Santiago, Iglesias, Lara, Antonio Nunez, Juan, Zugazagoitia, Jon, Blazquez, Maria, Cesar, Munoz, Parrilla, Lucia, Pernaut, Cristina, Otero, Irene, Cortes-Funes, Hernan (2013).

DOUBLET COMBINATION OF PLATINUM WITH PEMETREXED FOR ADVANCED NON-SMALL-CELL LUNG CANCER: A RETROSPECTIVE ANALYSIS OF A SINGLE INSTITUTION

Journal of Thoracic Oncology. Meeting Abstract. 8(2):583-584.
Rodriguez Garzotto, Analia, Cortijo, Susana, Ponce Aix, Santiago, Pernaut, Cristina, Otero, Irene, Ruiz Ares, Gustavo, Parrilla, Lucia, Blazquez, Maria, Rebollo, Franscico, Cortes-Funes, Hernan (2013).

USE AND COMPARISON OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED ANAEMIA (CIA) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)

Journal of Thoracic Oncology. Meeting Abstract. 8(2):1021-1022.
Isla, Dolores, De Las Penas, Ramon, Martinez-Banaclocha, Natividad, Massuti, Bartomeu, Angeles Sala, Maria, Bover, Isabel, Marse, Raquel, Insa, Amelia, Moran, Teresa, Artal, Angel, Diz, Pilar, Gomez-Codina, Jose, Laura Ortega, Ana, Gutierrez, Vanesa, Munoz, Jose, Alvarez De Mon, Melchor, Camps, Carlos, Garcia-Gomez, Ramon, Jurado, Jose M., Ponce-Aix, Santiago, Provencio, Mariano (2013).

INTERIM ANALYSIS OF THE SPANISH LUNG CANCER GROUP (SLCG) RANDOMIZED PHASE II TRIAL OF THORACIC RADIOTHERAPY (RT) CONCURRENT WITH CISPLATIN (P) PLUS ORAL VINORELBINE (OV) OR ETOPOSIDE (E) FOR UNRESECTABLE LOCALLY ADVANCED (LA) STAGE III NON-SMALL CELL LUNG CANCER (NSCLC). (GECP10/02)

Journal of Thoracic Oncology. Meeting Abstract. 8(2):408-408.
Massuti, Bartomeu, Lopez-Vivanco, Guillermo, Marti, Thomas M., Kotov, Ilya, Chaib, Imane, Ponce-Aix, Santiago, Garcia-Campelo, Rosario, Miguel Sanchez, Jose, Artal, Angel, Bover, Isabel, Taron, Miquel, Sanchez-Ronco, Maria, Rolfo, Christian, Stahel, Rolf, Rosell, Rafael (2013).

OUTCOME IN PEMETREXED/CISPLATIN-TREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS ACCORDING TO MRNA EXPRESSION LEVELS OF BRCA1, TS, AEG1 AND REV3

Journal of Thoracic Oncology. Meeting Abstract. 8(2):1040-1041.
Sanchez-Torres, Jose-Miguel, Rodriguez, Delvis, Oramas, Juana, Lopez Criado, Pilar, Antonio Macias, Jose, Bosch, Joaquim, Martinez-Banaclocha, Natividad, Diz, Pilar, Iglesias, Lara, Rolfo, Christian, Esquerdo, Gaspar, Juan, Oscar, Garde, Javier, Esteller, M., Rosell, Rafael (2013).

THE PHALCIS TRIAL (PHARMACOGENOMIC ALIMTA CISPLATIN): A CLINICAL TRIAL IN PROGRESS BY THE SPANISH LUNG CANCER GROUP

Journal of Thoracic Oncology. Meeting Abstract. 8(2):504-504.
Martin-Richard, Marta, Massuti, Bartomeu, Pineda, Eva, Alonso, Vicente, Marmol, Maribel, Castellano, Daniel, Fonseca, Emilio, Galan, Antonio, Llanos, Marta, Angeles Sala, Maria, Pericay, Carlos, Rivera, Fernando, Sastre, Javier, Segura, Angel, Quindos, Maria, Maisonobe, Pascal, TTD Tumores Tracto Digestivo Study (2013).

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

BMC CANCER. Article. 13(427):427-427.
[doi:10.1186/1471-2407-13-427]
Ciruelos E, Cortes-Funes H, Ghanem I, Manso L, Arteaga C (2013).

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer

ANTI-CANCER DRUGS. Review. 24(8):769-780.
[doi:10.1097/CAD.0b013e328363adc5]
Garcia-Donas, J., Leandro-Garcia, L. J., del Alba, A. Gonzlez, Morente, M., Alemany, I., Esteban, E., Arranz, J. A., Climent, M. A., Gallardo, E., Castellano, D. E., Bellmunt, J., Mellado, B., Puente, J., Moreno, F., Font, A., Hernando, S., Robledo, M., Rodriguez-Antona, C. (2013).

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma

ANNALS OF ONCOLOGY. Article. 24(9):2409-2414.
[doi:10.1093/annonc/mdt219]
Carrato, A., Gomez, A., Escudero, P., Chaves, M., Rivera, F., Marcuello, E., Gonzalez, E., Gravalos, C., Constenla, M., Luis Manzano, J., Losa, F., Maurel, J., Duenas, R., Massuti, B., Gallego, J., Aparicio, J., Anton, A., Aranda, E. (2013).

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

Clinical & Translational Oncology. Article. 15(9):705-711.
[doi:10.1007/s12094-012-0993-x]
Martín M, Ruiz A, Borrego MR, Barnadas A, González S, Calvo L, Vila MM, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Ribugent JD, López-Vega JM, Jara C, Espinosa E, Fernández CM, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Bofill JS, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Alvarez I, Carrasco E, Lluch A (2013).

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

JOURNAL OF CLINICAL ONCOLOGY. Article. 31(20):2593-2593.
[doi:10.1200/JCO.2012.46.9841]
Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A (2013).

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 31(20):2586-2586.
[doi:10.1200/JCO.2012.46.2408]
Gonzalez Martin, A., Redondo, A., Jurado, M., De Juan, A., Romero, I., Bover, I., Del Campo, J. M., Cervantes, A., Garcia, Y., Lopez-Guerrero, J. A., Mendiola, C., Palacios, J., Rubio, M. J., Poveda Velasco, A. (2013).

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

Clinical & Translational Oncology. Article. 15(7):509-525.
[doi:10.1007/s12094-012-0995-8]
Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernández Pastor LJ, Bellmunt J (2013).

Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain

Expert Opinion On Drug Safety. Review. 12(4):455-463.
[doi:10.1517/14740338.2013.781581]
Salazar, R., Cortes-Funes, H., Casado, E., Pardo, B., Lopez-Martin, A., Cuadra, C., Tabernero, J., Coronado, C., Garcia, M., Soto Matos-Pita, A., Miguel-Lillo, B., Cullell-Young, M., Iglesias Dios, J. L., Paz-Ares, L. (2013).

Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

CANCER CHEMOTHERAPY AND PHARMACOLOGY. Article. 72(1):75-83.
[doi:10.1007/s00280-013-2170-5]
Castellano D, Virizuela JA, Cruz J, Sepulveda JM, Sáez MI, Paz-Ares L (2013).

The role of pharmacogenomics in metastatic renal cell carcinoma (vol 31, pg S29, 2012)

CANCER AND METASTASIS REVIEWS. Correction. 32(1-2, SI):317-317.
[doi:10.1007/s10555-012-9416-2]
Alba, Emilio, Ciruelos, Eva, Lopez, Rafael, Manuel Lopez-Vega, Jose, Lluch, Ana, Martin, Miguel, Munoz, Montserrat, Sanchez-Rovira, Pedro, Angel Segui, Miguel, Rubio Liria, Marta, Perez-Alcantara, Ferran (2013).

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

Expert Review of Pharmacoeconomics & Outcomes Research. Article. 13(3):381-381.
[doi:10.1586/ERP.13.18]
Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, Vega E, Manneh R, Dorta M, Cortés-Funes H (2013).

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients

Clinical & Translational Oncology. Article. 15(6):467-471.
[doi:10.1007/s12094-012-0954-4]
Rodriguez-Garzotto, Analia, Ruppen, Isabel, Pilar Ximenez de Embun, M., Iglesias, Lara, Gravalos, Cristina, Agudo-Lopez, Alba, Perez, Carlos, Diaz Garcia, Vanesa, Lopez-Martin, Jose A., Ciruelos, Eva, Manso, Luis, Mendiola, Cesar, Agullo Ortuno, M. Teresa, Cortes-Funes, Hernan (2013).

Differential protein expression profile in skin biopsies from patients with hand-foot syndrome who have benefited from topical heparin treatment.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Constenla, Manuel, Aparicio, Jorge, Auxiliadora Gomez, M., Gravalos Castro, Cristina, Lopez-Gomez, Miriam, Luis Manzano, Jose, Dolores Pineda, Maria, Maria Cano, Juana, Sevilla, Isabel, Maria Vieitez de Prado, Jose, Viudez, Antonio, Lopez-Gomez, Luis, Carlos Camara, Juan, Lopez-Vivanco, Guillermo, Aranda, Fuensanta, Isabel Palomo-Jimenez, Paloma, Barbon, Ana, Feliu Batlle, Jaime (2013).

Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Zambetti, Milvia, Baselga, Jose, Eiermann, Wolfgang, Guillem, Vicente, Semiglazov, Vladimir, Lluch, Ana, Sabadell, Dolores, Bozhok, Alla, Byakhov, Mikhail J., Ojeda, Belen, Mansutti, Mauro, Mariani, Gabriella, Molitemi, Angela, Cortes-Funes, Hernan, Colozza, Marian, Pienkowski, Tadeusz, Magazzu, Domenico, Valagussa, Pinuccia, Bonadonna, Gianni, Gianni, Luca (2013).

Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO)

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Sotelo, Miguel J., Manso, Luis, Garcia Saenz, Jose Angel, Ciruelos, Eva M., Moreno, Fernando, Mendiola, Cesar, Callata, Hector, Ghanem, Ismael, Cabezas, Santiago, Gonzalez-Larriba, Jose-Luis, Diaz Rubio, Eduardo (2013).

Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Espinosa, Enrique, Gamez-Pozo, Angelo, Perez Carrion, Ramon Maria, Manso, Luis, Crespo, Carmen, Mendiola, Cesar, Alvarez, Isabel, Margeli, Mireia, Bayo, Juan L., Gonzalez, Xavier, Santaballa, Ana, Ciruelos, Eva, Angel Cabrera, Miguel, Anton, Antonio, Catalan, Gustavo, Alvarez Gallego, Jose Valero, Miramon, Jose, Lopez Vacas, Rocio, Zamora, Pilar (2013).

The Long-HER study: Clinical and molecular analysis of advanced HER2+breast cancer treated with trastuzumab and associated to long-term survival.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Ruiz-Borrego, Manuel, Garcia Saenz, Jose Angel, Hornedo, Javier, Manso, Luis, Calvo, Isabel, Lao, Juan, Gonzalez-Martin, Antonio, Feijoo, Margarita, Florin Gerico, Jesus, Morales, Serafin, Illarramendi, Jose J., Pedro Jimenez, Valero, Sanchez-Jimenez, Javier, Augusto Rodriguez, Cesar, Sanchez-Rovira, Pedro, Ayala, Francisco, Alvarez, Isabel, Antonio Virizuela, Juan, Lopez, Rafael, Rodriguez-Villanueva, Julio (2013).

EUFORIA study (Eribulin Use for the Treatment of Advanced Breast Cancer: Observational, Retrospective Analysis): Initial experience with eribulin in daily clinical practice in Spain

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Gil, Eva Maria Ciruelos, Brufsky, Adam, Im, Young-Hyuck, Kim, Sung-Bae, Clark, Emma, Knott, Adam, Ross, Graham, Miles, David (2013).

Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Ponce Aix, Santiago, Manneh Kopp, Ray, Manuel Sepulveda, Juan, Nunez, Juan A., Iglesias, Lara, Pascual, Tomas, Parrilla, Lucia, Ruiz Solis, Sebastian (2013).

Clinical value of PET/CT's SUV max at baseline, early follow-up, and end of treatment reevaluation as a prognostic factor in small cell lung cancer patients with extended disease.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Manso, Luis, Garcia-Palomo, Andres, Perez-Carrion, Ramon, Ignacio Chacon, Jose, Mielgo Rubio, Xabier, Gallegos Sancho, Isabel, Cassinello, Javier, Llorente, Rosa, Galve Calvo, Elena, Llorca, Cristina, Alvarez, Inaki, Fernandez, Antonio, Catalan, Gustavo, Garcia Lopez, Maria Jose, Dolores Torregrosa, Maria, Blanco, Esperanza, Bueno, Coralia, Perello, Antonia, Mendez, Miguel, Cortes-Funes, Hernan (2013).

Prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in routine clinical practice: Oncosur-Avalox-Observational cross-sectional study

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Gianni, Luca, Eiermann, Wolfgang, Semiglazov, Vladimir, Manikhas, Alexey, Lluch, Ana, Tjulandin, Sergei, Zambetti, Milvia, Vazquez, Federico, Byakhov, Mikhail J., Lichinitser, Mikhail, Climent, Miguel Angel, Ciruelos, Eva, Ojeda, Belen, Mansutti, Mauro, Bozhok, Alla, Magazzu, Domenico, Steinseifer, Jutta, Valagussa, Pinuccia, Baselga, Jose (2013).

Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT plus H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Ghanem, Ismael, Castaneda, Carlos, Perez-Campos, Ana, Toldos, Oscar, Sancho Perez, Blanca, Manso, Luis, Luis Rodriguez-Peralto, Jose, Calderon, Monica, Corles-Funes, Herman, Lora, David, Garcia-Martin, Rosa, Ciruelos, Eva (2013).

Molecular biomarkers as predictive factors of pCR for early triple-negative breast cancer

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Iwata, Hiroji, Baselga, Jose, Campone, Mario, Arteaga, Carlos L., Cortes, Javier, Jonat, Walter, De Laurentiis, Michelino, Ciruelos, Eva, Janni, Wolfgang, Bachelot, Thomas, Lonning, Per Eystein, Ma, Cynthia, O'Regan, Ruth, Di Tomaso, Emmanuelle, Bharani-Dharan, Bharani, Duval, Vincent, Lau, Helen, Germa, Caroline, Urban, Pabrick, Di Leo, Angelo (2013).

Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2-locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Llombart-Cussac, Antonio, Pivot, Xavier B., Biganzoli, Laura, Cortes-Funes, Hernan, Pritchard, Kathleen I., Pierga, Jean-Yves, Smith, Ian E., Thomssen, Christoph, Palacios, Gamma, Srock, Stefanie, Sampayo, Miguel, Cortes, Javier (2013).

A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Lopez-Vivanco, Guillermo, Marti, Thomas, Kotov, Ilya N., Chaib, Imane, Ponce-Aix, Santiago, Campelo, Rosario Garcia, Sanchez, Jose Miguel, Artal, Angel, Bover, Isabel, Taron, Miquel, Sanchez-Ronco, Maria, Rolfo, Christian Diego, Massuti, Bartomeu, Stahel, Rolf A., Rosell, Rafael, Spanish Lung Canc Grp (2013).

Components of homologous recombination and translesion synthesis (TLS) in pemetrexed/cisplatin-treated non-small-cell lung cancer (NSCLC) patients (p)

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(15, S).
Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F (2013).

Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers

CANCER TREATMENT REVIEWS. Review. 39(3):230-240.
[doi:10.1016/j.ctrv.2012.04.009]
Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA (2013).

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O-6-Methylguanine-DNA Methyltransferase Promoter

MOLECULAR CANCER THERAPEUTICS. Article. 12(5):809-818.
[doi:10.1158/1535-7163.MCT-12-0710]
Swain, Sandra M., Kim, Sung-Bae, Cortes, Javier, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Knott, Adam, Clark, Emma, Ross, Graham, Benyunes, Mark C., Baselga, Jose (2013).

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

LANCET ONCOLOGY. Article. 14(6):461-471.
[doi:10.1016/S1470-2045(13)70130-X]
Díaz-García CV, Agudo-López A, Pérez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J, Cortijo A, Martínez-Villanueva M, Iglesias L, García-Carbonero R, Fresno Vara JA, Gámez-Pozo A, Palacios J, Cortés-Funes H, Paz-Ares L, Agulló-Ortuño MT (2013).

DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification

CARCINOGENESIS. Article. 34(5):1031-1038.
[doi:10.1093/carcin/bgt022]
Kamieniak, M. M., Munoz-Repeto, I., Rico, D., Osorio, A., Urioste, M., Garcia-Donas, J., Hernando, S., Robles-Diaz, L., Ramon y Cajal, T., Cazorla, A., Saez, R., Garcia-Bueno, J. M., Domingo, S., Borrego, S., Palacios, J., van de Wiel, M. A., Ylstra, B., Benitez, J., Garcia, M. J. (2013).

DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas

BRITISH JOURNAL OF CANCER. Article. 108(8):1732-1742.
[doi:10.1038/bjc.2013.141]
Gamez-Pozo, Angelo, Ibarz Ferrer, Nuria, Ciruelos, Eva, Lopez-Vacas, Rocio, Garcia Martinez, Fernando, Espinosa, Enrique, Fresno Vara, Juan Angel (2013).

Shotgun proteomics of archival triple-negative breast cancer samples

Proteomics Clinical Applications. Article. 7(3-4, SI):283-291.
[doi:10.1002/prca.201200048]
Villacampa Auba, Felipe, Guerrero Ramos, Felix, Diez Sicilia, Laura, Garcia Gomez, Borja, Sepulveda Sanchez, Juan Manuel, Ospina Galeano, Irma Amparo, Garc Ia Gonzalez, Luc Ia, Jimenez Alcaide, Estibaliz, Duarte Ojeda, Jose Manuel, de la Rosa Kehrman, Federico, Castellano Gauna, Daniel, Diaz Gonzalez, Rafael (2013).

HOW DO GENETIC POLYMORPHISMS INFLUENCE IN SUNITINIB TREATED METASTATIC RENAL CARCINOMA?: A PROSPECTIVE OBSERVATIONAL STUDY AND VALIDATION.

JOURNAL OF UROLOGY. Meeting Abstract. 189(4, S):192-193.
Gomez-Martin, C., Salazar, R., Montagut, C., Gil-Martin, M., Nunez, J. A., Puig, M., Lin, X., Khosravan, R., Tursi, J. M., Lechuga, M. J., Bellmunt, J. (2013).

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

INVESTIGATIONAL NEW DRUGS. Article. 31(2):390-398.
[doi:10.1007/s10637-012-9830-x]
Caraceni, Augusto, Davies, Andrew, Poulain, Philippe, Cortes-Funes, Hernan, Panchal, Sunil J., Fanelli, Guido (2013).

Guidelines for the Management of Breakthrough Pain in Patients With Cancer

Journal of the National Comprehensive Cancer Network. Article. 11(1):29-36.
Angevin, Eric, Lopez-Martin, Jose A., Lin, Chia-Chi, Gschwend, Juergen E., Harzstark, Andrea, Castellano, Daniel, Soria, Jean-Charles, Sen, Paramita, Chang, Julie, Shi, Michael, Kay, Andrea, Escudier, Bernard (2013).

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

CLINICAL CANCER RESEARCH. Article. 19(5):1257-1268.
[doi:10.1158/1078-0432.CCR-12-2885]
Cortijo-Cascajares S, Nacle-López I, García-Escobar I, Aguilella-Vizcaíno MJ, Herreros-de-Tejada A, Cortés-Funes Castro H, Calleja-Hernández MÁ (2013).

Effectiveness of oxaliplatin desensitization protocols

Clinical & Translational Oncology. Article. 15(3):219-225.
[doi:10.1007/s12094-012-0909-9]
Castellano, Daniel E., Farfan, Carlos A., Angelo, Gamez, Sepulveda, Juan M., De Velasco, Guillermo, Villacampa, Felipe, Tejido, Angel, Dominguez, Mario, de la Rosa, Federico, Fresno, Juan A. (2013).

Analysis of molecular profiling of renal cell carcinoma: Identification of a 4-microRNA signature as a prognostic value in patients with stage I-II disease

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(6, S).
[doi:10.1200/jco.2013.31.6_suppl.395]
De Velasco, Guillermo, Castellano, Daniel E., Manuel Sepulveda, Juan, Villacampa, Felipe, Pascual, Tomas, Manneh, Ray, Parrilla, Lucia, Farfan, Carlos A., Cortes-Funes, Hernan (2013).

Long-term outcomes of cisplatin-based chemotherapy in patients with stage II-III germ cell tumors: Center 30-year experience of a single center

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(6, S).
[doi:10.1200/jco.2013.31.6_suppl.338]
Farfan, Carlos A., Castellano, Daniel E., Rodriguez-Antona, Cristina, Benitez, Julio, De Velasco, Guillermo, Villacampa, Felipe, de la Rosa, Federico, Andres, Eva, Manuel Sepulveda, Juan (2013).

Genetic polymorphisms and sunitinib outcome in metastatic renal-cell carcinoma: A prospective observational study and validation

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(6, S).
[doi:10.1200/jco.2013.31.6_suppl.403]
Garcia Alfonso, Pilar, Chaves-Conde, Manuel, Munoz, Andres, Salud, Antonia, Garcia-Giron, Carlos, Gravalos Castro, Cristina, Massuti, Bartomeu, Gonzalez Flores, Encarnacion, Queralt, Bernardo, Lopez Ladron, Amelia, Losa, Ferran, Oltra Ferrando, Amparo, Gomez Reina, Maria Jose, Garcia-Carbonero, Rocio, Garcia-Escobar, Ignacio, Aranda, Enrique (2013).

Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 31(4, S).
Lastra-Aras, Enrique, Robles-Diaz, Luis, Guillen-Ponce, Carmen, Alba, Emilio, Cruz, Juan-Jesus (2013).

SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs)

Clinical & Translational Oncology. Article. 15(1):20-25.
[doi:10.1007/s12094-012-0920-1]
Awada, A., Dirix, L., Manso Sanchez, L., Xu, B., Luu, T., Dieras, V., Hershman, D. L., Agrapart, V., Ananthakrishnan, R., Staroslawska, E. (2013).

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy

ANNALS OF ONCOLOGY. Article. 24(1):109-116.
[doi:10.1093/annonc/mds284]
Munoz-Repeto, Ivan, Jose Garcia, Maria, Kamieniak, Marta, Ramon y Cajal, Teresa, Domingo, Samuel, Cazorla, Alicia, Garcia Donas, Jesus, Hernando Polo, Susana, Garcia Sagredo, Jose Miguel, Hernandez, Elena, Lacambra, Carmen, Saez, Raquel, Robles, Luis, Borrego, Salud, Prat, Jaime, Palacios, Jose, Benitez, Javier (2013).

Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study

HISTOLOGY AND HISTOPATHOLOGY. Article. 28(1):133-144.
[doi:10.14670/HH-28.133]
Sternberg, Cora N., Skoneczna, Iwona A., Castellano, Daniel, Theodore, Christine, Blais, Normand, Voog, Eric, Bellmunt, Joaquim, Peters, Frank, Le-Guennec, Solenn, Cerbone, Linda, Risse, Marie-Laure, Machiels, Jean-Pascal (2013).

Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

ONCOLOGY. Article. 85(4):208-215.
[doi:10.1159/000354085]
Martin-Perez, Elena, Capdevila, Jaume, Castellano, Daniel, Jimenez-Fonseca, Paula, Salazar, Ramon, Beguiristain-Gomez, Adolfo, Alonso-Orduna, Vicente, Martinez del Pradoh, Purificacion, Villabona-Artero, Carles, Diaz-Perez, Jose A., Monleon, Antonio, Marazuela, Monica, Pachon, Vanessa, Sastre-Valera, Javier, Sevilla, Isabel, Castano, Angel, Garcia-Carbonero, Rocio (2013).

Prognostic Factors and Long-Term Outcome of Pancreatic Neuroendocrine Neoplasms: Ki-67 Index Shows a Greater Impact on Survival than Disease Stage. The Large Experience of the Spanish National Tumor Registry (RGETNE)

NEUROENDOCRINOLOGY. Article. 98(2):156-168.
[doi:10.1159/000355152]
Castellano, Daniel, Bajetta, Emilio, Panneerselvam, Ashok, Saletan, Stephen, Kocha, Walter, O'Dorisio, Thomas, Anthony, Lowell B., Hobday, Timothy, RADIANT-2 Study Grp (2013).

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study

ONCOLOGIST. Article. 18(1):46-53.
[doi:10.1634/theoncologist.2012-0263]

2012

Cozar, J. M., Solsona, E., Morote, J., Minana, B., Maroto, J. P., Gonzalez del Alba, A., Climent, M. A., Carles, J., Alcaraz, A., Castellano, D. (2012).

Recomendations on the Management of Controversies in Advanced Castrate-Resistant Prostate Cancer

Actas Urologicas Espanolas. Article. 36(10):569-577.
[doi:10.1016/j.acuro.2012.06.004]
Salvador J, Grávalos C, Albanell J, Barnadas A, Borrega P, García-Mata J, Garrido P, Gonzalez-Flores E, Isla D, Lomas M, Rodríguez-Lescure A, Cruz JJ, Alba E (2012).

Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital

Clinical & Translational Oncology. Article. 14(11):820-826.
[doi:10.1007/s12094-012-0873-4]
Castellano, Daniel, Antonio Virizuela, Juan, Cruz, Josefina, Manuel Sepulveda, Juan, Saenz, Maribel, Paz-Ares, Luis (2012).

The role of pharmacogenomics in metastatic renal cell carcinoma

CANCER AND METASTASIS REVIEWS. Review. 31(1):29-32.
[doi:10.1007/s10555-012-9356-x]
Castellano, Daniel, Bellmunt, Joaquim (2012).

The optimize project: beyond first-line therapy in metastatic renal cell carcinoma

CANCER AND METASTASIS REVIEWS. Editorial Material. 31(1):1-2.
[doi:10.1007/s10555-012-9393-5]
Pardo, Beatriz, Salazar, Ramon, Ciruelos, Eva, Cortes-Funes, Hernan, Garcia, Margarita, Majem, Margarita, Montes, Ana, Cuadra, Carmen, Soto-Matos, Arturo, Lebedinsky, Claudia, Alfaro, Vicente, Paz-Ares, Luis (2012).

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

MEDICAL ONCOLOGY. Article. 29(3):2240-2250.
[doi:10.1007/s12032-011-9979-8]
Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM (2012).

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

JOURNAL OF VIRAL HEPATITIS. Article. 19(9):623-634.
[doi:10.1111/j.1365-2893.2012.01586.x]
Duenas, Marta, Santos, Mirentxu, Aranda, Juan F., Bielza, Concha, Martinez-Cruz, Ana B., Lorz, Corina, Taron, Miquel, Ciruelos, Eva M., Rodriguez-Peralto, Jose L., Martin, Miguel, Larranaga, Pedro, Dahabreh, Jubrail, Stathopoulos, George P., Rosell, Rafael, Paramio, Jesus M., Garcia-Escudero, Ramon (2012).

Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes

PLoS One. Article. 7(8).
[doi:10.1371/journal.pone.0042494]
Gravalos, Cristina, Salut, Antonieta, Garcia-Giron, Carlos, Garcia-Carbonero, Rocio, Isabel Leon, Ana, Sevilla, Isabel, Maurel, Joan, Esteban, Beatriz, Garcia-Rico, Eduardo, Murias, Adolfo, Cortes-Funes, Hernan (2012).

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

Clinical & Translational Oncology. Article. 14(8):606-612.
[doi:10.1007/s12094-012-0843-x]
Castellano, Daniel, Carles, Joan, Esteban, Emilio, Manuel Trigo, Jose, Angel Climent, Miguel, Pablo Maroto, Jose, Garcia del Muro, Xavier, Font, Albert, Paz-Ares, Luis, Angel Arranz, Jose, Bellmunt, Joaquim (2012).

Recommendations for the optimal management of early and advanced urothelial carcinoma

CANCER TREATMENT REVIEWS. Review. 38(5):431-441.
[doi:10.1016/j.ctrv.2011.10.004]
Rivera, Fernando, Gravalos, Cristina, Garcia-Carbonero, Rocio (2012).

SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma

Clinical & Translational Oncology. Article. 14(7):528-535.
[doi:10.1007/s12094-012-0836-9]
Gravalos, Cristina, Salvador, Javier, Albanell, Joan, Barnadas, Agustin, Borrega, Pablo, Garcia-Mata, Jesus, Garrido, Pilar, Gonzalez-Flores, Encarnacion, Isla, Dolores, Lomas, Maria, Rodriguez-Lescure, Alvaro, Jesus Cruz, Juan, Alba, Emilio, Spanish Soc Med Oncology SEOM (2012).

Functions and workload of medical oncologists in Spain

Clinical & Translational Oncology. Article. 14(6):423-429.
[doi:10.1007/s12094-012-0819-x]
Espinosa, E., Gamez-Pozo, A., Sanchez-Navarro, I., Pinto, A., Castaneda, C. A., Ciruelos, E., Feliu, J., Fresno Vara, J. A. (2012).

The present and future of gene profiling in breast cancer

CANCER AND METASTASIS REVIEWS. Review. 31(1-2):41-46.
[doi:10.1007/s10555-011-9327-7]
Garcia-Velasco, Adelaida, Duran, Ignacio, Garcia, Elena, Taron, Miquel, Ballestin, Claudio, Castellanos, Daniel, Cortes-Funes, Hernan, Paz-Ares, Luis (2012).

Biological markers of cisplatin resistance in advanced testicular germ cell tumours

Clinical & Translational Oncology. Article. 14(6):452-457.
[doi:10.1007/s12094-012-0823-1]
Alcaraz, A., Medina, R., Maroto, P., Climent, M. A., Castellano, D., Carles, J. (2012).

Castration-Resistant Prostate Cancer: Where are We Going?

Actas Urologicas Espanolas. Review. 36(6):367-374.
[doi:10.1016/j.acuro.2011.10.010]
Castaneda, Carlos A., Andres, Eva, Barcena, Carmen, Gomez, Henry L., Cortes-Funes, Hernan, Ciruelos, Eva (2012).

Behaviour of breast cancer molecular subtypes through tumour progression

Clinical & Translational Oncology. Article. 14(6):481-485.
[doi:10.1007/s12094-012-0827-x]
Grande, Enrique, Capdevila, Jaume, Barriuso, Jorge, Anton-Aparicio, Luis, Castellano, Daniel (2012).

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

CANCER AND METASTASIS REVIEWS. Review. 31(1-2):47-53.
[doi:10.1007/s10555-011-9328-6]
Zamora, Pilar, Angel Fresno-Vara, Juan, Gamez-Pozo, Angelo, Perez-Carrion, Ramon, Manso, Luis, Crespo Massieu, Carmen, Mendiola, Cesar, Alvarez, Isabel, Margeli Vila, Mireia, Bayo Calero, Juan Lucas, Gonzalez, Xavier, Santaballa, Ana, Ciruelos Gil, Eva Maria, Afonso Gomez, Ruth, Lao Romera, Juan, Catalan, Gustavo, Alvarez Gallego, Jose Valero, Miramon Lopez, Jose, Salvador Bofill, Francisco Javier, Ruiz Borrego, Manuel (2012).

Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+metastatic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 30(15, S).
Mendiola, Cesar, Manneh, Ray, Pascual, Tomas, De Velasco, Guillermo, Vega, Estela, Manso, Luis, Ghanem, Ismael, Ciruelos, Eva M., Seoane, J., Cortes-Funes, Hernan (2012).

Neoadjuvant chemotherapy without a fixed number of cycles in advanced ovarian cancer not candidates for optimal primary surgery.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 30(15, S).
Vermorken, Jan Baptist, Peyrade, Frederic, Krauss, Juergen, Mesia, Ricard, Remenar, Eva, Gauler, Thomas C., Keilholz, Ulrich, Delord, Jean-Pierre, Schafhausen, Philippe, Erfan, Jozsef, Brummendorf, Tim H., Iglesias, Lara, Bethe, Ullrich, de La Bourdonnaye, Guillaume, Clement, Paul M. (2012).

Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 30(15, S).
Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J (2012).

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

BRITISH JOURNAL OF CANCER. Article. 106(10):1618-1625.
[doi:10.1038/bjc.2012.156]
Baselga, Jose, Martins Segalla, Jose Getulio, Roche, Henri, del Giglio, Auro, Pinczowski, Helio, Ciruelos, Eva M., Cabral Filho, Sebastiao, Gomez, Patricia, Van Eyll, Brigitte, Bermejo, Begona, Llombart, Antonio, Garicochea, Bernardo, Climent Duran, Miguel Angel, Gehm Hoff, Paulo Marcelo, Espie, Marc, Junior Gemeinder de Moraes, Andre Augusto, Ribeiro, Ronaldo Albuquerque, Mathias, Clarissa, Gil Gil, Miguel, Ojeda, Belen, Morales, Josefa, Ro, Sunhee Kwon, Li, Shell, Costa, Frederico (2012).

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 30(13):1484-1491.
[doi:10.1200/JCO.2011.36.7771]
Espinosa, Enrique, Berrocal, Alfonso, Lopez Martin, Jose Antonio, Gonzalez Cao, Maria, Cerezuela, Pablo, Ignacio Mayordomo, Jose, Algarra, Salvador Martin, Grp Espanol Melanoma GEM (2012).

Advances in cutaneous melanoma

Clinical & Translational Oncology. Article. 14(5):325-332.
[doi:10.1007/s12094-012-0804-4]
Yap, T. A., Cortes-Funes, H., Shaw, H., Rodriguez, R., Olmos, D., Lal, R., Fong, P. C., Tan, D. S., Harris, D., Capdevila, J., Coronado, C., Alfaro, V., Soto-Matos, A., Fernandez-Teruel, C., Siguero, M., Tabernero, J. M., Paz-Ares, L., de Bono, J. S., Lopez-Martin, J. A. (2012).

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

BRITISH JOURNAL OF CANCER. Article. 106(8):1379-1385.
[doi:10.1038/bjc.2012.99]
Capdevila, Jaume, Iglesias, Lara, Halperin, Irene, Segura, Angel, Martinez-Trufero, Javier, Angeles Vaz, Maria, Corral, Jesus, Obiols, Gabriel, Grande, Enrique, Jose Grau, Juan, Tabernero, Josep (2012).

Sorafenib in metastatic thyroid cancer

ENDOCRINE-RELATED CANCER. Article. 19(2):209-216.
[doi:10.1530/ERC-11-0351]
Paz-Ares, Luis, Lopez-Pousa, Antonio, Poveda, Andres, Balana, Carmen, Ciruelos, Eva, Bellmunt, Joaquim, Garcia del Muro, Javier, Provencio, Mariano, Casado, Antonio, Rivera-Herrero, Fernando, Izquierdo, Miguel Angel, Nieto, Antonio, Tanovic, Adnan, Cortes-Funes, Hernan, Maria Buesa, Jose (2012).

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

INVESTIGATIONAL NEW DRUGS. Article. 30(2):729-740.
[doi:10.1007/s10637-010-9561-9]
Hitt, R., Irigoyen, A., Cortes-Funes, H., Grau, J. J., Garcia-Saenz, J. A., Cruz-Hernandez, J. J., Spanish Head Neck Canc Cooperative (2012).

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

ANNALS OF ONCOLOGY. Article. 23(4):1016-1022.
[doi:10.1093/annonc/mdr367]
Zambetti, Milvia, Mansutti, Mauro, Gomez, Patricia, Lluch, Ana, Dittrich, Christian, Zamagni, Claudio, Ciruelos, Eva, Pavesi, Lorenzo, Semiglazov, Vladimir, De Benedictis, Elena, Gaion, Fernando, Bari, Mario, Morandi, Paolo, Valagussa, Pinuccia, Luca, Gianni (2012).

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

BREAST CANCER RESEARCH AND TREATMENT. Article. 132(3, SI):843-851.
[doi:10.1007/s10549-011-1660-6]
Gamez-Pozo, Angelo, Sanchez-Navarro, Iker, Calvo, Enrique, Teresa Agullo-Ortuno, Maria, Lopez-Vacas, Rocio, Diaz, Esther, Camafeita, Emilio, Nistal, Manuel, Madero, Rosario, Espinosa, Enrique, Antonio Lopez, Juan, Fresno Vara, Juan Angel (2012).

PTRF/Cavin-1 and MIF Proteins Are Identified as Non-Small Cell Lung Cancer Biomarkers by Label-Free Proteomics

PLoS One. Article. 7(3).
[doi:10.1371/journal.pone.0033752]
Sastre, Javier, Gravalos, Cristina, Rivera, Fernando, Massuti, Bartomeu, Valladares-Ayerbes, Manuel, Marcuello, Eugenio, Manzano, Jose L., Benavides, Manuel, Hidalgo, Manuel, Diaz-Rubio, Eduardo, Aranda, Enrique (2012).

First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study

ONCOLOGIST. Article. 17(3):339-345.
[doi:10.1634/theoncologist.2011-0406]
Cortes, Javier, Caralt, Mireia, Delaloge, Suzette, Cortes-Funes, Hernan, Pierga, Jean-Yves, Pritchard, Kathleen I., Bollag, David T., Miles, David W. (2012).

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery

EUROPEAN JOURNAL OF CANCER. Article. 48(4):475-481.
[doi:10.1016/j.ejca.2011.11.021]
Carles, Joan, Castellano, Daniel, Angel Climent, Miguel, Maroto, Pablo, Medina, Rafael, Alcaraz, Antonio (2012).

Castration-resistant metastatic prostate cancer: current status and treatment possibilities

Clinical & Translational Oncology. Article. 14(3):169-176.
[doi:10.1007/s12094-012-0780-8]
Baselga, Jose, Bradbury, Ian, Eidtmann, Holger, Di Cosimo, Serena, de Azambuja, Evandro, Aura, Claudia, Gomez, Henry, Dinh, Phuong, Fauria, Karine, Van Dooren, Veerle, Aktan, Gursel, Goldhirsch, Aron, Chang, Tsai-Wang, Horvath, Zsolt, Coccia-Portugal, Maria, Domont, Julien, Tseng, Ling-Min, Kunz, Georg, Sohn, Joo Hyuk, Semiglazov, Vladimir, Lerzo, Guillermo, Palacova, Marketa, Probachai, Volodymyr, Pusztai, Lajos, Untch, Michael, Gelber, Richard D., Piccart-Gebhart, Martine, NeoALTTO Study Team (2012).

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

LANCET. Article. 379(9816):633-640.
[doi:10.1016/S0140-6736(11)61847-3]
Gruenwald, Viktor, Karakiewicz, Pierre I., Bavbek, Sevil E., Miller, Kurt, Machiels, Jean-Pascal, Lee, Se-Hoon, Larkin, James, Bono, Petri, Rha, Sun Young, Castellano, Daniel, Blank, Christian U., Knox, Jennifer J., Hawkins, Robert, Anak, Oezlem, Rosamilia, Marianne, Booth, Jocelyn, Pirotta, Nicoletta, Bodrogi, Istvan, REACT Study Grp (2012).

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

EUROPEAN JOURNAL OF CANCER. Article. 48(3):324-332.
[doi:10.1016/j.ejca.2011.06.054]
Baselga, Jose, Cortes, Javier, Kim, Sung-Bae, Im, Seock-Ah, Hegg, Roberto, Im, Young-Hyuck, Roman, Laslo, Pedrini, Jose Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Swain, Sandra M., CLEOPATRA Study Grp (2012).

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 366(2):109-119.
[doi:10.1056/NEJMoa1113216]
Rodriguez Antolin, Alfredo, Duarte Ojeda, Jose Manuel, Romero Otero, Javier, Cabeza Rodriguez, Angeles, Castellano, Daniel, Dominguez Esteban, Mario, Diez Sicilia, Laura, Diaz Gonzalez, Rafael (2012).

Hormonal treatment in biochemical recurrence after radical prostatectomy

ARCHIVOS ESPANOLES DE UROLOGIA. Article. 65(1):111-121.
Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS (2012).

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

BREAST CANCER RESEARCH AND TREATMENT. Article. 131(1):295-306.
[doi:10.1007/s10549-011-1741-6]
Thomssen, Christoph, Pierga, Jean-Yves, Pritchard, Kathleen I., Biganzoli, Laura, Cortes-Funes, Hernan, Petrakova, Katarina, Kaufman, Bella, Duenne, Anja, Smith, Ian (2012).

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study

ONCOLOGY. Article. 82(4):218-227.
[doi:10.1159/000336892]

2011

Pavel, Marianne E., Hainsworth, John D., Baudin, Eric, Peeters, Marc, Hoersch, Dieter, Klimovsky, Judith, Lebwohl, David, Jehl, Valentine, Wolin, Edward M., Oberg, Kjell, Van Cutsem, Eric, Yao, James C., RADIANT 2 Study Grp (2011).

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

LANCET. Article. 378(9808):2005-2012.
[doi:10.1016/S0140-6736(11)61742-X]
Rini, Brian I., Escudier, Bernard, Tomczak, Piotr, Kaprin, Andrey, Szczylik, Cezary, Hutson, Thomas E., Michaelson, M. Dror, Gorbunova, Vera A., Gore, Martin E., Rusakov, Igor G., Negrier, Sylvie, Ou, Yen-Chuan, Castellano, Daniel, Lim, Ho Yeong, Uemura, Hirotsugu, Tarazi, Jamal, Cella, David, Chen, Connie, Rosbrook, Brad, Kim, Sinil, Motzer, Robert J. (2011).

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

LANCET. Article. 378(9807):1931-1939.
[doi:10.1016/S0140-6736(11)61613-9]
Calvo Aller, Emiliano, Maroto, Pablo, Kreif, Noemi, Gonzalez Larriba, Jose Luis, Lopez-Brea, Marta, Castellano, Daniel, Marti, Belen, Diaz Cerezo, Silvia (2011).

Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain

Clinical & Translational Oncology. Article. 13(12):869-877.
[doi:10.1007/s12094-011-0748-0]
Gravalos, Cristina, Garcia-Alfonso, Pilar, Afonso, Ruth, Arrazubi, Virginia, Arrivi, Antoni, Camara, Juan Carlos, Capdevila, Jaume, Gomez-Espana, Auxiliadora, Lacasta, Adelaida, Manzano, Jose Luis, Salgado, Mercedes, Sastre, Javier, Diaz-Rubio, Eduardo (2011).

Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

Clinical & Translational Oncology. Article. 13(12):862-868.
[doi:10.1007/s12094-011-0747-1]
Bellmunt, J., Gonzalez-Larriba, J. L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez-Gracia, J. L., Aguilar, G., Villanueva, X., Albanell, J., Calvo, A. (2011).

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

ANNALS OF ONCOLOGY. Article. 22(12):2646-2653.
[doi:10.1093/annonc/mdr023]
Garcia-Donas, Jesus, Esteban, Emilio, Javier Leandro-Garcia, Luis, Castellano, Daniel E., Gonzalez del Alba, Aranzazu, Angel Climent, Miguel, Angel Arranz, Jose, Gallardo, Enrique, Puente, Javier, Bellmunt, Joaquim, Mellado, Begona, Martinez, Esther, Moreno, Fernando, Font, Albert, Robledo, Mercedes, Rodriguez-Antona, Cristina (2011).

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

LANCET ONCOLOGY. Article. 12(12):1143-1150.
[doi:10.1016/S1470-2045(11)70266-2]
Pivot, Xavier, Schneeweiss, Andreas, Verma, Shailendra, Thomssen, Christoph, Passos-Coelho, Jose Luis, Benedetti, Giovanni, Ciruelos, Eva, von Moos, Roger, Chang, Hong-Tai, Duenne, Anja-Alexandra, Miles, David W. (2011).

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

EUROPEAN JOURNAL OF CANCER. Article. 47(16):2387-2395.
[doi:10.1016/j.ejca.2011.06.018]
Castellano, Daniel, Gonzalez-Larriba, Jose L., Anton-Aparicio, Luis M., Cassinello, Javier, Grande, Enrique, Esteban, Emilio, Sepulveda, Juan (2011).

Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

EXPERT OPINION ON PHARMACOTHERAPY. Review. 12(16):2433-2439.
[doi:10.1517/14656566.2011.590132]
Regan, Meredith M., Neven, Patrick, Giobbie-Hurder, Anita, Goldhirsch, Aron, Ejlertsen, Bent, Mauriac, Louis, Forbes, John F., Smith, Ian, Lang, Istvan, Wardley, Andrew, Rabaglio, Manuela, Price, Karen N., Gelber, Richard D., Coates, Alan S., Thuerlimann, Beat, BIG 1-98 Collaborative Grp, IBCSG (2011).

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

LANCET ONCOLOGY. Article. 12(12):1101-1108.
[doi:10.1016/S1470-2045(11)70270-4]
Smith, Ian, Pierga, Jean-Yves, Biganzoli, Laura, Cortes-Funes, Hernan, Thomssen, Christoph, Saracchini, Silvana, Nisenbaum, Bella, Pelaez, Ignacio, Duenne, Anja-Alexandra, Pritchard, Kathleen I. (2011).

Final overall survival results and effect of prolonged (a parts per thousand yen1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

BREAST CANCER RESEARCH AND TREATMENT. Article. 130(1):133-143.
[doi:10.1007/s10549-011-1695-8]
Coleman, Robert E., Marshall, Helen, Cameron, David, Dodwell, David, Burkinshaw, Roger, Keane, Maccon, Gil, Miguel, Houston, Stephen J., Grieve, Robert J., Barrett-Lee, Peter J., Ritchie, Diana, Pugh, Julia, Gaunt, Claire, Rea, Una, Peterson, Jennifer, Davies, Claire, Hiley, Victoria, Gregory, Walter, Bell, Richard, AZURE Investigators (2011).

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

NEW ENGLAND JOURNAL OF MEDICINE. Article. 365(15):1396-1405.
[doi:10.1056/NEJMoa1105195]
Garcia-Escobar, I., Sepulveda, J., Castellano, D., Cortes-Funes, H. (2011).

Therapeutic management of chronic lymphocytic leukaemia State of the art and future perspectives

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Review. 80(1):100-113.
[doi:10.1016/j.critrevonc.2010.10.006]
Tabernero, Josep, Dirix, Luc, Schoffski, Patrick, Cervantes, Andres, Antonio Lopez-Martin, Jose, Capdevila, Jaume, van Beijsterveldt, Ludy, Platero, Suso, Hall, Brett, Yuan, Zhilong, Knoblauch, Roland, Zhuang, Sen Hong (2011).

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

CLINICAL CANCER RESEARCH. Article. 17(19):6313-6321.
[doi:10.1158/1078-0432.CCR-11-1101]
del Campo, J. M., Hitt, R., Sebastian, P., Carracedo, C., Lokanatha, D., Bourhis, J., Temam, S., Cupissol, D., De Raucourt, D., Maroudias, N., Nutting, C. M., Compton, N., Midwinter, D., Downie, L., Biswas-Baldwin, N., El-Hariry, I., Harrington, K. J. (2011).

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

BRITISH JOURNAL OF CANCER. Article. 105(5):618-627.
[doi:10.1038/bjc.2011.237]
Gamez-Pozo, Angelo, Sanchez-Navarro, Iker, Calvo, Enrique, Diaz, Esther, Miguel-Martin, Maria, Lopez, Rocio, Agullo, Teresa, Camafeita, Emilio, Espinosa, Enrique, Antonio Lopez, Juan, Nistal, Manuel, Fresno Vara, Juan Angel (2011).

Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches

Molecular BioSystems. Article. 7(8):2368-2374.
[doi:10.1039/c1mb05113j]
Castaneda, Carlos A., Teresa Agullo-Ortuno, Maria, Fresno Vara, Juan Angel, Cortes-Funes, Hernan, Gomez, Henry L., Ciruelos, Eva (2011).

Implication of miRNA in the diagnosis and treatment of breast cancer

Expert Review of Anticancer Therapy. Review. 11(8):1265-1275.
[doi:10.1586/ERA.11.40]
Ariza, Aurelio, Balana, Carmen, Concha, Angel, Hitt, Ricardo, Homet, Blanca, Matilla, Alfredo, Alba, Emilio (2011).

Update on the diagnosis of cancer of unknown primary (CUP) origin

Clinical & Translational Oncology. Article. 13(7):434-441.
[doi:10.1007/s12094-011-0679-9]
Rosell, Rafael, Moran, Teresa, Felip, Enriqueta, Sanchez Torres, Jose Miguel, Borghaei, Hossein, Guan, Shanghong, Brown, Holly, Fitzgerald, Timothy, Clark, Jason, Sathyanarayanan, Sriram, Ayers, Mark, Hardwick, James, Lu, Brian, Yan, Li, Johnson, David (2011).

AN OPEN LABEL, RANDOMIZED PH II STUDY EVALUATING DALOTUZUMAB COMBINED WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER FOLLOWING FAILURE OF PRIOR CHEMOTHERAPY

Journal of Thoracic Oncology. Meeting Abstract. 6(6, 2):358-359.
Rodriguez Garzotto, A. A. A., Iglesias Docampo, L. C., Gravalos Castro, C., Lopez-Martin, J. A., Agullo Ortuno, T., Diaz Garcia, V., Homet, B., Ciruelos Gil, E. M., Manso, L., Mendiola, C., Gomez-Martin, C., Hitt, R., Gomez Camara, A., Cortes-Funes, H. (2011).

Phase II trial of topical heparin as treatment for patients (pts) with hand-foot syndrome (HFS) induced by capecitabine (CAP)

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 29(15, S).
Lopez-Pousa, A., Nguyen, B. Bui, Garcia del Muro, X., Martin Broto, J., Balana, C., Lavernia, J., Cruz, J., Maurel, J., Andres, R., Valverde, C. M., Fra, J., Martinez-Trufero, J., Lopez-Martin, J. A., Sevilla, I., Cubedo, R., Blay, J. (2011).

A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 29(15, S).
[doi:10.1200/jco.2011.29.15_suppl.10072]
Garcia Alfonso, P., Chaves, M., Munoz Martin, A., Salud Salvia, A., Vilchez, R., Yuste, A., Gravalos Castro, C., Queralt Merino, B., Gonzalez Flores, E., Lopez Ladron, A., Losa, F., Oltra Ferrando, A., Gomez Reina, M. J., Campos, J. M., Aranda, E. (2011).

Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC)

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 29(15, S).
Lopez-Martin, J. A., Vidal Losada, M., Cortes, J., Bermejo, B., Lluch Fernandez, A., Learoyd, M., Saunders, A., Stuart, M., Baselga, J. (2011).

Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P).

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 29(15, S).
[doi:10.1200/jco.2011.29.15_suppl.3105]
Grande Pulido, E., Castelo, B., Fonseca, P. J., Iglesias, L., Vaz, M. A., Barriuso, J., Izquierdo, M., Guadalix, S., Diez, J. J., Sepulveda, J. M. (2011).

Efficacy and tolerability of sunitinib in patients with advanced thyroid cancer out of a trial: A Spanish multicenter cohort.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 29(15, S).
Mendiola, C., Valdiviezo, N., Vega, E., Sanchez Munoz, A., Ciruelos, E. M., Manso, L., Ghanem, I., Dorta, M., Manneh, R., Flores, C. J., Cortes-Funes, H. (2011).

Altretamine for recurrent ovarian cancer or as maintenance after response to second-line therapy.

JOURNAL OF CLINICAL ONCOLOGY. Meeting Abstract. 29(15, S).
[doi:10.1200/jco.2011.29.15_suppl.e15589]
Castellano, Daniel, Grande, Enrique, Barriuso, Jorge (2011).

Advances in Pancreatic Neuroendocrine Tumor Treatment

NEW ENGLAND JOURNAL OF MEDICINE. Letter. 364(19):1872-1873.
[doi:10.1056/NEJMc1102746#SA3]
Medina-Polo, Jose, Antonio Nunez-Sobrino, Juan, Diaz-Gonzalez, Rafael (2011).

An unusual case of air within the bladder wall: Bladder pneumatosis?

INTERNATIONAL JOURNAL OF UROLOGY. Article. 18(5):375-377.
[doi:10.1111/j.1442-2042.2011.02748.x]
Licitra, L., Mesia, R., Rivera, F., Remenar, E., Hitt, R., Erfan, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., Stoerkel, S., Senger, S., Stroh, C., Vermorken, J. B. (2011).

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

ANNALS OF ONCOLOGY. Article. 22(5):1078-1087.
[doi:10.1093/annonc/mdq588]
Salazar, Fernanda, Angel Molina, Miguel, Sanchez-Ronco, Maria, Moran, Teresa, Luis Ramirez, Jose, Miguel Sanchez, Jose, Stahel, Rolf, Garrido, Pilar, Cobo, Manuel, Isla, Dolores, Bertran-Alamilloh, Jordi, Massuti, Bartomeu, Cardenal, Felipe, Manegold, Christian, Lianes, Pilar, Manuel Trig, Jose, Javier Sanchez, Jose, Taron, Miquel, Rosell, Rafael (2011).

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

LUNG CANCER. Article. 72(1):84-91.
[doi:10.1016/j.lungcan.2010.07.008]
Raymond, Eric, Hobday, Timothy, Castellano, Daniel, Reidy-Lagunes, Diane, Garcia-Carbonero, Rocio, Carrato, Alfredo (2011).

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

CANCER AND METASTASIS REVIEWS. Review. 30(1, 1):19-26.
[doi:10.1007/s10555-011-9291-2]
Smith, I. E., Pierga, J. -Y., Biganzoli, L., Cortes-Funes, H., Thomssen, C., Pivot, X., Fabi, A., Xu, B., Stroyakovskiy, D., Franke, F. A., Kaufman, B., Mainwaring, P., Pienkowski, T., De Valk, B., Kwong, A., Gonzalez-Trujillo, J. L., Koza, I., Petrakova, K., Pereira, D., Pritchard, K. I., ATHENA Study Grp (2011).

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

ANNALS OF ONCOLOGY. Article. 22(3):595-602.
[doi:10.1093/annonc/mdq430]
Castellano, Daniel (2011).

Gastroenteropancreatic neuroendocrine tumors. Where are we now?

CANCER AND METASTASIS REVIEWS. Editorial Material. 30(1, 1):1-1.
[doi:10.1007/s10555-011-9296-x]
Oberg, Kjell, Castellano, Daniel (2011).

Current knowledge on diagnosis and staging of neuroendocrine tumors

CANCER AND METASTASIS REVIEWS. Review. 30(1, 1):3-7.
[doi:10.1007/s10555-011-9292-1]
Castellano, Daniel, Salazar, Ramon, Raymond, Eric (2011).

Future perspectives on neuroendocrine tumors

CANCER AND METASTASIS REVIEWS. Review. 30(1, 1):35-40.
[doi:10.1007/s10555-011-9294-z]
Gravalos, Cristina, Gomez-Martin, Carlos, Rivera, Fernando, Ales, Inmaculada, Queralt, Bernardo, Marquez, Antonia, Jimenez, Ulpiano, Alonso, Vicente, Garcia-Carbonero, Rocio, Sastre, Javier, Colomer, Ramon, Cortes-Funes, Hernan, Jimeno, Antonio (2011).

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Clinical & Translational Oncology. Article. 13(3):179-184.
[doi:10.1007/s12094-011-0637-6]
Castellano, Daniel, Manuel Sepulveda, Juan, Garcia-Escobar, Ignacio, Rodriguez-Antolin, Alfredo, Sundlov, Anna, Cortes-Funes, Hernan (2011).

The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab

ONCOLOGIST. Article. 16(2):136-145.
[doi:10.1634/theoncologist.20100154]
Cortes-Funes, H., Ghanem, I. (2011).

Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer

Expert Review of Anticancer Therapy. Review. 11(2):165-168.
[doi:10.1586/ERA.10.234]
Regan, Meredith M., Price, Karen N., Giobbie-Hurder, Anita, Thuerlimann, Beat, Gelber, Richard D., Int Breast Canc Study Grp, BIG 1-98 Collaborative Grp (2011).

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

BREAST CANCER RESEARCH. Review. 13(3):209-209.
[doi:10.1186/bcr2837]

2010

Castaneda, Carlos A., Cortes-Funes, Hernan, Gomez, Henry L., Ciruelos, Eva M. (2010).

The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.

CANCER AND METASTASIS REVIEWS. Review. 29(4):751-759.
[doi:10.1007/s10555-010-9261-0]
Pockett, R. D., Castellano, D., McEwan, P., Oglesby, A., Barber, B. L., Chung, K. (2010).

The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain

EUROPEAN JOURNAL OF CANCER CARE. Article. 19(6):755-760.
[doi:10.1111/j.1365-2354.2009.01135.x]
Gravalos Castro, Cristina, Maurel Santasusana, Joan, Rivera Herrero, Fernando, Salazar Soler, Ramon, Sevilla Garcia, Isabel, Sastre Valera, Javier, Tabernero Caturla, Jose M., Gonzalez Flores, Encarnacion, Lomas Garrido, Maria, Isla Casado, Dolores (2010).

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer

Clinical & Translational Oncology. Article. 12(11):724-728.
[doi:10.1007/s12094-010-0586-5]
del Barco Berron, Sonia, Ciruelos Gil, Eva, Trias de Bes, Ignacio Tusquets, Munoz Mateu, Montserrat, Sanchez Rovira, Pedro, Rodriguez Lescure, Alvaro, Isla Casado, Dolores (2010).

SEOM clinical guidelines for the treatment of early breast cancer

Clinical & Translational Oncology. Article. 12(11):711-718.
[doi:10.1007/s12094-010-0584-7]
Hoskins, P., Vergote, I., Cervantes, A., Tu, D., Stuart, G., Zola, P., Poveda, A., Provencher, D., Katsaros, D., Ojeda, B., Ghatage, P., Grimshaw, R., Casado, A., Elit, L., Mendiola, C., Sugimoto, A., D'Hondt, V., Oza, A., Germa, J. R., Roy, M., Brotto, L., Chen, D., Eisenhauer, E. A. (2010).

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel

JOURNAL OF THE NATIONAL CANCER INSTITUTE. Article. 102(20):1547-1556.
[doi:10.1093/jnci/djq362]
Rustin, Gordon J. S., van der Burg, Maria E. L., Griffin, Clare L., Guthrie, David, Lamont, Alan, Jayson, Gordon C., Kristensen, Gunnar, Mediola, Cesar, Coens, Corneel, Qian, Wendi, Parmar, Mahesh K. B., Swart, Ann Marie, MRC OV05 Investigator, EORTC 55955 Investigator (2010).

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

LANCET. Article. 376(9747):1155-1163.
[doi:10.1016/S0140-6736(10)61268-8]
Agullo-Ortuno, M.T., Lopez-Rios, F, Paz-Ares L (2010).

Lung cancer genomic signatures.

Journal of Thoracic Oncology. Review. 5(10):1673-1691.
[doi:10.1097/JTO.0b013e3181f1900e]
Martin, A. Gonzalez, Casado, A., Arranz, J., Rubio, M. J., Calvo, E., Beltran, M., Mendiola, C., Sanchez, A., Santaballa, A., Cervantes, A. (2010).

RANDOMIZED PHASE II STUDY OF PACLITAXEL-CARBOPLATIN (PC) VERSUS GEMCITABINE-CARBOPLATIN (GC) FOLLOWED BY PACLITAXEL-CARBOPLATIN (PC) IN PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (PSROC): A GEICO (SPANISH GROUP FOR INVESTIGATION IN OVARIAN CANCER) STUDY

ANNALS OF ONCOLOGY. Meeting Abstract. 21(8):307-307.
Gravalos, Cristina, Grande, Enrique, Manel Gasent, Joan (2010).

The potential role of sunitinib in gastrointestinal cancers other than GIST.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Review. 76(1):36-43.
[doi:10.1016/j.critrevonc.2010.01.008]
Mesia, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J. -P., Bokemeyer, C., Curran, D., Gross, A., Vermorken, J. B. (2010).

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

ANNALS OF ONCOLOGY. Article. 21(10):1967-1973.
[doi:10.1093/annonc/mdq077]
Motzer, Robert J., Escudier, Bernard, Oudard, Stephane, Hutson, Thomas E., Porta, Camillo, Bracarda, Sergio, Grunwald, Viktor, Thompson, John A., Figlin, Robert A., Hollaender, Norbert, Kay, Andrea, Ravaud, Alain, RECORD-1 Study Grp (2010).

Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors

CANCER. Article. 116(18):4256-4265.
[doi:10.1002/cncr.25219]
Vergote, Ignace, Trope, Claes G., Amant, Frederic, Kristensen, Gunnar B., Ehlen, Tom, Johnson, Nick, Verheijen, Rene H. M., van der Burg, Maria E. L., Lacave, Angel J., Panici, Pierluigi Benedetti, Kenter, Gemma G., Casado, Antonio, Mendiola, Cesar, Coens, Corneel, Verleye, Leen, Stuart, Gavin C. E., Pecorelli, Sergio, Reed, Nick S., European Org Res Treatment Can, NCIC Clinical Trials Grp (2010).

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 363(10):943-953.
[doi:10.1056/NEJMoa0908806]
Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., Diaz-Perez, J. A., Martinez del Prado, M. P., Alonso Orduna, V., Sevilla-Garcia, I., Villabona-Artero, C., Beguiristain-Gomez, A., Llanos-Munoz, M., Marazuela, M., Alvarez-Escola, C., Castellano, D., Vilar, E., Jimenez-Fonseca, P., Teule, A., Sastre-Valera, J., Benavent-Vinuelas, M., Monleon, A., Salazar, R. (2010).

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)

ANNALS OF ONCOLOGY. Article. 21(9):1794-1803.
[doi:10.1093/annonc/mdq022]
Bang, Yung-Jue, Van Cutsem, Eric, Feyereislova, Andrea, Chung, Hyun C., Shen, Lin, Sawaki, Akira, Lordick, Florian, Ohtsu, Atsushi, Omuro, Yasushi, Satoh, Taroh, Aprile, Giuseppe, Kulikov, Evgeny, Hill, Julie, Lehle, Michaela, Ruschoff, Josef, Kang, Yoon-Koo, ToGA Trial Investigators, GRAVALOS CASTRO, MARIA CRISTINA (2010).

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

LANCET. Article. 376(9742):687-697.
[doi:10.1016/S0140-6736(10)61121-X]
Perea, Jose, Alvaro, Edurne, Rodriguez, Yolanda, Gravalos, Cristina, Sanchez-Tome, Eva, Rivera, Barbara, Colina, Francisco, Carbonell, Pablo, Gonzalez-Sarmiento, Rogelio, Hidalgo, Manuel, Urioste, Miguel (2010).

Approach to early-onset colorectal cancer: Clinicopathological, familial, molecular and immunohistochemical characteristics

WORLD JOURNAL OF GASTROENTEROLOGY. Article. 16(29):3697-3703.
[doi:10.3748/wjg.v16.i29.3697]
Calvo, Emiliano, Maroto, Pablo, Garcia del Muro, Xavier, Angel Climent, Miguel, Luis Gonzalez-Larriba, Jose, Esteban, Emilio, Lopez, Rafael, Paz-Ares, Luis, Bellmunt, Joaquim, Castellano, Daniel (2010).

Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.

CANCER AND METASTASIS REVIEWS. Review. 29 Suppl 1(1):1-10.
[doi:10.1007/s10555-010-9231-6]
Calvo, Emiliano, Maroto, Pablo, Garcia del Muro, Xavier, Angel Climent, Miguel, Luis Gonzalez-Larriba, Jose, Esteban, Emilio, Lopez, Rafael, Paz-Ares, Luis, Bellmunt, Joaquim, Castellano, Daniel (2010).

Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations

CANCER AND METASTASIS REVIEWS. Review. 29(1):11-20.
[doi:10.1007/s10555-010-9232-5]
Montero Luis, Angel, Perez Aguilar, Damian, Lopez Martin, Jose Antonio (2010).

Multidisciplinary management of soft tissue sarcomas

Clinical & Translational Oncology. Article. 12(8):543-553.
[doi:10.1007/s12094-010-0552-2]
Homet, Blanca, Hitt, Ricardo, Ghanem, Ismael, Cortes-Funes, Hernan (2010).

Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival

Clinical & Translational Oncology. Article. 12(8):574-575.
[doi:10.1007/s12094-010-0556-y]
Homet Moreno, Blanca, Garralda Cabanas, Elena, Hitt, Ricardo (2010).

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas

Clinical & Translational Oncology. Article. 12(7):468-472.
[doi:10.1007/s12094-010-0539-z]
Bellmunt, Joaquim, Maroto-Rey, Pablo, Trigo, Jose M., Carles, Joan, Guillem, Vicente, Lopez-Martin, Jose A., Anton-Torres, Antonio, Urruticoechea, Leyrer (2010).

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01

Clinical & Translational Oncology. Article. 12(7):503-508.
[doi:10.1007/s12094-010-0544-2]
Martinez-Trufero, J., Isla, D., Adansa, J. C., Irigoyen, A., Hitt, R., Gil-Arnaiz, I., Lambea, J., Lecumberri, M. J., Cruz, J. J., Spanish Head Neck Canc Treatment (2010).

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.

BRITISH JOURNAL OF CANCER. Review. 102(12):1687-1691.
[doi:10.1038/sj.bjc.6605697]
Duran, Ignacio, Garcia-Velasco, Adelaida, Ballestin, Claudio, Garcia, Elena, Martinez-Tello, Francisco, Pond, Gregory R., Garcia-Carbonero, Rocio, Cortes-Funes, Hernan, Paz-Ares, Luis (2010).

Expression of EGFR, HER-2/neu and KIT in germ cell tumours

Clinical & Translational Oncology. Article. 12(6):443-449.
[doi:10.1007/s12094-010-0532-6]
Dickgreber, Nicolas J., Sorensen, Jens Benn, Paz-Ares, Luis G., Schytte, Tine Kjestrup, Latz, Jane E., Schneck, Karen B., Yuan, Zheng, Miguel Sanchez-Torres, Jose (2010).

Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid

CLINICAL CANCER RESEARCH. Article. 16(10):2872-2880.
[doi:10.1158/1078-0432.CCR-09-3324]
Le Tourneau, Christophe, Faivre, Sandrine, Ciruelos, Eva, Dominguez, Maria J., Lopez-Martin, Jose A., Izquierdo, Miguel A., Jimeno, Jose, Raymond, Eric (2010).

Reports of Clinical Benefit of Plitidepsin (Aplidine), a New Marine-Derived Anticancer Agent, in Patients With Advanced Medullary Thyroid Carcinoma

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. Article. 33(2):132-136.
[doi:10.1097/COC.0b013e318199fb6e]
Gomez-Martin, Carlos, Rodriguez, Analia, Malon, Diego, Cortes-Funes, Hernan (2010).

Biliary cystadenocarcinoma with mesenchymal stroma

Clinical & Translational Oncology. Article. 12(3):234-237.
[doi:10.1007/s12094-010-0495-7]
Vaz Salgado, M. Angeles, Gonzalez Garcia, Carmen, Lopez Martin, Jose Antonio, Guerra, Eva, Benito, Amparo, Sepulveda, Juan M., Carrato, Alfredo (2010).

Porocarcinoma: Clinical Evolution

DERMATOLOGIC SURGERY. Article. 36(2):264-267.
[doi:10.1111/j.1524-4725.2009.01412.x]
Gianni, Luca, Eiermann, Wolfgang, Semiglazov, Vladimir, Manikhas, Alexey, Lluch, Ana, Tjulandin, Sergey, Zambetti, Milvia, Vazquez, Federico, Byakhow, Mikhail, Lichinitser, Mikhail, Angel Climent, Miguel, Ciruelos, Eva, Ojeda, Belen, Mansutti, Mauro, Bozhok, Alla, Baronio, Roberta, Feyereislova, Andrea, Barton, Claire, Valagussa, Pinuccia, Baselga, Jose (2010).

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

LANCET. Article. 375(9712):377-384.
[doi:10.1016/S0140-6736(09)61964-4]
Perez-Regadera, Jose, Sanchez-Munoz, Alfonso, DE LA CRUZ BERTOLO, FRANCISCO JAVIER, Ballestin, Claudio, Lora, David, Garcia-Martin, Rosa, Alonso-Carrion, Lorenzo, Mendiola, Cesar, Lanzos, Eduardo (2010).

Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 20(1):164-172.
[doi:10.1111/IGC.0b013e3181ad3e11]
Sanchez-Munoz, Alfonso, Mendiola, Cesar, Perez-Ruiz, Elisabeth, Rodriguez-Sanchez, Cesar A., Miguel Jurado, Jose, Alonso-Carrion, Lorenzo, Ghanem, Ismael, de Velasco, Guillermo, Quero-Blanco, Cristina, Alba, Emilio (2010).

Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

ONCOLOGY. Article. 79(1-2):98-104.
[doi:10.1159/000320602]

2009

Castellano, D., Garcia del Muro, X., Perez-Gracia, J. L., Gonzalez-Larriba, J. L., Abrio, M. V., Ruiz, M. A., Pardo, A., Guzman, C., Diaz Cerezo, S., Grande, E. (2009).

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-alpha as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

ANNALS OF ONCOLOGY. Article. 20(11):1803-1812.
[doi:10.1093/annonc/mdp067]
Castellano, D., Gonzalez Larriba, J., Anton Aparicio, L. M., Casinello, J., Grande, E., Esteban, E., Sepulveda, J., Rodriguez, A., Ghanem Canete, I. (2009).

Clinical, biochemical (PSA) and radiographic benefit with sunitinib as a single agent in metastatic chemoresistant and hormone-refractory prostate cancer (HRPC) patients

EJC SUPPLEMENTS. Meeting Abstract. 7(2):417-417.
[doi:10.1016/S1359-6349(09)71415-6]
Gonzalez-Billalabeitia, Enrique, Calzas, Julia, Castellano, Daniel, Mendiola, Cesar, Bezares, Susana, Valentin, Vicente, Hornedo, Javier, Ciruelo, Eva, Cortes-Funes, Hernan (2009).

Long-Term Follow-Up of an Anthracycline-Containing Metronomic Chemotherapy Schedule in Advanced Breast Cancer

Breast Journal. Letter. 15(5):551-553.
[doi:10.1111/j.1524-4741.2009.00783.x]
Gore, Martin E., Szczylik, Cezary, Porta, Camillo, Bracarda, Sergio, Bjarnason, Georg A., Oudard, Stephane, Hariharan, Subramanian, Lee, Se-Hoon, Haanen, John, Castellano, Daniel, Vrdoljak, Eduard, Schoffski, Patrick, Mainwaring, Paul, Nieto, Alejandra, Yuan, Jinyu, Bukowski, Ronald (2009).

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

LANCET ONCOLOGY. Article. 10(8):757-763.
[doi:10.1016/S1470-2045(09)70162-7]
Bellmunt, Joaquim, Calvo, Emiliano, Castellano, Daniel, Angel Climent, Miguel, Esteban, Emilio, Garcia del Muro, Xavier, Luis Gonzalez-Larriba, Jose, Maroto, Pablo, Manuel Trigo, Jose (2009).

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer

CANCER CHEMOTHERAPY AND PHARMACOLOGY. Article. 63(1):1-13.
[doi:10.1007/s00280-009-0955-3]

Bai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, Bosch A, Ehinger A, Niméus E, Hartman J, Acs B, Rimm DL ().

An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.

CLINICAL CANCER RESEARCH. Article.
[doi:10.1158/1078-0432.CCR-21-0325]
Cortijo-Cascajares, S, Cercos-Lleti, AC, Ortiz-Perez, S, Caro-Teller, JM, Ferrari-Piquero, JM ().

Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. Article.
[doi:10.1177/10781552211067429]
Usó M, Jantus-Lewintre E, Bremnes RM, Calabuig S, Blasco A, Pastor E, Borreda I, Molina-Pinelo S, Paz-Ares L, Guijarro R, Martorell M, Forteza J, Camps C, Sirera R ().

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.

Oncotarget. Article.
[doi:10.18632/oncotarget.10811]
Molina-Pinelo S, Salinas A, Moreno-Mata N, Ferrer I, Suarez R, Andrés-León E, Rodríguez-Paredes M, Gutekunst J, Jantus-Lewintre E, Camps C, Carnero A, Paz-Ares L ().

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.

Oncotarget. Article.
García-Heredia JM, Verdugo Sivianes EM, Lucena-Cacace A, Molina-Pinelo S, Carnero A ().

Numb-Like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy.

Oncotarget. Article.
[doi:10.18632/oncotarget.11553]
Zugazagoitia J, Ferrer I, Paz-Ares L ().

Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat.

LANCET ONCOLOGY. Article.
[doi:10.1016/S1470-2045(16)30506-X]
Resumen de privacidad

Este sitio web utiliza cookies para brindarle la mejor experiencia de usuario posible. La información de las cookies se almacena en su navegador y realiza funciones como reconocerle cuando regresa a nuestro sitio web y ayudar a nuestro equipo a comprender qué secciones del sitio web le resultan más interesantes y útiles.

Puede obtener más información acerca de nuestra política de cookies y política de privacidad.